ASCO Annual Meeting Express Print
Monday, June 2, 2014
Program data current as of Friday, May 9, 2014
Session Title: Highlights of the Day II Session Including Partners in Progress Award
Session Type: Highlights of the Day
Track: Special Session
Time: 7:30 AM - 9:00 AM
Location: E Hall D1
•
Chair
Alan P. Venook, MD - Chair
•
Partners in Progress Award
Michael S. Katz, MBA
•
Sarcoma
Dennis A. Priebat, MD
•
Central Nervous System Tumors
Michael Prados, MD
•
Myeloma
Saad Zafar Usmani, MD, FACP
•
Genitourinary (Prostate) Cancer
Mark N. Stein, MD
•
Breast Cancer (Plenary Session Highlights)
Eric P. Winer, MD
•
Discussion on Value of Cancer Care
Lowell E. Schnipper, MD
Session Title: ASCO/Radiological Society of North America (RSNA) Joint Session: Precision
Imaging for Precision Medicine
Session Type: Special Session
Track: Special Session
Time: 8:00 AM - 9:15 AM
Location: S100bc
•
Welcome and Introductions
N. Reed Dunnick, MD - Co-Chair
•
Quantitative Imaging
Daniel Carl Sullivan, MD
•
Companion Diagnostics: Pathway to Value
Hedvig Hricak, MD, PhD
•
Early Response Assessment: Accelerating Drug Development
David A. Mankoff, MD, PhD
•
Closing Comments
Clifford A. Hudis, MD, FACP - Co-Chair
Session Title: Cancer Survivorship Programs Across Different Health Care Settings: Past, Present,
and Future
Session Type: Education Session
Track: Patient and Survivor Care
Time: 8:00 AM - 9:15 AM
Location: S504
•
Overview of Cancer Survivorship Programs and Examples of Successful Academic Cancer
Survivorship Programs
Kevin C. Oeffinger, MD - Chair
•
Examples of Successful Community-Based Cancer Survivorship Programs
Keith Edward Argenbright, MD
•
Implementation of Survivorship Programs in the Setting of a Nationalized Health Care
System
Gillian Levitt, MBBS
•
Panel Question and Answer
Session Title: In Vivo Preclinical Models: Making Inroads into Personalized Therapy
Session Type: Education Session
Track: Tumor Biology
Time: 8:00 AM - 9:15 AM
Location: S406
•
Human Orthotopic Tumor Models in Mice Provide a New Platform for Discovery and
Translational in Brain Tumors
Robert Bachoo, MD, PhD - Chair
•
Acute Myeloid Leukemia Preclinical Modeling: Advances and Benefits for Future Treatments
Martin Carroll, MD
•
Preclinical In Vivo Models of Breast Cancers
Alana Welm, PhD
•
Panel Question and Answer
Session Title: Medulloblastoma: Modern Molecular Diagnostics and Clinical Decision Making
Session Type: Education Session
Track: Central Nervous System Tumors
Time: 8:00 AM - 9:15 AM
Location: E253
•
Managing Assets: Radiation Dosing, Timing, and Technologies for Optimal Outcomes in
Medulloblastoma
Torunn I. Yock, MD - Chair
•
Success through Science: Molecular Classification of Medulloblastoma-Driving Therapeutic
Development
Charles Eberhart, MD, PhD
•
Shedding Light on Adult Medulloblastoma: Current Management and Opportunities for
Advancement
Alba Ariela Brandes, MD
•
Panel Question and Answer
Session Title: Pharmacogenomics in the Era of Next-Generation Sequencing
Session Type: Education Session
Track: Cancer Genetics
Time: 8:00 AM - 9:15 AM
Location: S404
•
Application of Pharmacogenomics to Minimize Chemotherapy Toxicity
Daniel Louis Hertz, PharmD, PhD
•
Incidental and Unclear Pharmacogenomics Findings from Next-Generation Sequencing
Howard L. McLeod, PharmD - Chair
•
Pre-emptive Application of Pharmacogenomics to Optimize Therapeutics
Peter H. O'Donnell, MD
•
Panel Question and Answer
Session Title: Renal Cell Carcinoma from Small Renal Masses to Advanced Disease
Session Type: Education Session
Track: Genitourinary Cancer
Time: 8:00 AM - 9:15 AM
Location: E Hall D2
•
Management of Small Renal Masses and Surgery in Metastatic Disease
Jose A. Karam, MD
•
Improving Outcomes in Metastatic Renal Cell Carcinoma by Sequencing Therapy
Manuela Schmidinger, MD
•
New Agents, New Targets in Renal Cell Carcinoma
Michael B. Atkins, MD - Chair
•
Panel Question and Answer
Session Title: How to Smartly Use Smartphones, Twitter, and Social Media to Efficiently Enhance
Clinical Practice - Ticketed Session
Session Type: Meet the Professor Session
Track: Practice Management and Information Technology
Time: 8:00 AM - 9:15 AM
Location: E451a
•
How to Use Social Media and Cancer Communities in Clinical Practice
Matthew S. Katz, MD
•
How to Smartly Use Smartphones to Efficiently Enhance Clinical Practice
David L. Graham, MD
Session Title: Multimodality Management of Non-Small Cell Lung Cancer: Curative and Palliative
Care - Ticketed Session
Session Type: Clinical Problems in Oncology Session
Track: Lung Cancer
Time: 8:00 AM - 9:15 AM
Location: E451b
•
Radiation Therapy in Stage III Non-Small Cell Lung Cancer: Dose, Schedule, and Toxicity
Including Pneumonitis and Esophagitis
Billy W. Loo, MD, PhD
•
Surgery and Other Invasive Interventions as Part of Multimodality Management: Curative
and Palliative
Richard Battafarano, MD, PhD
•
Chemotherapy as Part of Chemoradiotherapy: Regimen, Schedule, and Toxicity Management
Everett E. Vokes, MD - Chair
Session Title: Next-Generation Sequencing Panels for Cancer Risk Assessment
Session Type: Clinical Science Symposium
Track: Cancer Prevention/Epidemiology
Time: 8:00 AM - 9:30 AM
Location: S100a
•
Chair
Adam J. Olszewski, MD
•
Multigene panel testing in patients suspected to have Lynch syndrome. (Abstract 1509)
Matthew B. Yurgelun
•
Next-Generation Sequencing in Gastrointestinal Cancers
Stephen B. Gruber, MD, PhD, MPH
•
Prevalence of mutations in a panel of breast cancer susceptibility genes in patients with early
onset breast cancer. (Abstract 1510)
Kara Noelle Maxwell
•
Multiple-Gene Sequencing in Clinical Breast Cancer Risk Assessment
Allison W. Kurian, MD, MSc
•
A study of ovarian cancer patients tested with a 25-gene panel of hereditary cancer genes.
(Abstract 1511)
Lucy R. Langer
•
Emerging Strategies for Gynecologic Cancer Risk Assessment
Karen H. Lu, MD
•
Panel Question and Answer
Session Title: Gastrointestinal (Colorectal) Cancer
Session Type: Oral Abstract Session
Track: Gastrointestinal (Colorectal) Cancer
Time: 8:00 AM - 11:00 AM
Location: E Arie Crown Theater
•
Chair
George A. Fisher, MD, PhD
•
Chair
Emily K. Bergsland, MD
•
Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and
oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Results of the
German CAO/ARO/AIO-04 randomized phase III trial. (Abstract 3500)
Claus Rodel
•
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and
oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival
results at interim analysis. (Abstract 3501)
Hans-Joachim Schmoll
•
Adjuvant chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) versus 5fluorouracil/leucovorin (FL) for rectal cancer patients whose postoperative yp stage 2 or
3 after preoperative chemoradiotherapy: Updated results of 3-year disease-free survival from
a randomized phase II study (The ADORE). (Abstract 3502)
Yong Sang Hong
•
Clarifying the Role of Chemotherapy in Early-Stage Rectal Cancer
Carmen Joseph Allegra, MD
•
Panel Question and Answer
•
Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no
treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line
treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority
trial (AIO KRK 0207). (Abstract 3503^)
Dirk Arnold
•
Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment
with capecitabine + bevacizumab versus observation after induction treatment with
chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC). (Abstract 3504)
Miriam Koopman
•
At What Price Stability? Value of Maintenance Therapy
Leonard Saltz, MD
•
Panel Question and Answer
Panel Discussion
•
Treatment outcome according to tumor RAS mutation status in OPUS study patients with
metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab.
(Abstract 3505)
Carsten Bokemeyer
•
Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with
metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.
(Abstract 3506)
Fortunato Ciardiello
•
Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer
(CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT
database. (Abstract 3507)
Daniel J. Sargent
•
Impact of adjuvant chemotherapy with 5-FU or FOLFOX in colon cancers with microsatellite
instability: An AGEO multicenter study. (Abstract 3508)
David Tougeron
•
Value of Validated Biomarkers: Clinical and Financial Factors
Neal J. Meropol, MD
•
Panel Question and Answer
Panel Discussion
Session Title: Head and Neck Cancer
Session Type: Oral Abstract Session
Track: Head and Neck Cancer
Time: 8:00 AM - 11:00 AM
Location: E450
•
Chair
A. Dimitrios Colevas, MD
•
The KRAS-variant and cetuximab response in RTOG 0522. (Abstract 6000)
Joanne B. Weidhaas
•
Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT).
(Abstract 6001)
David Ira Rosenthal
•
Genomic profiling using targeted ultra-deep next-generation sequencing for prediction of
treatment outcome after concurrent chemoradiation: Results from the German ARO-0401
trial. (Abstract 6002)
Inge Tinhofer
•
Predictive/Prognostic Markers to Therapy
Vassiliki Papadimitrakopoulou, MD
•
Panel Question and Answer
•
Randomized phase III trial of concurrent chemoradiation with or without neoadjuvant
gemcitabine, carboplatin, and paclitaxel in locally advanced nasopharyngeal cancer.
(Abstract 6003)
Terence Tan
•
Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/
Cisplatin/5-Fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced
Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III factorial
study (NCT01086826). (Abstract 6004)
Maria Grazia Ghi
•
Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant
postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in
high-risk patients with squamous cell carcinoma of the head and neck (SCCHN). (Abstract
6005)
Kevin J. Harrington
•
E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable
oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to
induction chemotherapy (IC). (Abstract LBA6006)
Anthony Cmelak
•
Combined Modality Therapy for Locally Advanced Disease: Where Are We Going?
Quynh-Thu Le, MD
•
Panel Question and Answer
Panel Discussion
•
Randomized placebo-controlled trial (RCT) of erlotinib for prevention of oral cancer (EPOC).
(Abstract 6007)
William Nassib William
•
A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients
with 131I-refractory differentiated thyroid cancer (SELECT). (Abstract LBA6008)
Martin Schlumberger
•
New Treatment Standard in Radioactive Iodine-Refractory Thyroid Cancer?
A. Dimitrios Colevas, MD
•
Panel Question and Answer
Panel Discussion
Session Title: Myeloma
Session Type: Oral Abstract Session
Track: Lymphoma and Plasma Cell Disorders
Time: 8:00 AM - 11:00 AM
Location: E354a
•
Chair
Amit Balkrishna Agarwal, MD, PhD
•
Chair
Alexander M. Lesokhin, MD
•
Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus
bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.
(Abstract 8510^)
Paul G. Richardson
•
E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus
melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma (MM).
(Abstract 8511)
A. Keith Stewart
•
A Decade of Progress in Multiple Myeloma
Robert Z. Orlowski, MD, PhD
•
Panel Question and Answer
•
A phase Ib dose escalation trial of SAR650984 (Anti-CD-38 mAb) in combination with
lenalidomide and dexamethasone in relapsed/refractory multiple myeloma. (Abstract 8512)
Thomas G. Martin
•
Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed
or refractory multiple myeloma (RR MM). (Abstract 8513)
Henk M. Lokhorst
•
Efficacy of siltuximab in patients with previously treated multicentric Castleman’s disease
(MCD). (Abstract 8514)
Frits Van Rhee
•
Monoclonal Antibodies in B-Cell Malignancies
Madhav V. Dhodapkar, MBBS
•
Panel Question and Answer
Panel Discussion
•
Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed
myeloma patients: PFS1, PFS2, OS endpoints. (Abstract 8515)
Antonio Palumbo
•
Health-related quality of life (HRQOL) in transplant-ineligible patients (pts) with newly
diagnosed multiple myeloma (NDMM): Results from the first trial. (Abstract 8516^)
Michel Delforge
•
Survival benefit and cost of autologous hematopoietic stem cell transplantation (Auto HSCT)
in elderly patients with multiple myeloma (MM) using the SEER-Medicare database..
(Abstract 8517)
Gunjan L. Shah
•
Endpoints and Value in Myeloma
Luciano Costa, MD
•
Panel Question and Answer
Panel Discussion
Session Title: Gynecologic Cancer
Session Type: Poster Highlights Session
Track: Gynecologic Cancer
Time: 8:00 AM - 12:45 PM
Display and Networking Time: 8:00 AM - 11:00 AM
Display and Networking Location: E354b
Discussion Time: 11:30 AM - 12:45 PM
Discussion Location: E354a
•
Co-Chair
Matthew A. Powell, MD
•
Co-Chair
Levi S. Downs, MD
Board 1
•
A prospective evaluation of universal tumor testing strategies for Lynch syndrome in
endometrial cancer. (Abstract 5512)
Kari Lassen Ring
Board 2
•
Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial
carcinoma: Final study results. (Abstract 5513)
Vicky Makker
Board 3
•
Advanced or recurrent endometrial cancer (EC) and co-occurring mutations in multiple
oncogenic pathways. (Abstract 5514)
Alexandra Leary
Alexandra Leary
Board 4
•
Phase II, single stage, cohort expansion study of MK-2206 in recurrent endometrial serous
cancer. (Abstract 5515)
Panagiotis Konstantinopoulos
Board 5
•
Molecular profiling of clear cell ovarian carcinoma. (Abstract 5516)
Michael Friedlander
Board 6
•
Combination chemotherapy with temsirolimus and trabectedin for recurrent clear cell
carcinoma of the ovary: A phase II single arm clinical trial. (Abstract 5517)
Masashi Takano
Board 8
•
A phase II randomized open-label study of MM-121, a fully human monoclonal antibody
targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients
with platinum-resistant/refractory ovarian cancers. (Abstract 5519)
Joyce Liu
Board 9
•
Clinical and genetic aspects of ovarian stromal tumors: A report from the International
Ovarian and Testicular Stromal Tumor Registry. (Abstract 5520)
Kris Ann Pinekenstein Schultz
Board 10
•
Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly
paclitaxel for advanced ovarian cancer. (Abstract 5521)
Manish R. Patel
Board 11
•
Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE)
exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients (pts) with platinumresistant/refractory ovarian cancer (OvCa). (Abstract 5522)
John Martignetti
Board 12
•
Randomized phase II trial of NGR-hTNF with an anthracycline in platinum-refractory or resistant ovarian cancer (OC). (Abstract 5523)
Domenica Lorusso
Board 14
•
A phase I study of the vascular-disrupting agent BNC105P in combination with gemcitabinecarboplatin in platinum-sensitive ovarian cancer patients in first or second relapse. (Abstract
5524^)
Danny Rischin
Board 15
•
Adoption and impact of concurrent chemotherapy with radiation in the treatment of patients
with vaginal cancer: A National Cancer Data Base (NCDB) study. (Abstract 5525)
Malolan Sri Rajagopalan
Board 16
•
Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally
advanced cervical cancer: Final results of a multicenter phase II study (Sankai Gynecology
Study Group 013). (Abstract 5526)
Satoshi Yamaguchi
Board 17
•
Phase Ib/II with expansion of patients at the MTD study of olaparib plus weekly
(metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients. (Abstract 5527)
Saul E. Rivkin
Board 18
•
Phase II trial of intraperitoneal (IP) administration of catumaxomab (C) as consolidation
therapy for patients (pts) with relapsed epithelial ovarian cancer (OC) in second or third
complete remission: GEICO 1001 study. (Abstract 5528)
Ignacio Romero
Board 19
•
A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or
placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally
debulked primary ovarian cancer: The TRIO14 trial. (Abstract 5529)
Gottfried E. Konecny
Board 20
•
Phase II prospective study on trabectedin (T) in BRCA-mutated and BRCAness phenotype
advanced ovarian cancer (AOC) patients (pts): The MITO 15 trial. (Abstract 5530^)
Domenica Lorusso
Board 21
•
Meta-analysis of public microarray databases for prognostic and predictive gene signatures
of late-stage ovarian cancer. (Abstract 5531)
Michael J. Birrer
Board 22
•
Molecular profiling of serous ovarian carcinoma to identify extreme response phenotypes and
diagnostic discrepancies. (Abstract 5532)
Douglas A. Levine
Board 23
•
Real-time identification of tumor lesions and response to vintafolide treatment. (Abstract
5533)
Wael A. Harb
Board 24
•
Characterization of ovarian cancer long-term responders on olaparib. (Abstract 5534)
Stephanie Lheureux
Board 25
•
Biomarker correlates from the randomized phase 2 trial of the PARP inhibitor olaparib (O)
with or without the antiangiogenic TKI cediranib (C) in recurrent platinum-sensitive ovarian
cancer (NCT01116648). (Abstract 5535)
Jung-min Lee
Board 26
•
Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in
patients (pts) with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC). (Abstract
5536)
Brian Dougherty
•
Personalizing Endometrial and Clear Cell Treatment
Shannon Neville Westin, MD, MPH
•
Next Generation of Ovarian Cancer Targets
Russell J. Schilder, MD
•
Enhancing Chemotherapy with Novel Agents
Ignace Vergote, MD, PhD
•
Picking the Patients, Not the Drugs
David Michael Hyman, MD
•
Panel Question and Answer
Session Title: Melanoma/Skin Cancers
Session Type: Poster Highlights Session
Track: Melanoma/Skin Cancers
Time: 8:00 AM - 12:45 PM
Display and Networking Time: 8:00 AM - 11:00 AM
Display and Networking Location: E354b
Discussion Time: 11:30 AM - 12:45 PM
Discussion Location: E Arie Crown Theater
•
Co-Chair
Michael Andrew Postow, MD
•
Co-Chair
Geoffrey Thomas Gibney, MD
Board 27
•
Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and
distant metastases: Survival in the pivotal phase II and phase I studies. (Abstract 9012)
Karl D. Lewis
Board 28
•
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma:
Final update (30-month) of the pivotal ERIVANCE BCC study. (Abstract 9013)
Aleksandar Sekulic
Board 29
•
Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: Survival analysis of
6,908 cases from the National Cancer Data Base. (Abstract 9014)
Shailender Bhatia
Board 30
•
Sentinel node biopsy in the initial evaluation of 87 patients with Merkel cell carcinoma.
(Abstract 9015)
Eve Maubec
Board 31
•
Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: Impact
on tumor response and tolerance. (Abstract 9016)
Elisa Funck-Brentano
Board 32
•
BRAF mutation in circulating DNA of melanoma patients at baseline and intertumor
heterogeneity. (Abstract 9017)
Marc G. Denis
Board 33
•
Identification of multiple informative genomic mutations by deep sequencing of circulating
cell-free tumor DNA in plasma of metastatic melanoma patients. (Abstract 9018)
Dave S. B. Hoon
Board 34
•
Droplet digital PCR monitoring of BRAF and NRAS plasma DNA as biomarkers of treatment
response in stage IV melanoma. (Abstract 9019)
David Polsky
Board 35
•
Ultrasensitive detection and identification of BRAF V600 mutations in fresh frozen, FFPE, and
plasma samples of melanoma patients by enhanced-ice-cold-PCR. (Abstract 9020)
Alexandre How-kit
Board 36
•
Development and validation of a gene expression signature to distinguish malignant
melanoma from benign nevi. (Abstract 9021)
Colleen Rock
Board 37
•
Gene expression profile test (GEP) prediction of metastasis-free (MFS) and overall survival
(OS) in a cohort of cutaneous melanoma (CM) patients undergoing sentinel lymph node
biopsy (SLNB). (Abstract 9022)
David H. Lawson
Board 38
•
Analysis of TERT promoter mutations in pediatric melanoma. (Abstract 9023)
Armita Bahrami
Board 40
•
Clustered genomic variants specific to patients who develop immune-related colitis after
ipilimumab for prediction of toxicity. (Abstract 9024)
Ahmad A. Tarhini
Board 41
•
Systemic antitumor effect and clinical response in a phase 2 trial of intratumoral
electroporation of plasmid interleukin-12 in patients with advanced melanoma. (Abstract
9025^)
Adil Daud
Board 42
•
Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): Results
from a phase III trial in patients with stage IIIb-IV melanoma. (Abstract 9026)
Merrick I. Ross
Board 43
•
Efficacy of intralesional Rose Bengal in patients receiving injection of all existing melanoma
in phase II study PV-10-MM-02. (Abstract 9027)
Sanjiv S. Agarwala
Board 44
•
Assessment of immune and clinical efficacy after intralesional PV-10 in injected and
uninjected metastatic melanoma lesions. (Abstract 9028)
Amod Sarnaik
Board 45
•
Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene
laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV
melanoma. (Abstract 9029^)
Igor Puzanov
Board 46
•
Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with
metastatic uveal melanoma. (Abstract 9030)
Sophie Piperno-Neumann
Board 47
•
Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the
efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups.
(Abstract 9031)
Lisa Zimmer
Board 48
•
Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the
treatment of advanced melanomas with c-KIT mutation or amplification. (Abstract 9032)
Celeste Lebbe
Board 49
•
Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult
patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial. (Abstract 9033)
Jose Maria Piulats Rodriguez
Board 50
•
Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label
study of dabrafenib in previously treated metastatic melanoma (NCT01153763). (Abstract
9034)
Paolo Antonio Ascierto
Board 51
•
Treatment patterns and outcomes in BRAF V600E mutant melanoma patients with brain
metastases receiving vemurafenib in the real-world setting. (Abstract 9035)
Geoffrey Thomas Gibney
Board 52
•
A phase II single-arm study of pazopanib and paclitaxel as first-line treatment for patients
with advanced melanoma. (Abstract 9036)
John P. Fruehauf
•
New Treatment Approaches for Nonmelanoma Skin Cancers
Dirk Schadendorf, MD
•
Influence of Genomic Technology on Clinical Practice
Katherine L. Nathanson, MD
•
Evolving Utility of Intralesional Therapy for Melanoma
Axel Hauschild, MD
•
Melanoma Subsets and Outcomes of Patients with BRAF-Mutated Melanoma
Kim Allyson Margolin, MD
•
Panel Question and Answer
Session Title: Patient and Survivor Care
Session Type: Poster Highlights Session
Track: Patient and Survivor Care
Time: 8:00 AM - 12:45 PM
Display and Networking Time: 8:00 AM - 11:00 AM
Display and Networking Location: S102
Discussion Time: 11:30 AM - 12:45 PM
Discussion Location: S100bc
•
Co-Chair
Tara O. Henderson, MD, MPH
•
Co-Chair
Karen L. Smith, MD
Board 1
•
Health and functional status of long-term adult medulloblastoma/PNet survivors: A report
from the Childhood Cancer Survivor Study. (Abstract 9515)
Allison A. King
Board 2
•
Quality of life and cognitive dysfunction in breast cancer survivors on a feasibility study of
donepezil versus placebo. (Abstract 9516)
Julia Lawrence
Board 3
•
Cause-specific mortality among patients with Hodgkin lymphoma (HL) up to 40 years after
treatment. (Abstract 9517)
Michael Schaapveld
Board 4
•
Comparison of primary and secondary breast cancer in adolescents and young adults (AYA).
(Abstract 9518)
Melanie Goldfarb
Board 5
•
Long-term survivorship in adult primary glioblastoma: Clinical and neurological outcomes of a
large, single-center study. (Abstract 9519)
Katherine B. Peters
Board 6
•
Treatment summaries and care plans for post-treatment cancer survivors: Association of
quality of life with empowerment. (Abstract 9520)
Ellen Ingalls Beckjord
Board 7
•
The role of the physician in the prognostic accuracy of advanced cancer patients and their
caregivers. (Abstract 9521)
Rachel Jimenez
Board 8
•
Web-based stepped collaborative care intervention in the context of advanced cancer.
(Abstract 9522)
Jennifer Lynne Steel
Board 9
•
Palliative radiotherapy for bone metastases: Population-based utilization near end of life in a
Canadian province. (Abstract 9523)
Manpreet Singh Tiwana
Board 10
•
Utilization of antineoplastic chemotherapy near the end of life in patients with solid tumors.
(Abstract 9524)
Shilpa Paul
Board 11
•
Results from an interdisciplinary palliative rehabiliation program for patients living with
advanced cancer. (Abstract 9525)
Martin Robert Chasen
Board 12
•
Outpatient management of cancer-related pulmonary embolism: Analysis of 562 consecutive
patients from the EPIPHANY study. (Abstract 9526)
Paula Jiménez-Fonseca
Board 13
•
Cancer worry, anxiety, and behaviors in girls at familial or genetic risk for breast cancer.
(Abstract 9527)
Angela R. Bradbury
Board 14
•
Psychosocial outcomes of siblings of pediatric stem cell transplant survivors. (Abstract 9528)
David Kyle Buchbinder
Board 15
•
Distress and psychiatric morbidity in cancer patients: Prevalence and association with
mortality in a two-year longitudinal study. (Abstract 9529)
Caryn Mei-Hsien Chan
Board 16
•
Efficacy of a video-based psychological intervention for cancer-related insomnia: Results of a
randomized controlled trial. (Abstract 9530)
Josée Savard
Board 17
•
Effect of cognitive behavioral therapy for insomnia (CBT-I) and/or armodafinil on insomnia in
cancer survivors. (Abstract 9531)
Anita Roselyn Peoples
Board 18
•
Omega-3 fatty acids for aromatase inhibitor–induced musculoskeletal symptoms in women
with early-stage breast cancer (SWOG S0927). (Abstract 9532)
Dawn L. Hershman
Board 19
•
Effectiveness trial of a community-based supervised exercise program in cancer survivors.
(Abstract 9533)
Prue Cormie
Board 20
•
Effects of resistance training on fatigue and quality of life in breast cancer patients
undergoing radiotherapy. (Abstract 9534)
Karen Steindorf
Board 21
•
Physical activity during cancer treatment (PACT) study: Short- and long-term effects on
fatigue of an 18-week exercise intervention during adjuvant chemotherapy in patients with
breast or colon cancer. (Abstract 9535)
Anne Maria May
Board 22
•
Effect of exercise on weight, body fat, and serum inflammatory biomarkers in breast cancer
survivors with aromatase inhibitor arthralgias: The hormones and physical exercise (HOPE)
study. (Abstract 9536)
Melinda Irwin
Board 23
•
Genetic associations of fatigue and other symptom domains after breast cancer treatment:
Results from a prospective cohort study. (Abstract 9537)
Kate Webber
Board 24
•
Exercise-induced changes in gene expression, muscular strength, and cancer-related fatigue
in older prostate cancer patients. (Abstract 9538)
Karen Michelle Mustian
Board 25
•
Randomized trial of Tibetan yoga in breast cancer patients undergoing chemotherapy.
(Abstract 9539)
Lorenzo Cohen
•
Cancer Survivorship Outcomes
Paul C. Nathan, MD, MSc
•
Issues in End-of-Life Care
Michael Fisch, MD, MPH
•
The Impact of Cancer on Psychosocial and Behavioral Outcomes
Jennifer Ford, PhD
•
Exercise Interventions and More: Combatting Fatigue, Aches, and Pains in Cancer Survivors
Jennifer A. Ligibel, MD
•
Panel Question and Answer
Session Title: Tumor Biology
Session Type: Poster Highlights Session
Track: Tumor Biology
Time: 8:00 AM - 12:45 PM
Display and Networking Time: 8:00 AM - 11:00 AM
Display and Networking Location: S405
Discussion Time: 11:30 AM - 12:45 PM
Discussion Location: S406
•
Co-Chair
Christina M. Annunziata, MD, PhD
•
Co-Chair
Nicola Normanno
Board 1
•
Detection of BRAF mutations in urine and plasma cell-free DNA: Application to the diagnosis
and management of histiocytic disorder patients. (Abstract 11012)
Omar Ibrahim Abdel-Wahab
Board 2
•
Molecular and genomic characterization of invasive circulating tumor cells (iCTCs) from men
with metastatic castration-resistant prostate cancer (mCRPC). (Abstract 11013)
Terence W. Friedlander
Board 3
•
Monitoring EGFR T790M with plasma DNA in lung cancer patients treated with EGFR tyrosine
kinase inhibitor in prospective observational study. (Abstract 11014)
Naoko Sueoka-Aragane
Board 4
•
Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC).
(Abstract 11015)
Jeanne Tie
Board 5
•
Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and
deep sequencing. (Abstract 11016)
Scott Victor Bratman
Board 6
•
Gene expression profiles of primary tumors versus circulating tumor cells in metastatic breast
cancer. (Abstract 11017)
Wendy Onstenk
Board 7
•
BRCA1-like copy number profiles to predict benefit of high-dose alkylating chemotherapy in
high-risk breast cancer (BC): Results from randomized WSG AM-01 trial. (Abstract 11018)
Philip C. Schouten
Board 8
•
Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21
phase III chemotherapy trial. (Abstract 11019)
Karen A. Gelmon
Board 9
•
Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase
Ib clinical trial. (Abstract 11020)
Yingmiao Liu
Board 10
•
Enhancing the prognostic power of the Nottingham tumor grading system. (Abstract 11021)
Ritu Aneja
Board 11
•
Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts)
with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB
80203 (Alliance). (Abstract 11022)
Ace Joseph Hatch
Board 12
•
Relationship between RECIST response and variation of circulating tumor cells (CTC) for
patients enrolled in phase I trials. (Abstract 11023)
Christophe Massard
Board 13
•
Recurrence score and quantitative ER expression to predict in late distant recurrence risk in
ER+ BC after 5 years of tamoxifen. (Abstract 11024)
Norman Wolmark
Board 14
•
Return of individual research results: Policies and experiences of cancer genomic
researchers. (Abstract 11025)
Lynn G. Dressler
Board 15
•
The use of whole-genome sequencing in therapeutic decision-making in patients with
advanced malignancies. (Abstract 11026)
Howard John Lim
Board 16
•
Comprehensive molecular profiling of advanced gastric cancer (AGC) using NGS and
immunohistochemistry (IHC). (Abstract 11027)
Yasutoshi Kuboki
Board 17
•
Impact of next-generation sequencing (NGS) on treatment decisions in the community
oncology setting. (Abstract 11028)
Lindsay Carol Overton
Board 18
•
Next-generation sequencing (NGS)-based profiling of pancreatic acinar cell carcinoma for
identification of a recurrent SND1-BRAF fusion. (Abstract 11029)
Vincent A. Miller
Board 19
•
Multi-institutional multiplexed genetic analysis in lung adenocarcinoma (AC): The Lung
Cancer Mutation Consortium (LCMC I) experience. (Abstract 11030)
Dara Aisner
Board 20
•
A comprehensive analysis of molecular profiles across over 10,000 tumor and germ-line
exomes across more than 20 tumor types: Novel mechanisms and targets for clinical
treatment. (Abstract 11031)
Shahrooz Rabizadeh
Board 21
•
Intratumor heterogeneity (ITH) of lung adenocarcinomas defined by multiregion whole
exome sequencing (WES). (Abstract 11032)
Jianjun Zhang
Board 22
•
BRCAness in non-small cell lung cancer (NSCLC). (Abstract 11033)
Saiama Naheed Waqar
Board 23
•
Oncogenic ARAF as a new driver in lung adenocarcinoma. (Abstract 11034)
Luiz H. Araujo
Board 24
•
Efficacy of crizotinib in ROS1-rearranged lung cancer: The European experience. (Abstract
11035)
Julien Mazieres
Board 25
•
Identification of a lung cancer growth factor, LASEP1, as a serological and prognostic
biomarker and a therapeutic target. (Abstract 11036)
Atsushi Takano
•
Cell versus Cell-Free Candidate Biomarkers
Ben Ho Park, MD, PhD
•
Predictive versus Prognostic Biomarkers
Elise C. Kohn, MD
•
What Can Next-Generation Sequencing Do for You?
Eric Andrew Collisson, MD
•
Which Target is Next in Lung Cancer?
Alice Tsang Shaw, MD, PhD
•
Panel Question and Answer
Session Title: Pediatric Oncology
Session Type: Poster Highlights Session
Track: Pediatric Oncology
Time: 8:00 AM - 12:45 PM
Display and Networking Time: 8:00 AM - 11:45 AM
Display and Networking Location: S Hall A2
Discussion Time: 11:30 AM - 12:45 PM
Discussion Location: S504
•
Co-Chair
David Mark Loeb, MD, PhD
•
Co-Chair
Lisa Diller, MD
Board 319
•
Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children
and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform
neurofibromas (PNs). (Abstract 10018)
Brigitte C. Widemann
Board 320
•
A phase I study of ruxolitinib in children with relapsed/refractory solid tumors, leukemias, or
myeloproliferative neoplasms: A Children's Oncology Group Phase I Consortium study
(ADVL1011). (Abstract 10019)
Sarah K. Tasian
Board 321
•
Results of nimotuzumab and vinorelbine, radiation, and re-irradiation for diffuse pontine
glioma in childhood. (Abstract 10020)
Maura Massimino
Board 322
•
Hearts too small for body size after doxorubicin for childhood ALL: Grinch syndrome.
(Abstract 10021)
Steven E. Lipshultz
Board 323
•
Risk and impact of pulmonary complications in survivors of childhood cancer: A report from
the Childhood Cancer Survivor Study (CCSS). (Abstract 10022)
Andrew Charles Dietz
Board 324
•
Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin
lymphoma: A report from the Childhood Cancer Survivor Study (CCSS). (Abstract 10023)
Lee Jones
Board 325
•
Late mortality and relapse after dexrazoxane (DRZ) treatment: An update from the Children’s
Oncology Group (COG). (Abstract 10024)
Eric Jessen Chow
Board 326
•
Cardiac outcomes in aging survivors of childhood cancer exposed to cardiotoxic therapy: A
report from the St. Jude Lifetime (SJLIFE) Cohort Study. (Abstract 10025)
Daniel A. Mulrooney
Board 327
•
Immunotherapy (IT) with ch14.18/CHO for high-risk neuroblastoma: First results from the
randomised HR-NBL1/SIOPEN trial. (Abstract 10026)
Ruth L Ladenstein
Board 328
•
Genetic modification of T cells with a novel bispecific chimeric antigen receptor to enhance
the control of high-grade glioma (HGG). (Abstract 10027)
Meenakshi Hegde
Board 329
•
Immune activation and clinical responses following long-term infusion of anti-GD2 antibody
ch14.18/CHO in combination with interleukin-2 in high-risk neuroblastoma patients. (Abstract
10028)
Holger N. Lode
Board 330
•
Validation of the MIBG SIOPEN scoring method in two independent high-risk neuroblastoma
trials. (Abstract 10029)
Ariane Boubaker
Board 331
•
A neuroblastoma risk classification model for developing countries: A study from the
International Neuroblastoma (NB) Risk Group (INRG) database. (Abstract 10030)
Wendy B. London
Board 332
•
Validation of postinduction Curie scores in high-risk neuroblastoma. (Abstract 10031)
Gregory A Yanik
Board 333
•
A phase 2 study of vincristine and irinotecan in metastatic diffuse anaplastic Wilms tumor:
Results from the Children’s Oncology Group AREN0321 study. (Abstract 10032)
Najat C. Daw
Board 334
•
Phase II study of 131I-MIBG with vincristine and 5 days of irinotecan for patients with
relapsed or refractory neuroblastoma. (Abstract 10033)
Steven G. DuBois
Board 335
•
Historical gold standard for time-to-progression (TTP) and progression-free survival (PFS)
from relapsed/refractory neuroblastoma modern era (2002-2014) patients. (Abstract 10034)
Wendy B. London
Board 336
•
Clinical application of comprehensive next-generation sequencing-based genomic profiling for
identification of actionable genomic alterations in pediatric solid tumors and hematolymphoid
malignancies: The Foundation Medicine pediatric experience. (Abstract 10035)
Matthew J. Hawryluk
Board 337
•
Molecular analysis of solid tumors (MAST): A protocol for comprehensive preclinical
evaluation of pediatric solid tumors. (Abstract 10036)
Sara Michele Federico
Board 338
•
Molecular profiling of 267 pediatric cancers to identify potential clinically relevant targets.
(Abstract 10037)
Todd Maney
Board 339
•
Association of genetic variants involved in drug metabolism and transport with efficacy and
toxicity of chemotherapeutic treatment in osteosarcoma patients. (Abstract 10038)
Hanneke I. Vos
Board 340
•
Subsequent neoplasms in the fifth and sixth decades of life in the Childhood Cancer Survivor
Study cohort. (Abstract 10039)
Lucie Marie Turcotte
Board 341
•
Influence of polymorphisms discovered in cell-based model of cytarabine sensitivity on
outcome in pediatric AML: A Children's Oncology Group Study. (Abstract 10040)
Christine L. Phillips
Board 342
•
Treatment and outcome of patients with relapsed clear cell sarcoma of the kidney (CCSK): A
combined SIOP and AIEOP study. (Abstract 10041)
Saskia L Gooskens
Board 343
•
Increased risk of second malignant neoplasms (SMN) in young children with embryonal
rhabdomyosarcoma (ERMS): Evidence for a cancer predisposition syndrome? (Abstract
10042)
Renata Parada Amorim
•
Introduction of New Agents into Childhood Cancer Therapy
Lindsay Baker Kilburn, MD
•
Late Cardiopulmonary Complications of Cancer Therapy
Cindy L. Schwartz, MD, MPH
•
Immune Therapy in Childhood Cancer: Expanding Its Role
Paul M. Sondel, MD, PhD
•
Neuroblastoma Classification Variation by Resource Availability
Julia Lynne Glade Bender, MD
•
Panel Question and Answer
Session Title: Breast Cancer - HER2/ER
Session Type: General Poster Session
Track: Breast Cancer
Time: 8:00 AM - 11:45 AM
Location: S Hall A2
Board 1
•
Total estrogen blockade and chemotherapy in high-risk premenopausal early breast cancer
(BC): Long-term follow-up of a phase II study. (Abstract 537)
Francesco Recchia
Board 2
•
Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR
+) metastatic breast cancer. (Abstract 538)
Murtuza M. Rampurwala
Board 3
•
Identification of patients with hormone receptor–positive breast cancer who need adjuvant
tamoxifen therapy for more than 5 years. (Abstract 539)
Chiao-En Wu
Board 4
•
A simple, validated model for identifying cases that are unlikely to benefit from the 21-gene
recurrence score (RS) assay. (Abstract 540)
Michele Maiko Gage
Board 5
•
Changes in androgen receptor (AR) expression and its phosphorylated isoforms, in breast
cancer (BC) patients treated with neoadjuvant letrozole. (Abstract 541)
Angel Guerrero
Board 6
•
Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC)
patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin
(Met) to placebo (Pl). (Abstract 542)
Mira F. Liebman
Board 7
•
Predictive factors for late (>5 years) distant recurrences in estrogen receptor (ER)-positive,
human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients: >20year follow-up. (Abstract 543)
Jaskirat Singh Randhawa
Board 8
•
IGF-1 receptor activation and intrinsic tamoxifen resistance in postmenopausal breast cancer
patients. (Abstract 544)
Karin Beelen
Board 9
•
Enzalutamide plus exemestane: A pilot study to assess safety, pharmacokinetics, and effects
on circulating estrogens in women with advanced hormone-positive breast cancer. (Abstract
545)
Lee Steven Schwartzberg
Board 10
•
Effect of multifocality and multicentricity on outcome in early breast cancer: A systematic
review and meta-analysis. (Abstract 546)
Francisco Emilio Vera-Badillo
Board 11
•
Association between androgen receptor (AR) expression, Ki-67, and the 21-gene recurrence
score in early breast cancer. (Abstract 547)
Francisco Emilio Vera-Badillo
Board 12
•
First-line pertuzumab (P), trastuzumab (H), and taxane therapy for HER2-positive locally
recurrent/metastatic breast cancer (LR/mBC): Interim safety results (N=704) from PERUSE.
(Abstract 548^)
Thomas Denis Bachelot
Board 13
•
Combined IHC4 score and local recurrence in breast cancer. (Abstract 549)
Roopa Lakhanpal
Board 14
•
Comparison of test results and clinical outcomes of patients assessed with both MammaPrint
and Oncotype DX with pathologic variables: An independent study. (Abstract 550)
David J. Dabbs
Board 15
•
Adjuvant denosumab for breast cancer: What efficacy in the D-CARE trial will translate into
cost effectiveness? (Abstract 551)
Nathan William Dana Lamond
Board 16
•
Cardiology monitoring substudy in the PERSEPHONE trial: 6 versus 12 months of
trastuzumab. (Abstract 552)
Louise Hiller
Board 17
•
A phase I study of the AKT inhibitor MK-2206 plus hormonal therapy in postmenopausal
women with estrogen receptor positive (ER+) metastatic breast cancer (MBC). (Abstract
553)
Cynthia X. Ma
Board 18
•
Intracellular intermolecular relationships of LKB1 in breast cancer. (Abstract 554)
Binafsha Manzoor Syed
Board 19
•
Estrogen receptor-positive (ER+) metastatic breast cancer (MBC) patients (pts) with extreme
responses (ERs) to capecitabine having tumors with genomic alterations in DNA repair and
chromatin remodeling genes. (Abstract 555)
Maren K. Levin
Board 20
•
A phase II clinical trial of HDACi (vorinostat) and AI therapy in breast cancer with molecular
imaging correlates. (Abstract 556)
Hannah M. Linden
Board 21
•
Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the
IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function
suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone
receptor-positive (HR+) early breast cancer (BC). (Abstract 557)
Juerg Bernhard
Board 22
•
SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast
cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous
delivery. (Abstract 558)
Julie Gralow
Board 23
•
An estimation model for Oncotype DX recurrence score using routine histopathologic
variables. (Abstract 559)
Hyunseok Kim
Board 24
•
Preclinical activity of MCLA-128, an ADCC enhanced bispecific IgG1 antibody targeting the
HER2:HER3 heterodimer. (Abstract 560)
Cecile Geuijen
Board 25
•
Does increasing the daily tamoxifen dose in patients with diminished CYP2D6 activity
increase toxicity? (Abstract 561)
Daniel Louis Hertz
Board 26
•
Competing risks of mortality by PAM50 intrinsic subtype: BC tamoxifen-treated cohort.
(Abstract 562)
Judy-Anne W. Chapman
Board 27
•
The impact of intratumoral heterogeneity on the prognosis of ER-positive/HER2-negative
breast cancer. (Abstract 563)
Masahiro Oikawa
Board 28
•
Predictive value of angiogenesis-related gene profiling in patients with HER2-negative
metastatic breast cancer (MBC) treated with bevacizumab and weekly paclitaxel (Bev-Pac).
(Abstract 564)
Andrés Redondo
Board 29
•
Chromosomal copy number alterations (CNAs) for risk assessment of ductal carcinoma in situ
(DCIS). (Abstract 565)
Anosheh Afghahi
Board 30
•
Does endocrine therapy in mucinous and tubular breast cancer improve outcome? (Abstract
566)
Nicola Jane Mitchell
Board 31
•
Clinical outcomes of estrogen receptor (ER)-negative and progesterone receptor (PgR)positive invasive breast cancer. (Abstract 567)
Melissa Chan
Board 32
•
Enobosarm: A targeted therapy for metastatic, androgen receptor positive, breast cancer.
(Abstract 568)
Beth Overmoyer
Board 33
•
Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5azacitidine (5-AZA) and entinostat in advanced breast cancer. (Abstract 569)
Roisin M. Connolly
Board 34
•
The impact of the Oncotype DX recurrence score pathology-clinical (RSPC) on the predicted
recurrence risk for node negative breast cancer patients: A cancer center experience.
(Abstract 570)
Barbara A. Wexelman
Board 35
•
Breast cancer subtypes according to body mass index and insulin resistance. (Abstract 571)
Grazia Arpino
Board 37
•
Cremophor EL-free formulation of paclitaxel: A randomized, multicenter, safety, and efficacy
study of nanosomal paclitaxel lipid suspension (NPLS) versus paclitaxel in women with
metastatic breast cancer (MBC). (Abstract 573)
Ateeq Ahmad
Board 38
•
Prognosis of small tumors according to KI67 and IHC subtypes. (Abstract 574)
Antonella Ferro
Board 39
•
Relation of genes in estrogen and vitamin D signaling to bone mineral density loss in
aromatase inhibitors treatment. (Abstract 575)
Sonia Servitja
Board 40
•
Phase 2 trial of trastuzumab and/or everolimus in hormone-resistant, HER2-negative
metastatic breast cancer. (Abstract 576^)
Amelia Bruce Zelnak
Board 41
•
Follicle stimulating hormone (FSH) as a surrogate parameter for the effectiveness of
endocrine therapy with or without zoledronic acid in premenopausal patients with breast
cancer: An analysis of the prospective ABCSG-12 trial. (Abstract 577)
Georg Pfeiler
Board 42
•
Breast cancer treatment with everolimus and exemestane for ER+ women: Results of the
first interim analysis of the noninterventional trial BRAWO. (Abstract 578)
Diana Lueftner
Board 43
•
Relative bone loss during aromatase inhibitors therapy: The B-ABLE cohort. (Abstract 579)
Sonia Servitja
Board 44
•
Gene expression profiling for identification of FYN in tamoxifen resistance and as predictor of
early recurrence in patients treated with endocrine therapy. (Abstract 580)
Henrik Jorn Ditzel
Board 45
•
Bone turnover markers at 3 months of aromatase inhibitor therapy for prediction of 1-year
bone mineral density loss: The B-ABLE cohort. (Abstract 581)
Ignacio Tusquets
Board 46
•
Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and
overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years
of adjuvant chemotherapy. (Abstract 582)
Joyce O'Shaughnessy
Board 47
•
Population-based evaluation of 21-gene assay in treatment decision making for early breast
cancer in Ontario. (Abstract 583)
Mark Norman Levine
Board 48
•
ERP29 genetic polymorphism and breast cancer susceptibility and prognosis. (Abstract 584)
Gustavo Jacob Lourenco
Board 49
•
Estrogen levels in premenopausal (prem) patients (pts) with hormone-receptor positive (HR
+) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or
tamoxifen (T) in the SOFT trial: SOFT-EST substudy. (Abstract 585)
Meritxell Bellet
Board 50
•
Impact of 21-gene RT-PCR assay on adjuvant therapy for stage I breast cancer. (Abstract
586)
Fanny Le Du
Board 51
•
A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal
antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or
metastatic ER+/PR+, HER2-negative breast cancer. (Abstract 587)
Michaela Jane Higgins
Board 52
•
Residual estrogen receptor availability during fulvestrant 500 mg therapy in patients with
metastatic breast cancer. (Abstract 588)
Michel van Kruchten
Board 53
•
The value of tamoxifen and trastuzumab in breast cancer treatment: A study based on
uptake and use in Sweden. (Abstract 589)
Nils Erik Wilking
Board 54
•
Clinical and pathologic correlation of the activated form of the androgen receptor (AR) in
breast cancer (BC). (Abstract 590)
Philippe Jamme
Board 55
•
A phase 1 study to assess the food effect on the pharmacokinetics (PK) of entinostat.
(Abstract 591)
Denise A. Yardley
Board 56
•
Effect of age and tumor size on prognostic outcome of women with breast cancer. (Abstract
592)
Shaheenah S. Dawood
Board 57
•
Genes associated with serum estrone, estrone conjugates, and androstenedione
concentrations in postmenopausal women with estrogen receptor-positive breast cancer.
(Abstract 593)
Tanda M. Dudenkov
Board 58
•
Impact of marital status on prognostic outcome of women with breast cancer. (Abstract 594)
Shaheenah S. Dawood
Board 59
•
Breast cancer in young women: A single center study. (Abstract 595)
Joanna Rodriguez
Board 60
•
Characteristics of breast cancer in Ghana and prevalence of aggressive disease and high
mortality. (Abstract 596)
Evelyn Mawunyo Jiagge
Board 61
•
Factors influencing recurrence in long-term survivors with early-stage breast cancer of low
risk. (Abstract 597)
Xerxes Pundole
Board 62
•
Phase I-II study of the histone deacetytase inhibitor vorinostat plus sequential weekly
paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. (Abstract
598)
Yifan Tu
Board 63
•
Differential effects of metformin on breast cancer proliferation according to insulin resistance
and tumor subtype in a presurgical trial. (Abstract 599)
Andrea De Censi
Board 64
•
Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial.
(Abstract 600)
Xavier B. Pivot
Board 65
•
Lapatinib or trastuzumab with taxane therapy as first-line treatment in metastatic breast
cancer (MBC): A biomarker analysis in NCIC CTG MA.31. (Abstract 601)
Wendy R. Parulekar
Board 66
•
Transcriptional expression of Bcl-2 as predictive of response to neoadjuvant chemotherapy
with trastuzumab in HER2-positive ER-positive breast cancer patients. (Abstract 602)
Maki Tanioka
Board 67
•
Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial.
(Abstract 603)
Pooja Prem Advani
Board 68
•
Phase I/II study of neoadjuvant eribulin mesylate, carboplatin, and trastuzumab (ECH) for
operable HER2 positive (HER2+) breast cancer. (Abstract 604^)
Lee Steven Schwartzberg
Board 69
•
Relationship between tumor biomarkers (BM) and efficacy in TH3RESA, a phase 3 study of
trastuzumab emtansine (T-DM1) versus treatment of physician’s choice (TPC) in HER2positive advanced breast cancer (BC) previously treated with trastuzumab and lapatinib.
(Abstract 605)
Sung-Bae Kim
Board 70
•
Trastuzumab emtansine (T-DM1) plus capecitabine (X) in patients with HER2-positive MBC:
MO28230 TRAX-HER2 phase 1 results. (Abstract 606)
Karen A. Gelmon
Board 71
•
Survival among elderly breast cancer patients by receipt of human epidermal growth factor
receptor 2-targeted therapy: A matched analysis of national registry data. (Abstract 607)
Jaqueline Willemann Rogerio
Board 72
•
Association of basal marker expression with outcome and trastuzumab resistance in HER2positive breast cancer. (Abstract 608)
Alice P. Chung
Board 73
•
Retrospective analysis of toxicity in patients (pts) with liver metastases (mets) from phase 3
studies of trastuzumab emtansine (T-DM1) in pts with metastatic breast cancer (MBC).
(Abstract 609)
David Miles
Board 74
•
Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of
biosimilars: A physician survey in the United States and emerging markets. (Abstract 610)
Philip Edward Lammers
Board 75
•
Long-term population-based outcomes of adjuvant trastuzumab in HER2-positive early breast
cancer: The British Columbia experience. (Abstract 611)
Stephen K. L. Chia
Board 76
•
Identification and targeting of M-phase progression downstream of HER2 in trastuzumabsensitive and -resistant breast cancer cell lines. (Abstract 612)
E. Aubrey Thompson
Board 77
•
Comparison of recurrent and nonrecurrent breast cancer patients undergoing AE37 peptide
vaccine therapy. (Abstract 613)
Erika J Schneble
Board 78
•
Preliminary results from TRASTYVERE study: A retrospective analysis of HER2-positive
(HER2) metastatic breast cancer (MBC) patients treated in Spain with lapatinib (L) plus
trastuzumab (T). (Abstract 614)
Joaquin Gavila
Board 79
•
Phase I/II study of adoptive T-cell therapy following in vivo priming with a HER2/neu vaccine
in patients with advanced-stage HER2+ breast cancer. (Abstract 615)
Mary L. Disis
Board 80
•
A phase I trial of the safety and immunogenicity of a DNA-based vaccine encoding the
HER2/neu (HER2) intracellular domain in subjects with HER2+ breast cancer. (Abstract 616)
Mary L. Disis
Board 81
•
Effect of serum HER2, TIMP-1, and CAIX on outcome in HER2+ metastatic breast cancer
patients treated in first line with lapatinib or trastuzumab combined with taxane: NCIC CTG
MA.31. (Abstract 617)
Diep Ho
Board 82
•
Correlation of 64Cu DOTA-trastuzumab positron emission tomography (PET) imaging with
HER2 status by immunohistochemistry (IHC). (Abstract 618)
Joanne E. Mortimer
Board 83
•
Phase II study of neoadjuvant weekly paclitaxel and carboplatin with lapatinib in HER2+
breast cancer. (Abstract 619^)
Andrea Li Ann Wong
Board 84
•
Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast
cancer. (Abstract 620)
Marcus Schmidt
Board 85
•
Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX
plus trastuzumab (TZ) in HER2+ breast cancer (BC). (Abstract 621^)
Jordi Rodon Ahnert
Board 86
•
Preclinical in vitro and in vivo evaluation of antitumor activity of poly (ADP-ribose)
polymerase inhibition and trastuzumab combined therapy in HER2-overexpressing breast
cancer. (Abstract 622)
Ignacio Tusquets
Board 87
•
A multicenter randomized study comparing 6 versus 12 months of trastuzumab in
combination with dose-dense docetaxel following FEC as adjuvant treatment of women with
axillary-node–positive or high-risk, node-negative breast cancer overexpressing HER2.
(Abstract 623)
Dimitrios Mavroudis
Board 88
•
Long-term results on trastuzumab (T) in elderly patients (EP) with locally advanced or
metastatic HER2-positive breast cancer (BC). (Abstract 624)
Christian Jackisch
Board 89
•
Evidence of PIK3CA and TP53 co-mutation in breast cancer identification on next-generation
sequencing (NGS) of ERBB2 (HER2)-amplified residual disease following preoperative antiHER2 therapy. (Abstract 625)
Frankie Ann Holmes
Board 90
•
Toward clinical development of SYD985, a novel HER2-targeting antibody-drug conjugate
(ADC). (Abstract 626)
Gijs Verheijden
Board 91
•
Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors
(aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC). (Abstract 627^)
Cristina Cruz Zambrano
Board 92
•
Predictive value of CTCs biomarkers status in patients with metastatic breast cancer (MBC)
receiving anti-HER2 therapy. (Abstract 628)
Zefei Jiang
Board 93
•
Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER
+/- locally recurrent or metastatic breast cancer (BC): Results from two phase II,
multicenter, single-arm studies. (Abstract 629^)
Stefan Gluck
Board 94
•
Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for
progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A
meta-analysis. (Abstract 630^)
Chee Lee
Board 95
•
Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled analysis
by HER2 and ER status. (Abstract 631^)
Chris Twelves
Board 96
•
Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in
patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline
and/or a taxane: NCCTG N0733 (Alliance). (Abstract 632)
Paul Haluska
Board 97
•
Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for nodenegative, HER2-positive breast cancer (BC). (Abstract 633)
Neil M. Iyengar
Board 98
•
Racial/ethnic (RE) differences in the occurrence of HER2 and hormone receptor (HR)defined breast cancer (BC) in California (CA). (Abstract 634)
Scarlett Lin Gomez
Board 99
•
Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as
first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results
from a phase II, single-arm, multicenter study. (Abstract 635^)
Shannon Puhalla
Board 100
•
Anti-HER2 CD4 T helper type 1 response in breast cancer: Is there a role for
immunorestoration? (Abstract 636)
Jashodeep Datta
Board 101
•
New graded prognostic index for breast cancer patients (pts) with brain metastases (BCBM).
(Abstract 637)
Manmeet Singh Ahluwalia
Board 102
•
Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine
versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer
patients. (Abstract 638)
Elizabeth Ann Mittendorf
Board 103
•
Immunohistochemical (IHC) prediction of lapatinib efficacy in HER2-positive advanced breast
cancer patients. (Abstract 639)
Renata Duchnowska
Board 104
•
Survher: A retrospective multicenter study comparing demographic and tumor characteristics
of clinical trials versus clinical practice patients with HER2-positive breast cancer. (Abstract
640)
Grazia Arpino
Board 105
•
Long-term follow up (FU) of patients with durable complete response (DCR) after
chemotherapy (CT) and HER2-targeting systemic therapy (HER2-Tx) for HER2+ metastatic
breast cancer (MBC). (Abstract 641)
Giuseppe Gullo
Board 106
•
Projecting the cost-effectiveness of pertuzumab with trastuzumab and docetaxel in the
neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early breast
cancer. (Abstract 642)
Joseph B. Babigumira
Board 107
•
Trastuzumab (T) and pertuzumab (P)-mediated antibody-dependent cell-mediated
cytotoxicity (ADCC) in tyrosine kinase inhibitor (TKI)-treated breast cancer (BC) cell lines.
(Abstract 643)
Denis Collins
Board 108
•
Effect of adjuvant trastuzumab (T) among patients treated with neoadjuvant T-based
chemotherapy. (Abstract 644)
Mariana Chavez-Mac Gregor
Board 109
•
Meta-analysis of stomatitis incidence in everolimus (EVE) clinical studies and its relationship
with efficacy. (Abstract 645)
Hope S. Rugo
Board 110
•
Disparities among older women with de novo stage IV breast cancer treated with
trastuzumab from 1999 to 2009. (Abstract 646)
Ines Maria Vaz Duarte Luis
Board 111
•
Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with
adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).
(Abstract 647)
Amylou C. Dueck
Board 112
•
Neoadjuvant chemotherapy with nonpegylated liposome-encapsulated doxorubicin (NPLD)
plus cyclophosphamide followed by trastuzumab plus nabpaclitaxel for HER2-positive breast
cancer (BC). (Abstract 648)
Silvana Saracchini
Board 113
•
Correlation of high levels of HER2 measured by multiplex mass spectrometry with increased
overall survival in patients treated with anti-HER2-based therapy. (Abstract 649)
Paolo Nuciforo
Board 114
•
T-DM1 in HER2-positive breast cancer brain metastases (BM). (Abstract 650)
Rupert Bartsch
Board 115
•
A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with
multiple treatment regimens in patients with advanced HER2-positive solid tumors. (Abstract
651)
Donald A. Richards
Board 116A
•
Comparison of weight loss among early-stage breast cancer patients post chemotherapy:
Nutrition education in combination with weight loss acupuncture versus nutrition education
alone. (Abstract TPS652)
Jami Aya Fukui
Board 116B
•
A phase II randomized, double-blind, placebo-controlled multicenter trial evaluating the
efficacy and safety of enzalutamide in combination with exemestane in estrogen or
progesterone receptor-positive and HER2-normal advanced breast cancer. (Abstract TPS653)
Denise A. Yardley
Board 117A
•
Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+)
breast cancer: A phase II feasibility study. (Abstract TPS654)
Erica L. Mayer
Board 117B
•
Phase II, randomized, placebo-controlled study of BYL719 or buparlisib (BKM120) with
letrozole for neoadjuvant treatment of postmenopausal women with HR+/HER2-, PIK3CA
mutant or wild-type, breast cancer (BC). (Abstract TPS655^)
Ingrid A. Mayer
Board 118A
•
PERSEPHONE: Duration of trastuzumab with chemotherapy in patients with HER2-positive
early breast cancer—Six versus twelve months. (Abstract TPS656)
Helena Margaret Earl
Board 118B
•
Bevacizumab plus paclitaxel optimization study with interventional maintenance endocrine
therapy in advanced or metastatic ER-positive HER2-negative breast cancer: JBCRG-M04
(BOOSTER) trial. (Abstract TPS657)
Shigehira Saji
Board 119A
•
A single--blind, randomized, placebo--controlled phase II study to evaluate the impact of oral
bisphosphonate treatment on bone mineral density in osteopenic women receiving adjuvant
aromatase inhibitors: Interim analysis of “BONADIUV” trial. (Abstract TPS658)
Vieri Scotti
Board 119B
•
A phase III randomized trial of niraparib versus physician’s choice in previously treated,
HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC1307-BCG and BIG5-13. (Abstract TPS659)
Konstantinos Tryfonidis
Board 120A
•
Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in participants
with brain metastases from HER2+ breast cancer. (Abstract TPS660)
Otto Metzger-Filho
Board 120B
•
Prevention of stomatitis in patients with hormone receptor–positive advanced breast cancer
treated with everolimus plus exemestane: A phase II study of a steroid-based mouthwash.
(Abstract TPS661)
Hope S. Rugo
Board 121A
•
A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with adotrastuzumab emtansine (T-DM1), in HER2+ metastatic breast cancer (MBC). (Abstract
TPS662)
Virginia F. Borges
Board 121B
•
A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with capecitabine
and trastuzumab, in HER2+ metastatic breast cancer (MBC). (Abstract TPS663)
Erika Paige Hamilton
Board 122A
•
RTOG 1119: Phase II randomized study of whole brain radiotherapy with concurrent
lapatinib in patients with brain metastasis from HER2-positive breast cancer—A collaborative
study of RTOG and KROG (NCT01622868). (Abstract TPS664)
David M. Peereboom
Board 122B
•
Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept
study of ganetespib in first-line treatment of women with metastatic breast cancer. (Abstract
TPS665^)
David A. Cameron
Board 123A
•
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive
breast cancer. (Abstract TPS666)
Kevin Kalinsky
Board 123B
•
A phase II study with lead-in safety cohort of cabazitaxel (C) plus lapatinib (L) as therapy for
HER2+ metastatic breast cancer (MBC) with intracranial metastases (mets). (Abstract
TPS667)
Denise A. Yardley
Board 124A
•
A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in
patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast
cancer. (Abstract TPS668)
Rachel A. Freedman
Board 124B
•
Phase Ib trial of trastuzumab emtansine (TE) in combination with lapatinib (L) plus nabpaclitaxel in metastatic HER2-neu overexpressed breast cancer patients: STELA trial.
(Abstract TPS669)
Tejal Amar Patel
Board 125A
•
Phase 2 feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by
eribulin mesylate with or without prophylactic growth factor (GF) for adjuvant treatment of
early-stage breast cancer (EBC). (Abstract TPS670^)
Tiffany A. Traina
Board 125B
•
A single arm, open-label, phase 2 study of MGAH22 (margetuximab) [fc-optimized chimeric
anti-HER2 monoclonal antibody (mAb)] in patients with relapsed or refractory advanced
breast cancer whose tumors express HER2 at the 2+ level by immunohistochemistry and
lack evidence of HER2 gene amplification by FISH. (Abstract TPS671^)
Mark D. Pegram
Board 126A
•
Phase I study of BYL719 and trastuzumab-MCC-DM1 (T-DM1) in HER2-positive metastatic
breast cancer (MBC) patients with progression on trastuzumab and taxane-based therapy.
(Abstract TPS672)
Sarika Jain
Session Title: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Session Type: General Poster Session
Track: Breast Cancer
Time: 8:00 AM - 11:45 AM
Location: S Hall A2
Board 127
•
Predictors of surgery types after neoadjuvant therapy for advanced stage breast cancer.
(Abstract 1034)
Jamila Alazhri
Board 128
•
Final results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced
metastatic breast cancer (MBC). (Abstract 1035)
Denise A. Yardley
Board 129
•
Prophylactic ciprofloxacin to prevent febrile neutropenia in adjuvant breast cancer patients
receiving docetaxel (nonanthracycline) regimens. (Abstract 1036)
Meena Okera
Board 130
•
Outcomes of 3-weekly doxorubicin and cyclophosphamide followed by paclitaxel (AC/T) in a
randomized trial (RCT) compared to a case-control matched British Columbia (BC) breast
cancer population. (Abstract 1037)
Sheridan Marie Wilson
Board 131
•
ABCB1 polymorphism as a prognostic factor in breast cancer patients with neoadjuvant
chemotherapy. (Abstract 1038)
Hee Jun Kim
Board 132
•
The effects of omega-3 fatty acids on chemotherapy-induced neuropathy and inflammation
in patients with breast cancer. (Abstract 1039)
Ali Esfahani
Board 133
•
Phase II clinical studies of UTD1, an epothilone analog, in metastatic breast cancer.
(Abstract 1040)
Binghe Xu
Board 134
•
Randomized phase II trial comparing docetaxel with or without low-dose metronomic oral
cyclophosphamide in first-line treatment of non-triple-negative advanced breast cancer.
(Abstract 1041)
Leiping Wang
Board 135
•
Comparison of six cycles of epirubicin and paclitaxel (ET) versus four cycles of epirubicin and
cyclophosphamide, followed by four cycles of paclitaxel (EC-T) as adjuvant therapy for
operable breast cancer in women with positive axillary nodes. (Abstract 1042)
Peng Yuan
Board 136
•
Prognostic effect of eribulin-induced liver dysfunction in metastatic breast cancer. (Abstract
1043)
Takayuki Kobayashi
Board 137
•
Three-arm randomized phase II study evaluating oral vinorelbine plus capecitabine versus
paclitaxel plus gemcitabine versus docetaxel plus gemcitabine as first-line chemotherapy in
patients with metastatic breast cancer: Final results (NorCap-CA223 trial). (Abstract 1044)
Saverio Cinieri
Board 138
•
Toxicity and prediction of survival benefit with metronomic chemotherapy in metastatic
breast cancer. (Abstract 1045)
Rabab Mohamed Gaafar
Board 139
•
HIP1 expression and response to chemotherapy in breast cancer. (Abstract 1046)
Mireia Margeli
Board 141
•
First safety results of an international phase II study evaluating oral vinorelbine as a single
agent as first-line chemotherapy for metastatic breast cancer patients with bone metastases
(NorBreast-228 trial). (Abstract 1048)
Guenther G. Steger
Board 142
•
Survival with docetaxel plus capecitabine comparing with vinorelbine plus capecitabine
followed by capecitabine maintenance treatment as first-line therapy in patients with
advanced breast cancer: A phase III randomized clinical trial. (Abstract 1049)
Binghe Xu
Board 143
•
Influence of pluripotent stem cell gene polymorphisms on breast cancer susceptibility and
response to chemotherapy in a north Indian cohort. (Abstract 1050)
Gaurav Agarwal
Board 144
•
Nabrax: Neoadjuvant therapy of breast cancer with weekly single-agent nab-paclitaxel—Final
efficacy and biomarkers analysis of GEICAM 2011-02 trial. (Abstract 1051)
Miguel Martin
Board 145
•
Adding VEGFR-TKIs to chemotherapy and/or hormonal therapy in advanced breast cancer
patients: Results of a meta-analysis. (Abstract 1052)
Yucai Wang
Board 146
•
Phase II study of pseudomonas aeruginosa-mannose-sensitive hemagglutinin in combination
with capecitabine for HER2-negative metastatic breast cancer pretreated with anthracycline
and taxane. (Abstract 1053)
Fangfang Lv
Board 147
•
Paclitaxel-induced severe sensory peripheral neuropathy is associated with NDRG-1 genetic
variant and negative NDRG-1 expression in nerve tissue. (Abstract 1054)
Raghav Sundar
Board 148
•
Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer
patients: A validation study. (Abstract 1055)
Kai Chen
Board 149
•
Bayesian network meta-analysis, comparison of cardiac events associated with liposomal
doxorubicin, epirubicin, and doxorubicin in breast cancer. (Abstract 1056)
Norihiro Yamaguchi
Board 150
•
Assessing the value of weekly blood analysis in patients with localized breast cancer
receiving adjuvant treatment with weekly paclitaxel. (Abstract 1057)
Raul Diez-Fernandez
Board 151
•
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with
weekly paclitaxel (WP) or eribulin (E) followed by doxorubicin and cyclophosphamide (AC) in
women with locally advanced HER2-negative breast cancer (LABC): NSABP FB-9. (Abstract
1058)
Jame Abraham
Board 152
•
Acute toxicity in African American and Caucasian patients with adjuvant/neoadjuvant
chemotherapy for breast cancer. (Abstract 1059)
Mansoor Ul Haq
Board 153
•
Effect of low-dose, short-course sunitinib (Su) on tumor vasculature and tumor blood flow for
enhancement of chemotherapy efficacy in breast cancer. (Abstract 1060)
Andrea Li Ann Wong
Board 154
•
Correlation between clinical tumor stiffness by elastography and response to neoadjuvant
chemotherapy in patients with breast cancer. (Abstract 1061)
Mitsuhiro Hayashi
Board 155
•
A pilot study of dose-dense (biweekly) carboplatin plus paclitaxel with or without
trastuzumab as neoadjuvant treatment for breast cancer. (Abstract 1062)
Teng Zhu
Board 156
•
Is guideline-adherent adjuvant treatment an equivalent option for elderly patients who
cannot participate in adjuvant clinical breast cancer trials? A retrospective multicenter cohort
study of 4,142 patients. (Abstract 1063)
Lukas Schwentner
Board 157
•
Stemness gene expression profile and correlation with clinicopathologic features (CPfs) in
breast cancer (BC) patients (pts). (Abstract 1064)
Giovanni Benedetti
Board 158
•
Application of a dynamic retraining for each patient using case-specific training cohorts to
predict survival in breast cancer patients. (Abstract 1065)
Balazs Gyorffy
Board 159
•
A phase II neoadjuvant trial of sequential triweekly nanoparticle albumin-bound paclitaxel
and cyclophosphamide followed by 5-fluorouracil/epirubicin/ cyclophosphamide in the
treatment of operable breast cancer. (Abstract 1066)
Norio Masumoto
Board 160
•
Impact of pharmacogenetics on docetaxel as neoadjuvant treatment of breast cancer.
(Abstract 1067)
Hanjing Xie
Board 161
•
Cardiovascular magnetic resonance imaging compared to echocardiogram for detecting
doxorubicin-induced cardiotoxicity. (Abstract 1068)
Haleem J. Rasool
Board 162
•
The efficacy and safety of paclitaxel injection concentrate for nano-dispersion (PICN) at two
different doses versus paclitaxel albumin-stabilized nanoparticle formulation in subjects with
metastatic breast cancer (MBC). (Abstract 1069)
Minish Mahendra Jain
Board 163
•
Additional metabolic effects at the neoadjuvant chemotherapy (NCT) of locally advanced
breast cancer (LABC). (Abstract 1070)
Natalya A Abramova
Board 164
•
Neoadjuvant chemotherapy for patients with breast cancer during pregnancy (BCP).
(Abstract 1071)
Sibylle Loibl
Board 165
•
Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative
metastatic breast cancer (MBC): A randomized, placebo-controlled phase II trial. (Abstract
1072)
Frederik Marme
Board 166
•
Response rates of taxane rechallenge in metastatic breast cancer patients, previously treated
with adjuvant taxanes. (Abstract 1073)
Arzu Oguz
Board 167
•
Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in
metastatic breast cancer (MBC). (Abstract 1074)
Robert Wesolowski
Board 168
•
Safety and efficacy of nab-paclitaxel (nab-P) in patients (pts) with metastatic breast cancer
(MBC): Real-world results from a U.S. health insurance database. (Abstract 1075)
Debra A. Patt
Board 169
•
Does chemotherapy schedule matter when combining with bevacizumab? A stratified metaanalysis of randomized controlled trials. (Abstract 1076)
Twan Ying Chang
Board 170
•
Comparison of the clinical treatment score with the adjuvant online score and the risk for
recurrence score for estimating prognosis in early-stage high-risk breast cancer patients: A
Hellenic Cooperative Oncology Group study. (Abstract 1077)
Kyriaki Pliarchopoulou
Board 171
•
Chemosensitivity and endocrine sensitivity predicted by mammaprint and blueprint in the
Neoadjuvant Breast Registry Symphony Trial (NBRST). (Abstract 1078)
Pat W. Whitworth
Board 172
•
High-dose methotrexate for metastatic breast cancer to the central nervous system: A singleinstitution review of 46 patients. (Abstract 1079)
Margaret A. Schwartz
Board 173
•
Effect of overexpression of human kinesin-14 family motor HSET on tumor progression and
clinical outcomes in breast cancer patients. (Abstract 1080)
Vaishali Pannu
Board 174
•
Adjuvant taxane therapy for early-stage breast cancer: A real-world comparison of
chemotherapy regimens in Ontario. (Abstract 1081)
Sofia Torres
Board 175
•
Nonmetastatic inflammatory breast cancer: Evolution of invasive disease-free (IDFS) and
overall survival (OS) over a 21-year period. (Abstract 1082)
Mahmoud Fekih
Board 176
•
Developing and evaluation of a new clinicopathologic response index after neoadjuvant
chemotherapy as a predictor of clinical outcomes in locally advanced breast cancers.
(Abstract 1083)
Tarek M. A. Abdel-Fatah
Board 177
•
Predicting chemotherapy response in invasive breast cancer. (Abstract 1084)
David Harrison
Board 178
•
Amilorides: Familiar antihypertensive medications with a novel potential against breast
cancer. (Abstract 1085)
Jean Paul Atallah
Board 179
•
Centrosome declustering agents: Potential interphase-targeting antimetastatic
chemotherapeutics. (Abstract 1086)
Vaishali Pannu
Board 180
•
Treatment and prognosis of breast cancer patients with brain metastases according to
intrinsic subtype. (Abstract 1087)
Sayaka Kuba
Board 181
•
Cosmetic outcome within one year of breast-conserving surgery, after external beam or
intraoperative radiotherapy for early breast cancer: Objective assessment of patients from a
randomized controlled trial. (Abstract 1088)
Norman R. Williams
Board 182
•
Accuracy of ultrasound during neoadjuvant therapy for breast cancer to predict pathologic
response. (Abstract 1089)
Michael Luke Marinovich
Board 183
•
Local therapy and overall survival for stage IV breast cancer: SEER 1988-2010. (Abstract
1090)
Alexandra Thomas
Board 184
•
Indocyanine green fluorescence imaging system as an alternative to the conventional
sentinel lymph node mapping using a radiotracer in breast cancer. (Abstract 1091)
Tomoharu Sugie
Board 185
•
The influence of radiotherapy on sleep disturbances in breast cancer patients. (Abstract
1092)
Sheela Hanasoge
Board 186
•
Do hospitals in a large metropolitan area utilize published breast cancer care practices and
guidelines? (Abstract 1093)
Christine B. Weldon
Board 187
•
Why women are choosing mastectomy: Influences beyond the surgeon. (Abstract 1094)
Andrea Marie Covelli
Board 188
•
Postoperative complications in nipple-sparing mastectomy. (Abstract 1095)
Erin M Garvey
Board 189
•
Evaluation of cardiac dose reduction with deep inspiration breath hold in patients with leftsided breast cancer receiving adjuvant radiotherapy. (Abstract 1096)
Rosanna Yeung
Board 190
•
The role of surgery in patients with primary metastatic breast cancer (PMBC) receiving
monoclonal antibody treatment. (Abstract 1097)
Jana Barinoff
Board 192
•
A multicenter prospective study of image-guided radiofrequency ablation for small breast
carcinomas. (Abstract 1099)
Takayuki Kinoshita
Board 193
•
Development of a novel nomogram predicting nonsentinel lymph node metastases among
patients with breast cancer after neoadjuvant chemotherapy (NACT): A transSENTINA
substudy. (Abstract 1100)
Cornelia Liedtke
Board 195
•
Mapping of the axilla: Lymph node involvement in level 1, 2, and 3 of the axilla and in the
interpectoral region in early breast cancer. (Abstract 1102)
Andreas Jakob
Board 196
•
The prognostic B2-Score for metastatic breast cancer: An external evaluation of 852
patients. (Abstract 1103)
Achim Wöckel
Board 197
•
Investigating the regulation of e-cadherin mRNA and protein expression by integrin a3ß1 in
breast cancer cells. (Abstract 1104)
Anupam Batra
Board 198
•
Differential response of neoadjuvant chemotherapy with taxane-carboplatin versus taxaneepirubicin in patients with locally advanced triple-negative breast cancer. (Abstract 1105)
Jiayu Wang
Board 199
•
A phase II study of tivantinib (ARQ-197) for metastatic triple-negative breast cancer.
(Abstract 1106)
Sara M. Tolaney
Board 200
•
Frequent BRCA1/2 and BARD1 germline mutations in triple-negative breast cancer patients.
(Abstract 1107)
Jacques De Greve
Board 201
•
The relationship between body mass index, diabetes, and triple-negative breast cancer
prognosis. (Abstract 1108)
Jose Maria Pacheco
Board 202
•
Histopathologic and immunohistochemical findings in triple-negative breast cancers showing
clinical progressive disease during neoadjuvant chemotherapy. (Abstract 1109)
Yuko Tanabe
Board 203
•
Expression of PD-L1 and NY-ESO-1 in early and advanced triple-negative breast cancer.
(Abstract 1110)
Anna Tessari
Board 204
•
Pretreatment neutrophil to lymphocyte ratio may be an useful tool in predicting survival in
early triple-negative breast cancer patients. (Abstract 1111)
Mirco Pistelli
Board 205
•
The role of CHFR as a predictive marker of response to taxane-based preoperative
chemotherapy in triple-negative breast cancer. (Abstract 1112)
Elisavet Paplomata
Board 206
•
Survival outcomes across ethnicities in triple-negative breast cancer. (Abstract 1113)
Moira Katherine Rushton
Board 207
•
The impact of TSG101 in triple-negative breast cancers. (Abstract 1114)
Shiva D.J. Sharma
Board 208
•
Pretreatment platelets count levels as a prognostic factor in triple-negative breast cancer in a
Hispanic cohort. (Abstract 1115)
Saul Campos Gomez
Board 209
•
Antitumoral activity of EC70124, a novel multitarget kinase inhibitor, in triple-negative breast
cancer. (Abstract 1116)
Maria D. Cuenca-Lopez
Board 210
•
Similarities between the biology of breast cancer in Kenya among blacks and that seen
among whites elsewhere. (Abstract 1117)
Nicolas Anthony Othieno-Abinya
Board 211
•
Mutant p53: A therapeutic target for the treatment of triple-negative breast cancer?
(Abstract 1118)
Naoise C. Synnott
Board 212
•
Evaluation of BRCA1/2 mutation status among women with triple-negative breast cancer.
(Abstract 1119)
Axel Muendlein
Board 214
•
Classification of molecular subtypes of triple-negative breast cancer using reverse phase
protein arrays (RPPAs). (Abstract 1121)
Hiroko Masuda
Board 215
•
The outcome of special histologic types of triple-negative breast cancer (TNBC). (Abstract
1122)
Katarzyna Pogoda
Board 216
•
Outcomes of patients with triple-negative breast cancer compared to non-triple negative
breast cancer: A single-center study. (Abstract 1123)
Caroline M. Hamm
Board 217
•
Surgical removal of primary tumor in metastatic breast cancer: Impact on health-related
quality of life (HR-QOL) in a randomized controlled trial (RCT). (Abstract 1124)
Rajendra A. Badwe
Board 218
•
Prognostic value of routinely determined tumor infiltrating lymphocytes in triple-negative
breast cancer. (Abstract 1125)
Jana Pahole Golicnik
Board 219
•
CK14, FOXA1, and androgen receptor (AR) expression in patients (pts) with triple-negative
breast cancer (TNBC). (Abstract 1126)
Ayca Gucalp
Board 220
•
The yield of staging investigations in triple-negative breast cancer patients. (Abstract 1127)
Renee Elizabeth Lester
Board 221
•
Effect of afatinib alone and in combination with dasatinib in triple-negative breast cancer cell
lines. (Abstract 1128)
Mohamed F.K. Ibrahim
Board 222
•
Correlation of Notch1 expression with clinical characteristics, signaling biomarkers, and
survival in breast cancer patients. (Abstract 1129)
Aleksandra Filipovic
Board 223
•
Association of TP53 codon 72 polymorphism with TP53 mutation in triple-negative breast
cancer (TNBC) patients. (Abstract 1130)
Mathilde Födermayr
Board 224
•
Evaluation of lymphocyte infiltrate composition in triple-negative mammary carcinomas and
its association with clinical-pathologic and demographic data. (Abstract 1131)
Geraldine Eltz Lima
Board 225
•
BRCA-mutation status combined with BCL2 protein in prediction of relapse in triple-negative
breast cancer (TNBC) treated with adjuvant anthracycline-based chemotherapy. (Abstract
1132)
Katerina Bouchalova
Board 226
•
A randomized, parallel-arm, phase II trial to assess the efficacy of preoperative ixabepilone
with or without cetuximab in patients with triple-negative breast cancer (TNBC). (Abstract
1133)
Angel Augusto Rodriguez
Board 227A
•
FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in
patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast
cancer. (Abstract TPS1134)
Fabrice Andre
Board 227B
•
Tailored neoadjuvant epirubicin and cyclophosphamide and nanoparticle albumin bound
(nab)-paclitaxel for newly diagnosed breast cancer. (Abstract TPS1135)
Mustafa Khasraw
Board 228A
•
A randomized phase II trial of upfront docetaxel and vinorelbine followed by either
maintenance oral vinorelbine or observation in patients with HER2-negative locally advanced
(LA) or metastatic (M) breast cancer (BC). (Abstract TPS1136)
Fadi Sami Farhat
Board 228B
•
MINT: Multi-institutional, neoadjuvant therapy MammaPrint project. (Abstract TPS1137)
Charles E. Cox
Board 229A
•
A phase II study of eribulin in patients with HER2-negative, metastatic breast cancer:
Evaluation of efficacy, toxicity, and patient-reported outcomes. (Abstract TPS1138)
Otto Metzger-Filho
Board 229B
•
Use of microRNA to identify stage IV breast cancer patients to be targeted with
phospholipase A2 disrupted cisplatin carrying liposomes: An ongoing phase I trial. (Abstract
TPS1139)
Ulrik Niels Lassen
Board 230A
•
Phase I dose-escalating study to evaluate the safety, tolerability, and pharmacokinetic and
pharmacodynamic profiles of Foxy-5 in patients with metastatic breast, colorectal, or
prostate cancer. (Abstract TPS1140)
Peter Grundtvig Soerensen
Board 230B
•
NSABP B-51/RTOG 1304: Randomized phase III clinical trial evaluating the role of
postmastectomy chest wall and regional nodal XRT (CWRNRT) and post-lumpectomy RNRT
in patients (pts) with documented positive axillary (Ax) nodes before neoadjuvant
chemotherapy (NC) who convert to pathologically negative Ax nodes after NC. (Abstract
TPS1141)
Eleftherios P. Mamounas
Board 231A
•
Preoperative PARPi and irradiation (POPI) for women with an incomplete response to
neoadjuvant chemotherapy (NAC) for breast cancer: A phase I trial. (Abstract TPS1142)
Richard C. Zellars
Board 231B
•
SGN-LIV1A, an antibody-drug conjugate (ADC), in patients with LIV-1–positive breast cancer.
(Abstract TPS1143)
Ana Kostic
Board 232A
•
A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with
advanced androgen receptor-positive triple-negative breast cancer. (Abstract TPS1144)
Tiffany A. Traina
Board 232B
•
TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in
patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)—Evaluating the
homologous recombination deficiency (HRD) biomarker. (Abstract TPS1145)
Erica L. Mayer
Board 233A
•
tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or
carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative
breast cancer (mTNBC). (Abstract TPS1146)
Denise A. Yardley
Board 233B
•
Concurrent adjuvant systemic therapy and accelerated radiotherapy in triple-negative breast
cancer: A feasibility trial. (Abstract TPS1147)
Rene Eleanor Ashworth
Board 234A
•
TBCRC028: A phase Ib/II trial of GDC-0941 (a PI3K inhibitor) in combination with cisplatin in
metastatic androgen receptor-negative triple-negative breast cancer (TNBC). (Abstract
TPS1148)
Vandana Gupta Abramson
Board 234B
•
Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin
versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with
early-stage triple-negative breast cancer (TNBC). (Abstract TPS1149)
Gunter Von Minckwitz
Session Title: Pediatric Oncology
Session Type: General Poster Session
Track: Pediatric Oncology
Time: 8:00 AM - 11:45 AM
Location: S Hall A2
Board 344
•
Correlation of childhood acute lymphoblastic leukemia subclones carrying intragenic IKZF1
deletions with relapse. (Abstract 10043)
Peter Hoogerbrugge
Board 345
•
A comprehensive safety trial of chimeric antibody 14.18 (ch14.18) with GM-CSF, IL-2, and
isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: A Children's
Oncology Group study. (Abstract 10044)
Mehmet Fevzi Ozkaynak
Board 346
•
IGF-1R inhibition effect on a yes/SFK bypass resistance pathway: Rational basis for
cotargeting IGF-1R and yes/SFK kinase in rhabdomyosarcoma. (Abstract 10045)
Xiaolin Wan
Board 347
•
Identification of PDGFR-ß activation as a potential bypass resistance pathway in a
rhabdomyosarcoma (RMS) model of acquired resistance to IGF-1 receptor blockade.
(Abstract 10046)
Christine Heske
Board 348
•
Preclinical evidence of craniofacial adverse effect of zoledronic acid in newborn mice:
Potential consequences in pediatric osteosarcoma and Ewing’s sarcoma patients. (Abstract
10047)
Francoise Redini
Board 349
•
Preclinical evidence of positive effect of l-MTP-PE alone or combined with zoledronic acid in
osteosarcoma. (Abstract 10048)
Francoise Redini
Board 350
•
Regorafenib antitumor activity alone and in combination with radio or chemotherapy in
preclinical models of pediatric solid tumors. (Abstract 10049)
Estelle Daudigeos-Dubus
Board 351
•
Molecular screening for cancer treatment optimization (MOSCATO 01) in pediatric patients:
First feasibility results of a prospective molecular stratification trial. (Abstract 10050)
Birgit Geoerger
Board 352
•
Phase I study of proteasome inhibitor bortezomib in combination with irinotecan in patients
with relapsed/refractory neuroblatoma. (Abstract 10051)
Rajen Mody
Board 353
•
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory
solid tumors. (Abstract 10052)
Holly Jane Meany
Board 354
•
Prospective assessment of renal function using cystatin C and functional MRI in children with
newly diagnosed renal tumors. (Abstract 10053)
Elizabeth Fox
Board 355
•
Effect of nerve growth factor administered as eye-drop on visual function in children with
optic glioma-associated visual impairement: A controlled, crossover clinical trial. (Abstract
10054)
Riccardo Riccardi
Board 356
•
A combination chemotherapy, temozolomide (TMZ) with etoposide (VP), in relapsed or
refractory pediatric solid cancer: Preliminary report of randomized phase II study of two
different outpatient setting regimens (rPII). (Abstract 10055)
Atsushi Ogawa
Board 357
•
Complete radiographic responses in pediatric patients with BRAFV600-positive tumors
including high-grade gliomas: Preliminary results of an ongoing phase 1/2a safety and
pharmacokinetics (PK) study of dabrafenib. (Abstract 10056)
Mark W. Kieran
Board 358
•
Heat-shock protein 90 inhibition in pediatric sarcomas. (Abstract 10057)
Fernanda Irene Arnaldez
Board 359
•
Adolescent and young adult oncology (AYAO) patient enrollments onto National Cancer
Institute (NCI)-supported trials from 2000 to 2010. (Abstract 10058)
Nita Seibel
Board 360
•
Evaluation of ciclopirox efficacy in rhabdomyosarcoma. (Abstract 10059)
Alaa Altahan
Board 361
•
IVADo treatment of type II and type III pleuropulmonary blastoma (PPB): A report from the
International PPB Registry. (Abstract 10060)
Leslie Ann Doros
Board 362
•
A phase I study of panobinostat in pediatric patients with refractory solid tumors, including
CNS tumors. (Abstract 10061)
Paul James Wood
Board 363
•
Similar exposure and pharmacokinetics of bevacizumab in pediatric and adult cancer
patients: Analysis of individual data of 152 pediatric patients. (Abstract 10062)
Kelong Han
Board 364
•
Protein network mapping of retinoblastomas for the identification of therapeutic targets.
(Abstract 10063)
Elisa Baldelli
Board 365
•
First-in-pediatrics phase I study of crenolanib besylate (CP-868,596-26) administered during
and after radiation therapy (RT) in newly diagnosed diffuse intrinsic pontine glioma (DIPG)
and recurrent high-grade glioma (HGG). (Abstract 10064)
Cynthia Wetmore
Board 366
•
A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A
Pediatric Brain Tumor Consortium report. (Abstract 10065)
Anuradha Banerjee
Board 367
•
Phase II trial of cixutumumab in combination with temsirolimus in pediatric patients with
recurrent or refractory sarcoma: A report from the Children’s Oncology Group. (Abstract
10066)
Lars M. Wagner
Board 368
•
Characterization of KIAA1549:BRAF fusion in young pilocytic astrocytoma patients through
fluorescence in situ hybridization. (Abstract 10067)
Marileila Varella-Garcia
Board 369
•
The role of MEK inhibition in neuroblastoma tumor cells. (Abstract 10068)
Peter E. Zage
Board 370
•
Evaluation of resources used during care of children with high-risk neuroblastoma (HR NBL)
via merging of cooperative group trial data and administrative data. (Abstract 10069)
Rochelle Bagatell
Board 371
•
Phase 1 trial of decitabine and CT antigen-specific vaccine in relapsed pediatric solid tumors.
(Abstract 10070)
Rani George
Board 372
•
Fenretinide (4-HPR)/Lym-X-Sorb (LXS) oral powder plus ketoconazole in patients with highrisk (HR) recurrent or resistant neuroblastoma: A New Approach to Neuroblastoma Therapy
(NANT) Consortium trial. (Abstract 10071)
Barry James Maurer
Board 373
•
Discrepancies in treatment of osteosarcoma according to insurance coverage: A review of
the National Cancer Data Base. (Abstract 10072)
Mimi Longo
Board 374
•
Preclinical evaluation of PARP inhibitors in combination with DNA-damaging agents in a
Ewing sarcoma orthotopic xenograft model. (Abstract 10073)
Elizabeth Stewart
Board 375
•
Postrecurrence survival for pediatric extracranial malignant germ cell tumors: A report from
the Malignant Germ Cell Tumors International Collaborative (MaGIC) Group. (Abstract
10074)
Furqan Shaikh
Board 376
•
Metastatic melanoma presenting during childhood: NCI Pediatric Oncology Branch
experience. (Abstract 10075)
Melinda S. Merchant
Board 377
•
Proton radiation for treatment of infratentorial brain tumors in infants and very young
children. (Abstract 10076)
Christine E. Hill-Kayser
Board 378
•
Outcomes after proton radiotherapy for localized childhood ependymoma (EP). (Abstract
10077)
Christine E. Hill-Kayser
Board 379
•
A phase I study of cabozantinib (XL184) in children and adolescents with recurrent or
refractory solid tumors, including CNS tumors: A Children’s Oncology Group phase I
consortium trial. (Abstract 10078)
Meredith K. Chuk
Board 380
•
Risk of subsequent malignant neoplasms in long-term retinoblastoma survivors following
chemotherapy and radiotherapy. (Abstract 10079)
Jeannette R Wong
Board 381
•
Individual risk prediction of major cardiovascular events after cancer: A Childhood Cancer
Survivor Study report. (Abstract 10080)
Eric Jessen Chow
Board 382
•
Myocardial strain for detection of treatment-related cardiac dysfunction in adult survivors of
childhood cancer: Results from the St. Jude lifetime cohort study. (Abstract 10081)
Gregory T. Armstrong
Board 383
•
Breast cancer following spinal radiotherapy for a childhood cancer: A report from the
Childhood Cancer Survivor Study (CCSS). (Abstract 10082)
Chaya S. Moskowitz
Board 384
•
Plasma microRNAs: Novel markers of cardiotoxicity in children undergoing anthracycline
chemotherapy. (Abstract 10083)
Kasey Joanne Leger
Board 385
•
Risk of second thyroid cancer (STC) among survivors of childhood cancer. (Abstract 10084)
Rafaela Naves
Board 386
•
Extracting predictor variables for late effects of childhood cancer treatments from clinical
notes. (Abstract 10085)
Robert M Johnson
Board 387
•
Young and uninsured: Insurance patterns of recently diagnosed adolescent and young adult
cancer survivors in the AYA HOPE study. (Abstract 10086)
Helen M. Parsons
Board 388
•
Investigating the effectiveness of the cognitive remediation and cognitive behavior therapy
skills training program (CRCST). (Abstract 10087)
Jun Zhao
Board 389
•
Transitioning childhood cancer survivors to adult care: A survey of pediatric oncologists.
(Abstract 10088)
Lisa Brazzamano Kenney
Board 390
•
Contraceptive recommendations for young women during cancer treatment: Examining
contraceptive knowledge of pediatric oncology clinicians. (Abstract 10089)
Sloane L. York
Board 391
•
Knowledge, attitudes, and beliefs of parents toward whole-genome sequencing in pediatric
cancer. (Abstract 10090)
Jenny Ruiz
Board 392
•
Effect of topical clonidine on the duration and severity of radiation-induced oral mucositis
(OM) in a translational hamster model. (Abstract 10091)
Pierre Attali
Board 393
•
Mediating role of emotional symptoms on assessment of health-related quality of life of adult
survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. (Abstract
10092)
I-Chan Huang
Board 394
•
Cardiotoxicity and second malignant neoplasms associated with dexrazoxane in children and
adolescents: A systematic review of randomized trials and nonrandomized studies. (Abstract
10093)
Furqan Shaikh
Board 395A
•
SIOPEL 6: A multicenter open-label randomized phase III trial of the efficacy of sodium
thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy
for standard-risk hepatoblastoma (SR-HB). (Abstract TPS10094)
Rudolf Maibach
Board 395B
•
Phase I/IIa multicenter trial for high-risk and recurrent neuroblastoma: Anti-GD2 antibody
(ch14.18) immunotherapies using M-CSF or G-CSF. (Abstract TPS10095)
Hiroshi Kawamoto
Session Title: Sarcoma
Session Type: General Poster Session
Track: Sarcoma
Time: 8:00 AM - 11:45 AM
Location: S Hall A2
Board 241
•
Efficacy of novel proteasome inhibitory platinum complex against osteosarcoma. (Abstract
10534)
Kentaro Igarashi
Board 242
•
Impact of excision repair cross-complementation group 1 (ERCC1) protein on survival of
patients with osteosarcoma treated with cisplatin-based chemotherapy. (Abstract 10535)
Kentaro Igarashi
Board 243
•
Molecular targeted therapy for osteosarcoma using glycogen synthase kinase-3 beta (GSK3ß) inhibitors. (Abstract 10536)
Shingo Shimozaki
Board 244
•
Is non-HD–MTX based, dose-dense, combination chemotherapy a valid choice in
osteosarcoma in developing world? (Abstract 10537)
Jyoti Bajpai
Board 245
•
A controlled, nonrandomized clinical research on chemotherapy combined with re-endostatin
for stage IIB ostosarcoma. (Abstract 10538)
Hairong Xu
Board 246
•
Dendritic cells immunotherapy for patients with malignant bone and soft tissue tumors.
(Abstract 10539)
Hideji Nishida
Board 247
•
Outcome and prognostic factors in localized osteosarcoma with uniform chemotherapy
protocol: A single-center experience of 234 cases. (Abstract 10540)
Vijaya Murugan
Board 248
•
Gemcitibine (G) and docetaxel (D) in relapsed and unresectable high-grade osteosarcoma
after failure of standard multimodal therapy. (Abstract 10541)
Emanuela Palmerini
Board 249
•
Osteosarcoma of the head and neck (OHN): A multicenter case series of 79 adult patients in
the Netherlands. (Abstract 10542)
Eline Boon
Board 250
•
Mouse models to study cancer stem cells in osteosarcoma. (Abstract 10543)
Nino Carlo Rainusso
Board 251
•
Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with
gastrointestinal stromal tumor. (Abstract 10544)
Dong Hoe Koo
Board 252
•
Impact of underestimation of risk on treatment duration and recurrence in GIST patients.
(Abstract 10545)
Annie Guérin
Board 253
•
Correlation of PET/CT and CT RECIST response in GIST patients with PDGFRA D842V gene
mutations treated with crenolanib. (Abstract 10546)
Jennifer Madeline Matro
Board 254
•
MDCT and clinicopathologic characteristics of small bowel gastrointestinal stromal tumors
(GISTs) in 102 patients: A single-institute experience. (Abstract 10547)
Akshay Dwarka Baheti
Board 255
•
Do CT features predict the behavior of treatment-naive gastric GIST? (Abstract 10548)
Ailbhe C. O'Neill
Board 256
•
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients (pts) with
gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatmentuse (TU) trial. (Abstract 10549)
Peter Reichardt
Board 257
•
Analysis of serum protein biomarkers and circulating tumor (ct) DNA for activity of dovitinib
in patients (pts) with tyrosine kinase inhibitor (TKI)-refractory gastrointestinal stromal
tumors (GIST). (Abstract 10550)
Changhoon Yoo
Board 258
•
Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: A report of
the U.K. Managed Access Program. (Abstract 10551)
Marco Maruzzo
Board 259
•
Second primary malignances (SPMs) in patients with gastrointestinal stromal tumors (GIST):
The potential influence of imatinib treatment. (Abstract 10552)
Anna Estival
Board 260
•
Prognostic value of miR-196, IDO, and AXL in patients (p) with localized gastrointestinal
stromal tumors (GIST). (Abstract 10553)
Jose Luis Cuadra-Urteaga
Board 261
•
Metastatic pattern of late metastases of gastrointestinal stromal tumors and the contribution
radiation therapy for disease control. (Abstract 10554)
Peter Hohenberger
Board 262
•
Effect of secondary KIT mutations on growth of GIST cells in the absence of selective
pressure by imatinib in isogenic models of imatinib resistance. (Abstract 10555)
Susanne Grunewald
Board 263
•
Predictive ability of blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in
gastrointestinal stromal tumors (GIST). (Abstract 10556)
Jennifer M. Racz
Board 264
•
The relationship between overall survival (OS) and progression-free survival (PFS) in
gastrointestinal stromal tumor (GIST). (Abstract 10557)
Ipek Özer Stillman
Board 265
•
Extra-gastrointestinal stromal tumors (eGISTs): Experience of a cooperative group. (Abstract
10558)
Matias Chacon
Board 266
•
Relationship of grade to prognosis in localized primary angiosarcoma of the breast (PAOB).
(Abstract 10559)
Manjari Pandey
Board 267
•
A phase I/II study of azacitidine in combination with temozolomide in patients with
unresectable or metastatic soft tissue sarcoma or malignant mesothelioma. (Abstract 10560)
Gleneara Elizabeth Bates
Board 268
•
Radiologic signs of adipocytic maturation (AM) in dedifferentiated liposarcoma (ddLPS)
patients (pts) treated with trabectedin (T): Correlation with disease control. (Abstract 10561)
Sree Harsha Tirumani
Board 269
•
Detection of MDM2 gene amplification in soft tissue sarcoma by FISH. (Abstract 10562)
Hiroaki Kimura
Board 270
•
Phase I study of NBTXR3 nanoparticles, in patients with advanced soft tissue sarcoma (STS).
(Abstract 10563)
Sylvie Bonvalot
Board 271
•
Synovial sarcoma: Evaluation of response to treatment with gemcitabin and docetaxel.
(Abstract 10564)
Sausan Abouharb
Board 272
•
Clinical features, outcomes, and prognostic factors in patients with extraskeletal
osteosarcoma. (Abstract 10565)
Sheila Thampi
Board 273
•
Patterns of chemotherapy administration in soft tissue sarcoma (STS) and impact on overall
survival (OS): A National Cancer Database (NCDB) analysis. (Abstract 10566)
Sujana Movva
Board 274
•
Phase II study of eribulin mesylate in patients (pts) with advanced soft tissue sarcoma
(STS). (Abstract 10567)
Yoichi Naito
Board 275
•
Alliance A091103: A multicenter phase II study of the angiopoietin-1 and -2
peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS). (Abstract 10568)
Sandra P. D'Angelo
Board 276
•
Predictive biomarkers of trabectedin (TR) and olaparib (OL) synergism in preclinical models
of bone and soft tissue sarcoma (BSTS). (Abstract 10569)
Ymera Pignochino
Board 277
•
Late relapse in soft tissue sarcoma: Prognostic factors for recurrence after 3 years. (Abstract
10570)
Karim Boudadi
Board 278
•
Phase I study of neoadjuvant gemcitabine combined with radiation therapy for patients with
high-risk extremity and trunk soft tissue sarcomas. (Abstract 10571)
William W. Tseng
Board 279
•
Trabectedin-related liver toxicity in soft tissue sarcoma patients: Always a good reason to
discontinue the treatment? (Abstract 10572)
Bruno Vincenzi
Board 280
•
Nilotinib as co-adjuvant treatment with doxorubicin in sarcomas: Phase I trial results—A
Spanish Group for Research on Sarcoma (GEIS) study. (Abstract 10573)
Javier Martin Broto
Board 281
•
Prognostic value of peroxisome proliferator-activated receptor gamma expression on clinical
outcome of myxoid liposarcoma. (Abstract 10574)
Akihiko Takeuchi
Board 282
•
Locally advanced high-grade extremity soft tissue sarcoma: Response with novel approach to
neoadjuvant chemoradiation using induction spatially fractionated GRID radiotherapy
(SFGRT). (Abstract 10575)
Mohammed Mohiuddin
Board 283
•
Survival and outcomes of critically ill sarcoma patients admitted to the intensive care unit.
(Abstract 10576)
Rohan Gupta
Board 284
•
Prognostic factors for high-grade soft tissue sarcomas (STS) in the extremities treated by
perioperative chemotherapy with ifosfamide (IFO) and doxorubicin hydrochloride (ADM):
Using the data from Japan Clinical Oncology Group trial (JCOG0304). (Abstract 10577)
Kazuhiro Tanaka
Board 285
•
Primary epithelioid angiosarcoma. (Abstract 10578)
Silvia Stacchiotti
Board 286
•
Pazopanib in uterine sarcoma (UtS): Review of two European Organisation for Research and
Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft
tissue sarcoma (STS). (Abstract 10579)
Isabelle Laure Ray-Coquard
Board 287
•
Correlation of different CT densities of untreated dedifferentiated liposarcoma (ddLPS) with
rate of growth. (Abstract 10580)
Sree Harsha Tirumani
Board 288
•
Improved survival in an exhaustive population based on a cohort of liposarcoma (LPS)
patients treated in expert centers according to clinical practice guidelines (CPG'S):
Experience from Rhone Alpes (RA) region. (Abstract 10581)
Olfa Derbel
Board 289
•
Predictors of overall survival in patients diagnosed with desmoplastic small round cell tumor
(DSRCT). (Abstract 10582)
Alexander Noor Shoushtari
Board 290
•
Defining the chemotherapy (CT) response in well-differentiated (WD) and dedifferentiated
(DD) liposarcomas (LPS) of the retroperitoneum (RP): A tertiary referral cancer center
experience. (Abstract 10583)
Neeta Somaiah
Board 291
•
Prognostic factors in hemangioendotheliomas (HE): Analysis based on the Surveillance,
Epidemiology, and End Results (SEER) program. (Abstract 10584)
Monica Reddy Muppidi
Board 292
•
Multicenter retrospective analysis of 31 patients with aggressive angiomyxoma. (Abstract
10585)
Roberta Sanfilippo
Board 293
•
The role of pazopanib in various histologic subtypes of metastatic soft tissue sarcomas.
(Abstract 10586)
Kwai Han Yoo
Board 294
•
A phase 1b food effect study of the first-in-class, oral, selective inhibitor of nuclear export
(SINE) selinexor (KPT-330) in patients (pts) with advanced sarcomas. (Abstract 10587)
Mrinal M. Gounder
Board 295
•
Malignancy grade and immunohistochemical myogenic/rhabdomyoblastic differentiation as
an outcome determinant in retroperitoneal liposarcoma. (Abstract 10588)
Alessandro Gronchi
Board 296
•
Extraskeletal myxoid chondrosarcoma: A retrospective analysis of 69 patients with localized
disease and molecularly confirmed diagnosis. (Abstract 10589)
Anna Paioli
Board 297
•
Aplidine in patients with dedifferentiated liposarcomas: A French Sarcoma Group (FSG)
study. (Abstract 10590)
Antoine Italiano
Board 298
•
Brain metastases in sarcoma patients: Incidence and outcome. (Abstract 10591)
Mathias Hoiczyk
Board 299
•
Activity of chemotherapy in a series of patients with locally advanced or metastatic
pleomorphic rhabdomyosarcoma: A retrospective analysis. (Abstract 10592)
Michela Libertini
Board 300
•
Mitomycin C, doxorubicin, and cisplatin as a safe and effective preoperative chemoradiation
cocktail for soft tissue sarcomas. (Abstract 10593)
Meera Sridharan
Board 301
•
Phase II study of gemcitabine (GEM) plus sirolimus (SIR) in previously treated patients with
advanced soft tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS)
study. (Abstract 10594)
Xavier Garcia del Muro
Board 302
•
Diversity and heterogeneity in molecular analysis of advanced sarcomas: The clinical,
regulatory, and financial challenge for drug development and precision medicine. (Abstract
10595)
Vivek Subbiah
Board 303
•
14-day continuous infusion ifosfamide in advanced refractory sarcomas. (Abstract 10596)
Arun S. Singh
Board 304
•
Modified isolated lung perfusion technique for allowance of prolonged perfusion without
acute lung injury: A preclinical study with doxorubicin. (Abstract 10597)
Pedro Augusto Reck dos Santos
Board 305
•
Predictive value of BRCA1 haplotype for trabectedin efficacy in patients with advanced softtissue sarcoma. (Abstract 10598)
Audrey Laroche
Board 306
•
Low-dose gemcitabine doxorubicin and docetaxel combination in patients with
advanced/unresectable/metastatic sarcoma who failed prior chemotherapy: Updated
analysis. (Abstract 10599)
Vivek Narasimhan
Board 307A
•
Phase 1 dose escalation trial of intravenous radium 223 dichloride alpha-particle therapy in
osteosarcoma. (Abstract TPS10600)
Vivek Subbiah
Board 307B
•
A phase I/II study of sunitinib in young patients with advanced gastrointestinal stromal
tumor. (Abstract TPS10601)
Arnauld Verschuur
Board 308A
•
Rego-SARC: Activity and safety of regorafenib (RE) in patients with metastatic soft-tissue
sarcoma (STS) previously treated with anthracyclin-based chemotherapy—A multinational,
randomized, placebo-controlled phase II trial. (Abstract TPS10602)
Stephanie Clisant
Board 308B
•
SARC023: Phase I/II trial of ganetespib in combination with sirolimus for refractory sarcomas
and malignant peripheral nerve sheath tumors (MPNST). (Abstract TPS10603)
AeRang Kim
Board 309A
•
A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue
sarcomas. (Abstract TPS10604)
Lauren Elizabeth Nye
Session Title: ASCO/European CanCer Organisation (ECCO) Joint Session: Value and Cancer Care
Session Type: Special Session
Track: Special Session
Time: 9:45 AM - 11:00 AM
Location: S100bc
•
Welcome and Introductions
Martine J. Piccart-Gebhart, MD, PhD - Co-Chair
•
ESMO-EONS: Value and the Exchange between Physicians, Nurses, and Patients
Elisabeth De Vries, MD, PhD
•
Cancer Care in Cost-Restrained Health Care Systems
Richard Sullivan, PhD
•
American Perspective on Globally Defining Value in Cancer Care
Lowell E. Schnipper, MD
•
Closing Comments
Clifford A. Hudis, MD, FACP - Co-Chair
Session Title: Cancer Genomics and Inherited Risk: Recent Advances and Current Challenges
Session Type: Education Session
Track: Cancer Genetics
Time: 9:45 AM - 11:00 AM
Location: S404
•
Next-Generation Sequencing: Basic Principles and Interplay of Tumor and Germ-Line
Genomes
Stephen J. Chanock, MD - Chair
•
Application of "Panel Tests" in Practice
Allison W. Kurian, MD, MSc
•
New Syndromes and New Conundrums Posed by Next-Generation Sequencing
Kenneth Offit, MD, MPH
•
Panel Question and Answer
Session Title: Golden Jubilee: 50 Years of Advances in Sarcoma
Session Type: Education Session
Track: Sarcoma
Time: 9:45 AM - 11:00 AM
Location: S406
•
Surgical Advances in Soft Tissue and Bone Sarcoma
Robert Mikael Henshaw, MD
•
Advances in Sarcoma Radiation Oncology
Dian Wang, MD, PhD
•
Moving the Needle: From Conventional Chemotherapy to Targeted Therapy in Sarcoma
Shreyaskumar Patel, MD - Chair
•
Panel Question and Answer
Session Title: Navigating a Changing Sea: Optimizing Treatment of Hormone Receptor–Positive
Breast Cancer
Session Type: Education Session
Track: Breast Cancer
Time: 9:45 AM - 11:00 AM
Location: N Hall B1
•
How Long Is Long Enough? Defining Optimal Duration and Selection of Adjuvant Endocrine
Therapy for Breast Cancer
Ian E. Smith, MD - Chair
•
Understanding, Predicting, and Managing Toxicity of Endocrine Therapy
N. Lynn Henry, MD, PhD
•
Ovarian Suppression in Premenopausal Patients: Why, How, When?
Deborah Toppmeyer, MD
•
Panel Question and Answer
Session Title: Tumor Boards: Optimizing the Structure and Improving Efficiency of
Multidisciplinary Treatment of Patients with Cancer Worldwide
Session Type: Education Session
Track: Professional Development
Time: 9:45 AM - 11:00 AM
Location: S504
•
Effect of Tumor Boards on the Diagnosis and Treatment of Patients with Cancer:
International Perspectives
Nagi S. El Saghir, MD, FACP - Chair
•
Tumor Boards: What to Do and What Not to Do
Lesley Fallowfield, DPhil
•
What We Know about Tumor Boards: Research from the United States
Nancy Lynn Keating, MD, MPH
•
Incorporation of Guidelines into the Structure of Tumor Boards
Robert W. Carlson, MD
•
Panel Question and Answer
Session Title: Tips for Successful Contract Negotiation - Ticketed Session
Session Type: Meet the Professor Session
Track: Professional Development
Time: 9:45 AM - 11:00 AM
Location: E451a
•
Tips for Successful Contract Negotiation
Joan M. Gilbride, JD
•
Tips for Successful Contract Negotiation
Margaret J. Davino, JD, MBA
Session Title: Raising the Bar: Moving toward Improved Outcomes in Myelodysplastic Syndromes
- Ticketed Session
Session Type: Clinical Problems in Oncology Session
Track: Leukemia, Myelodysplasia, and Transplantation
Time: 9:45 AM - 11:00 AM
Location: E451b
•
Controversies in Transplant for Myelodysplastic Syndrome
John Koreth, MBBS
•
Novel Therapies: Moving beyond One Drug
Jean-Pierre J. Issa, MD - Chair
Session Title: Genitourinary (Nonprostate) Cancer
Session Type: Oral Abstract Session
Track: Genitourinary Cancer
Time: 9:45 AM - 12:45 PM
Location: E Hall D1
•
Chair
Stephen Michael Keefe, MD
•
Chair
Guru Sonpavde, MD
•
Final results of EORTC intergroup randomized phase III trial comparing immediate versus
deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0
transitional cell carcinoma (TCC) of the bladder. (Abstract 4500)
Cora N. Sternberg
•
Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma.
(Abstract 4501)
Andrea Borghese Apolo
•
Bladder Cancer: A Perennial Question and a New Direction
Dean F. Bajorin, MD
•
Panel Question and Answer
•
Validation of a 16-gene signature for prediction of recurrence after nephrectomy in stage IIII clear cell renal cell carcinoma (ccRCC). (Abstract 4502)
Bernard J. Escudier
•
Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or
sunitinib-treated patients with renal cell carcinoma (RCC). (Abstract 4503)
Toby Johnson
•
Emerging Biomarkers in Renal Cell Carcinoma
Martin Henner Voss, MD
•
Panel Question and Answer
Panel Discussion
•
Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma
(mRCC). (Abstract 4504)
Hans J. Hammers
•
Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell
carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial. (Abstract 4505)
Nizar M. Tannir
•
Tackling Novel Combinations and Rare Histologies in Renal Cell Carcinoma
Primo Lara, MD
•
Panel Question and Answer
Panel Discussion
•
International randomized, double-blind, placebo-controlled, phase 3 study of linsitinib (OSI906, L) in patients (pts) with locally advanced or metastatic adrenocortical carcinoma (ACC).
(Abstract 4507)
David I. Quinn
•
Management of clinical stage I seminomatous testicular cancer: A report from SWENOTECA.
(Abstract 4508)
Torgrim Tandstad
Session Title: Health Services Research
Session Type: Oral Abstract Session
Track: Health Services Research
Time: 9:45 AM - 12:45 PM
Location: E253
•
Chair
Craig Evan Pollack, MD
•
Chair
Helen M. Parsons, PhD, MPH
•
Impact of state-specific Medicaid policies on timely receipt of breast cancer surgery.
(Abstract 6500)
Michael T. Halpern
•
Low-dose computed tomography lung cancer screening in the Medicare program: Projected
clinical, resource, and budget impact. (Abstract 6501)
Joshua A. Roth
•
Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of
metastatic colorectal cancer (mCRC). (Abstract 6502)
Daniel A. Goldstein
•
Using Health Services Research to Inform Health Policy
Sandra L. Wong, MD, MS
•
Panel Question and Answer
•
Is advanced imaging in early-stage breast cancer ever warranted? Exploring benchmarks for
an ASCO Choosing Wisely quality measure. (Abstract 6503)
Tian Zhang
•
Relationship between surgical oncologic outcomes and publically reported hospital quality
measures. (Abstract 6504)
Jason Dennis Wright
•
Measuring compliance to oral antineoplastic agents: A comparison between administrative
data and medical records. (Abstract 6505)
Winson Y. Cheung
•
Methodologic Issues in Measuring Quality Using Administrative Data
Michael J. Hassett, MD, MPH
•
Panel Question and Answer
Panel Discussion
•
MD Anderson’s Oncology Expert Advisor powered by IBM Watson: A Web-based cognitive
clinical decision support tool. (Abstract 6506)
Koichi Takahashi
•
Initial utilization of Oncotype DX in the Medicare population between 2005 and 2007.
(Abstract 6508)
Michaela Ann Dinan
•
Is the Future Here? Novel Technologies in Decision Making
Alok A. Khorana, MD
•
Panel Question and Answer
Panel Discussion
Session Title: Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Session Type: Oral Abstract Session
Track: Lung Cancer
Time: 9:45 AM - 12:45 PM
Location: E Hall D2
•
Chair
Scott N. Gettinger, MD
•
Chair
Maria Catherine Pietanza, MD
•
A multinational phase III randomized trial with or without consolidation chemotherapy using
docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell
lung cancer (CCheIN). (Abstract 7500)
Keunchil Park
•
A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P)
following complete tumor resection with or without adjuvant chemotherapy in patients (pts)
with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT
results. (Abstract 7501)
Karen Kelly
•
Should We Add to Definitive Therapy for Non-Small Cell Lung Cancer?
Nasser H. Hanna, MD
•
Panel Question and Answer
•
Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer.
(Abstract 7502)
Ben J. Slotman
•
Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of
patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese
randomized phase III trial. (Abstract 7503)
Takashi Seto
•
Revisiting Radiation in Small Cell Lung Cancer
Walter John Curran, MD
•
Panel Question and Answer
Panel Discussion
•
A randomized phase III study of cisplatin (CDDP), etoposide (ETOP) and irinotecan versus
topotecan as second-line chemotherapy in patients with sensitive relapsed small-cell lung
cancer (SCLC): Japan Clinical Oncology Group study JCOG0605 (Abstract 7504)
Koichi Goto
•
Randomized phase II-III study of bevacizumab in combination with chemotherapy in
previously untreated extensive small-cell lung cancer: Results from the IFCT-0802 trial.
(Abstract 7505)
Jean-Louis Pujol
•
A randomized double-blind phase II trial of platinum (P) plus etoposide (E) with or without
concurrent ZD6474 (Z) in patients (pts) with previously untreated extensive-stage (ES) small
cell lung cancer (SCLC): Hoosier Oncology Group LUN06-113. (Abstract 7506)
Rachel E. Sanborn
•
Randomized trial of arginine deprivation with pegylated arginine deiminase in patients with
malignant pleural mesothelioma. (Abstract 7507)
Peter Wojciech Szlosarek
•
To Target the Tumor or the Stroma
Lee M. Krug, MD
•
Panel Question and Answer
Panel Discussion
Session Title: Hereditary Breast and Colon Cancer, and Clinical Oncology: Past, Present, and
Future
Session Type: Education Session
Track: Cancer Genetics
Time: 11:30 AM - 12:45 PM
Location: S404
•
50 Years of Clinical Cancer Genetics
James M. Ford, MD - Chair
•
Advances in Lynch Syndrome
Noralane M. Lindor, MD
•
The Future of Hereditary Breast Cancer and Ovarian Cancer Syndrome
Fergus J. Couch, PhD
•
Panel Question and Answer
Session Title: Rare but Real: Management of Pseudomyxoma Peritonei, Gallbladder Cancer, and
Periampullary Cancers
Session Type: Education Session
Track: Gastrointestinal (Noncolorectal) Cancer
Time: 11:30 AM - 12:45 PM
Location: N Hall B1
•
Pseudomyxoma Perotonei
David P. Ryan, MD - Chair
•
Gallbladder Cancer
Bettina G. Muller, MD
•
Ampullary Cancer
Tanios S. Bekaii-Saab, MD
•
Panel Question and Answer
Session Title: The Management of Intra-abdominal Sarcomas - Ticketed Session
Session Type: Meet the Professor Session
Track: Sarcoma
Time: 11:30 AM - 12:45 PM
Location: E451a
•
Radiation Therapy in Intra-abdominal Sarcoma: When to Consider, When to Avoid
David G. Kirsch, MD, PhD
•
The Multidisciplinary Evaluation and Management of Intra-abdominal Sarcoma
Frederick C. Eilber, MD
Session Title: Clinical Conundrums in Lymphoid Malignancies: Uncommon Problems in Common
Diseases and Common Problems in Uncommon Diseases - Ticketed Session
Session Type: Clinical Problems in Oncology Session
Track: Lymphoma and Plasma Cell Disorders
Time: 11:30 AM - 12:45 PM
Location: E451b
•
Myc-Positive Diffuse Large B-Cell Lymphoma: More Than One Disease, More Than One
Approach?
Jonathan W. Friedberg, MD
•
PET Peeves: How to Handle Positive Interim PET Scans in Aggressive Lymphomas and
Positive Post-treatment Scans in Follicular Lymphoma
Ann S. LaCasce, MD - Chair
•
POEMS Syndrome: A Case-Based Approach to Evaluation and Best Management
Angela Dispenzieri, MD
Session Title: ASCO Annual Business Meeting (ASCO Members Only)
Session Type: Special Session
Track: Special Session
Time: 12:00 PM - 1:00 PM
Location: S100a
•
Session Title: ASCO Book Club: Mountains Beyond Mountains
Session Type: Special Session
Track: Special Session
Time: 1:15 PM - 2:30 PM
Location: S103
•
Moderator
Teresa Gilewski, MD - Co-Chair
•
Moderator
Lawrence N. Shulman, MD - Co-Chair
Session Title: Cancer Nanotechnology: Path to New Diagnostics and Therapeutics
Session Type: Education Session
Track: Developmental Therapeutics
Time: 1:15 PM - 2:30 PM
Location: S100bc
•
Moderator
Piotr Grodzinski, PhD - Chair
•
Nanodiagnostics in Cancer Research
Antoni Ribas, MD, PhD
•
New Approaches to Targeted Nano-Enabled Therapies for Cancer
Justin Hanes, PhD
•
Nanoparticle Delivery Platform for Solid Tumors
Mark E. Davis, PhD
•
Panel Question and Answer
Session Title: Chronic Lymphocytic Leukemia Therapy: An Update on Frontline and Novel
Therapies
Session Type: Education Session
Track: Leukemia, Myelodysplasia, and Transplantation
Time: 1:15 PM - 2:30 PM
Location: E450
•
Fifty Years of Frontline Therapy for Chronic Lymphocytic Leukemia: Evolving Standards of
Care
Susan Mary O'Brien, MD - Chair
•
Novel Targeted Therapies in the Management of Chronic Lymphocytic Leukemia
Jennifer R. Brown, MD
•
Genetically Engineered T Cells and Beyond: Immune Modulation Therapy in Chronic
Lymphocytic Leukemia
David L. Porter, MD
•
Panel Question and Answer
Session Title: From Genetics to Geriatric Medicine in Bladder Cancer
Session Type: Education Session
Track: Genitourinary Cancer
Time: 1:15 PM - 2:30 PM
Location: E Hall D2
•
Optimizing Chemotherapy for the Patient with Bladder Cancer
Matthew I. Milowsky, MD - Chair
•
What Has The Cancer Genome Atlas Taught Us?
William Y. Kim, MD
•
The Bladder Cancer Genome: Progress and Limitations
Bogdan Czerniak, MD, PhD
•
Panel Question and Answer
Session Title: Internet, Social Media, Privacy Regulations, and Clinical Trials
Session Type: Education Session
Track: Clinical Trials
Time: 1:15 PM - 2:30 PM
Location: S504
•
Social Media in Clinical Trials
Michael A. Thompson, MD, PhD
•
A Bioinformatician's View of the Use of Social Media in Clinical Trials
Robert Stephen Miller, MD
•
The Use of Social Media from an Academic and Personal Perspective
Oliver Bogler, PhD - Chair
•
Panel Question and Answer
Session Title: Predisposition to Pediatric and Hematologic Cancers: A Moving Target
Session Type: Education Session
Track: Cancer Genetics
Time: 1:15 PM - 2:30 PM
Location: S404
•
Hereditary Cancer Syndromes That Affect Children and Adolescents
David Malkin, MD
•
Pediatric Cancers in the Adult Population and Adult Cancers in the Pediatric Population
Kim E, Nichols, MD, PhD
•
Predisposition to Hematologic Malignancies
Joshua D. Schiffman, MD - Chair
•
Panel Question and Answer
Session Title: Survivorship in Gynecologic Cancer: Enduring the Treatment, Surviving the Cure
Session Type: Education Session
Track: Gynecologic Cancer
Time: 1:15 PM - 2:30 PM
Location: E354a
•
There Is No Little Blue Pill for This: Female Sexuality after Gynecologic Cancer
Don S. Dizon, MD
•
When Size Really Matters: Management of Exercise, Nutrition, and Obesity after Gynecologic
Cancer Diagnosis
Amanda Nickles Fader, MD
•
Finding the Function in Gastrointestinal Dysfunction: Etiology, Diagnosis, and Treatment of
the Gastrointestinal Effects of Pelvic Radiation Therapy
Linda R. Duska, MD - Chair
•
Panel Question and Answer
Session Title: The Winds of Change: Cancer Disparities in the Health Care Reform Era
Session Type: Education Session
Track: Health Services Research
Time: 1:15 PM - 2:30 PM
Location: E253
•
The Changing Landscape of Cancer Disparities
Nina A. Bickell, MD, MPH - Chair
•
The Cancer Care Quality Conundrum: Will Improvement Eliminate Disparities?
Steven J. Katz, MD, MPH
•
The Affordable Care Act, State Medicaid Exchanges, and Cancer Care Disparities: The
Expected and the Unexpected
Dennis Andrulis, PhD
•
Panel Question and Answer
Session Title: Time to Look Again: Emerging Biology and Therapeutics in Small Cell and Large Cell
Neuroendocrine Cancers, Thymoma/Thymic Carcinomas, and Mesothelioma
Session Type: Education Session
Track: Lung Cancer
Time: 1:15 PM - 2:30 PM
Location: E Arie Crown Theater
•
Thymoma and Thymic Carcinoma
Ronan Joseph Kelly, MD, MBA - Chair
•
Current Therapy for Small Cell Lung Cancer
Roman K. Thomas, MD
•
Current and Future Therapy for Mesothelioma
Marjorie Glass Zauderer, MD, MS
•
Panel Question and Answer
Session Title: From Immunotherapy Research to Clinical Vaccines - Ticketed Session
Session Type: Meet the Professor Session
Track: Tumor Biology
Time: 1:15 PM - 2:30 PM
Location: E451a
•
The Historical Role of Targeting the Immune Environment
George Coukos, MD, PhD
•
Future Directions in Immune Targeting
Carl H. June, MD
Session Title: Clinical Research in Children with Cancer: Challenges and Opportunities - Ticketed
Session
Session Type: Clinical Problems in Oncology Session
Track: Pediatric Oncology
Time: 1:15 PM - 2:30 PM
Location: E451b
•
Phase II Trials in Newly Diagnosed Children with Cancer
Peter C. Adamson, MD - Chair
•
Can Science Meet Alternative Medicine for Children with Cancer?
Kara M. Kelly, MD
•
Ethical Tensions in Childhood Cancer Research
Eric Kodish, MD
Session Title: Exploring the Spectrum of Sarcoma Genome
Session Type: Clinical Science Symposium
Track: Sarcoma
Time: 1:15 PM - 2:45 PM
Location: S406
•
Chair
David Morgan Thomas, MBBS, PhD
•
Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel
treatment modalities. (Abstract 10509)
Sujana Movva
•
Preliminary analysis of the mutational landscape of non-rhabdomyosarcoma soft tissue
sarcoma: A Children's Oncology Group study. (Abstract 10510)
Raphael Asher Wilson
•
Identifying the Mutational Landscape of Sarcomas
Javed Khan, MD
•
The driver landscape of angiosarcoma. (Abstract 10511)
Sam Behjati
•
Whole-exome and targeted sequencing of angiosarcomas: Target identification and
treatment implications. (Abstract 10512)
Vinod Ravi
•
Histology-Specific Drivers and Targets in Soft Tissue Sarcomas
Robert G. Maki, MD, PhD
•
Panel Question and Answer
Session Title: Gastrointestinal (Noncolorectal) Cancer
Session Type: Oral Abstract Session
Track: Gastrointestinal (Noncolorectal) Cancer
Time: 1:15 PM - 4:15 PM
Location: E Hall D1
•
Chair
Emil Lou, MD, PhD
•
Chair
Karyn A. Goodman, MD
•
A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with
capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic
cancer (mPC). (Abstract 4000)
Herbert Hurwitz
•
Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients
with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07
study. (Abstract 4001^)
Florence Huguet
•
ABC-03: A randomized phase II trial of cediranib (AZD2171) or placebo in combination with
cisplatin/gemcitabine (CisGem) chemotherapy for patients (pts) with advanced biliary tract
cancer (ABC). (Abstract 4002)
Juan W. Valle
•
Pancreatobiliary Cancer: Two Steps Forward, One Step Back?
Andrew H. Ko, MD
•
Panel Question and Answer
•
Phase III study of apatinib in advanced gastric cancer: A randomized, double-blind, placebocontrolled trial. (Abstract 4003)
Shukui Qin
•
Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or
esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial.
(Abstract 4004)
Harry H. Yoon
•
RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab (RAM) plus
paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of metastatic
gastroesophageal junction and gastric adenocarcinoma (mGC) following disease progression
on first-line platinum- and fluoropyrimidine-containing combination therapy—Efficacy analysis
in Japanese and Western patients. (Abstract 4005)
Shuichi Hironaka
•
STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib
after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC) (Abstract
4006^)
Jordi Bruix
•
The Angiogenesis Dilemma
Lee M. Ellis, MD
•
Panel Question and Answer
Panel Discussion
•
RTOG 0436: A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and
radiation for patients with esophageal cancer treated without surgery. (Abstract 4007)
David H. Ilson
•
Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabineradiotherapy in gastric cancer (GC): The final report on the ARTIST trial. (Abstract 4008)
Jeeyun Lee
•
Refining Therapy for Locally Advanced Esophagogastric Cancer
James Posey, MD
•
Panel Question and Answer
Panel Discussion
Session Title: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Session Type: Poster Highlights Session
Track: Breast Cancer
Time: 1:15 PM - 6:00 PM
Display and Networking Time: 1:15 PM - 4:15 PM
Display and Networking Location: E354b
Discussion Time: 4:45 PM - 6:00 PM
Discussion Location: E Hall D1
•
Co-Chair
Steven J. Isakoff, MD, PhD
•
Co-Chair
Deborah Toppmeyer, MD
Board 1
•
German Adjuvant Intergroup Node Positive (GAIN) study: A phase III trial to compare IDDETC versus EC-TX in patients with node-positive primary breast cancer—Final efficacy
analysis. (Abstract 1009)
Volker Jochen Moebus
Board 2
•
Adjuvant gemcitabine for high-risk breast cancer (BC) patients: Final survival results of the
randomized phase III SUCCESS-A study. (Abstract 1010)
•
Adjuvant gemcitabine for high-risk breast cancer (BC) patients: Final survival results of the
randomized phase III SUCCESS-A study. (Abstract 1010)
Wolfgang Janni
Board 3
•
Phase III study of vinflunine plus gemcitabine versus paclitaxel plus gemcitabine in the firstline treatment of anthracycline pretreated advanced breast cancer. (Abstract 1011)
Antonio Llombart
Board 4
•
Randomized phase III study of taxane versus TS-1 as first-line treatment for metastatic
breast cancer (SELECT BC). (Abstract 1012)
Fumikata Hara
Board 5
•
Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant
to anthracycline and resistant to taxane: A phase III study versus capecitabine. (Abstract
1013^)
Matti S. Aapro
Board 6
•
ARTemis: A randomised trial of bevacizumab with neoadjuvant chemotherapy (NACT) for
patients with HER2-negative early breast cancer—Primary endpoint, pathological complete
response (pCR). (Abstract 1014)
Helena Margaret Earl
Board 7
•
Resource utilization in patients with breast cancer treated with generic versus branded
docetaxel. (Abstract 1015)
Stephen E. Jones
Board 8
•
Outcome of male patients and black patients enrolled in S0221, an intergroup chemotherapy
study. (Abstract 1016)
G. Thomas Budd
Board 9
•
Randomized phase II study of weekly paclitaxel with or without carboplatin followed by
cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA
HER2-negative breast cancer. (Abstract 1017)
Kenji Tamura
Board 11
•
Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triplenegative breast cancer (TNBC): Hoosier Oncology Group BRE09-146. (Abstract 1019^)
Sujaata Dwadasi
Board 14
•
Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by
postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCAassociated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96.
(Abstract 1021)
George Somlo
Board 15
•
Efficacy of neoadjuvant carboplatin/docetaxel chemotherapy in sporadic and BRCAassociated triple-negative breast cancer (TNBC). (Abstract 1022)
Priyanka Sharma
Board 16
•
A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation
(Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC). (Abstract 1098)
Adi Diab
Board 17
•
Triple-negative breast cancer subtypes and pathologic complete-response rate to
neoadjuvant chemotherapy: Results from the GEICAM/2006-2003 study. (Abstract 1024)
Angela Santonja
Board 18
•
In silico analysis of a multifactorial consensus signature (ConSig) for predicting response to
anthracycline (A)-based neoadjuvant chemotherapy (NAC) in triple-negative breast cancer
(TNBC) patients (pts). (Abstract 1025)
Natalie Heather Turner
Board 19
•
Biomarker panel (TheraPrint) analyzed as a predictor of response to neoadjuvant
chemotherapy in patients with locally advanced breast cancer. (Abstract 1026)
Peter D. Beitsch
Board 20
•
Quantitative assessment of CD3, CD8, and CD20 in tumor-infiltrating lymphocytes and
predictive value for response to neoadjuvant chemotherapy in breast cancer. (Abstract 1027)
Jason R. Brown
Board 21
•
Next-generation sequencing (NGS) in relapsed/refractory triple-negative breast cancer
(TNBC) in Israel. (Abstract 1028)
Noa Ben-Baruch
Board 22
•
Genomic and protein alterations in 126 triple-negative (TN) metaplastic breast cancers.
(Abstract 1029)
Sherri Z. Millis
Board 23
•
Uncovering the dynamic relationship between Ki-67 and mitotic indices in breast cancer.
(Abstract 1030)
Guilherme Henrique Cantuaria
Board 24
•
Evaluation of the adjuvant radiation treatment-effect heterogeneity using genomic signature
for locoregional relapse and long-term outcome. (Abstract 1031)
Maggie Chon U Cheang
Board 25
•
Patterns of care for omission of radiation therapy for elderly women with early-stage breast
cancer receiving hormonal therapy. (Abstract 1032)
Peyman Kabolizadeh
Board 26
•
Late axillary recurrence after negative SLNB. (Abstract 1033)
Cindy Brown Matsen
•
Clinical Trials: Learning from Success and Failure
Joseph A. Sparano, MD
•
Platinums, PARP Inhibitors, and Predictor of Response
Steven J. Isakoff, MD, PhD
•
Deconstructing the Molecular Portrait of Breast Cancer
Aleix Prat, MD
•
Local Therapy: Who Benefits?
Eleanor Elizabeth Harris, MD
•
Panel Question and Answer
Session Title: Cancer Prevention/Epidemiology
Session Type: Poster Highlights Session
Track: Cancer Prevention/Epidemiology
Time: 1:15 PM - 6:00 PM
Display and Networking Time: 1:15 PM - 4:15 PM
Display and Networking Location: S102
Discussion Time: 4:45 PM - 6:00 PM
Discussion Location: S100a
•
Co-Chair
Kala Visvanathan, MD, MHS
•
Co-Chair
Carrie A. Thompson, MD
Board 1
•
Patient-reported outcomes and behavioral risk factors as predictors of chemoprevention
adherence among women in the National Surgical Adjuvant Breast and Bowel Program
(NSABP) Breast Cancer Prevention P-1 trial. (Abstract 1512)
Stephanie R. Land
Board 2
•
Risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. (Abstract
1513)
Hildur Helgadottir
Board 3
•
Effect of exercise and dietary fish consumption on risk of recurrence in colon cancer: A
multinational study. (Abstract 1514)
Mohammed Shaik
Board 4
•
Antioxidant micronutrients and renal cell carcinoma: Results from the Women’s Health
Initiative. (Abstract 1515)
Won Jin Ho
Board 5
•
Atypical glandular cells and atypical cells of unknown origin in screening and subsequent risk
of cervical cancer. (Abstract 1516)
Par Sparen
Board 6
•
Thailand experiences on cervical cancer prevention using vinegar. (Abstract 1517)
Khunying Kobchitt Limpaphayom
Board 7
•
Estimating the impact of screening on three decades of cervical cancer incidence. (Abstract
1518)
Daniel Xiao Yang
Board 8
•
Use of a SNP panel to refine risk estimates in women at high risk of breast cancer: Results
from two randomized tamoxifen prevention trials. (Abstract 1519)
Jack M. Cuzick
Board 9
•
Frequency of occult findings in contralateral prophylactic mastectomy as it relates to
preoperative MRI or BRCA testing. (Abstract 1520)
Lillian M. Erdahl
Board 10
•
RPFNA cytologic atypia and short-term breast cancer risk in the prevention era. (Abstract
1521)
Whitney L. Michaels
Board 11
•
Founder effect and a high prevalence of BRCA1 mutations among young Mexican triplenegative breast cancer (TNBC) patients. (Abstract 1522)
Cynthia Mayte Villarreal-Garza
Board 12
•
Association of the single nucleotide polymorphism TNRC9 rs3803662 on mammographic
density and estrogen receptor-positive breast cancer risk in Japanese women. (Abstract
1523)
Nobuyasu Yoshimoto
Board 13
•
Pharmacokinetic analysis of tamoxifen metabolites in premenopausal women with early
breast cancer: A substudy of NCIC CTG MA.12 randomized clinical trial. (Abstract 1524)
Shahbal Bill Kangarloo
Board 14
•
Mammographic density and breast cancer in women from high-risk families. (Abstract 1525)
Marina Pollán
Board 15
•
EGFR mutation screening in non-small cell lung cancer: Results from an access program in
Brazil. (Abstract 1526)
Luciola De Barros Pontes
Board 16
•
Clinical and molecular characteristics of non-small cell lung cancer patients harboring PIK3CA
mutations. (Abstract 1527)
Sebastian Yves Friedrich Michels
Board 17
•
Racial/ethnic variations in lung cancer incidence and mortality, adjusted for smoking
behavior: Results from the Women's Health Initiative. (Abstract 1528)
Manali I. Patel
Board 18
•
Circulating microRNA signature and lung cancer outcome in low-dose computed tomography
(LDCT) screening. (Abstract 1529)
Stefano Sestini
Board 19
•
Lung cancer detection by low-dose computerized tomography (LDCT) and digital
tomosynthesis (DT) for lung cancer screening in a high-risk population: A comparison of
detection methods. (Abstract 1530)
Natthaya Triphuridet
Board 20
•
Death less than one month from diagnosis in children with cancer: A population-based
analysis. (Abstract 1531)
Adam L. Green
Board 21
•
Influence of metformin use on the transformation of monoclonal gammopathy of
undetermined significance into multiple myeloma. (Abstract 1532)
Su-Hsin Chang
Board 22
•
Risk factors for melanoma among survivors of non-Hodgkin lymphoma in the U.S. elderly
population. (Abstract 1533)
Clara JK Lam
Board 23
•
Risk of death from cardiovascular disease in long-term breast cancer survivors: A comparison
with women from the general population. (Abstract 1534)
Milada Cvancarova
Board 24
•
Cancer patients’ preferences for return of somatic and germline whole-exome sequencing
results: Data from the CANSEQ study. (Abstract 1535)
Stacy W. Gray
Board 25
•
Survival after second primary lung cancer following non-Hodgkin lymphoma: A U.S.
population-based study. (Abstract 1536)
LINA INAGAKI
•
Lifestyle Factors, Adherence, and Cancer Risk
Leslie L. Robison, PhD
•
Cervical Cancer Screening
Robert A. Smith, PhD
•
Breast Cancer Risk and Risk Assessment
Abenaa M. Brewster, MD, MHS
•
Lung Cancer: Molecular Genetics and Screening
David Paul Carbone, MD, PhD
•
Panel Question and Answer
Session Title: Developmental Therapeutics - Immunotherapy
Session Type: Poster Highlights Session
Track: Developmental Therapeutics
Time: 1:15 PM - 6:00 PM
Display and Networking Time: 1:15 PM - 4:15 PM
Display and Networking Location: S405
Discussion Time: 4:45 PM - 6:00 PM
Discussion Location: S406
•
Co-Chair
Charlotte Eielson Ariyan, MD, PhD
•
Co-Chair
Jonathan S. Cebon, MBBS, FRACP, PhD
Board 1
•
Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in
patients naive to, or progressed on, ipilimumab (IPI). (Abstract 3009)
Jeffrey S. Weber
Board 2
•
Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in
patients (pts) with melanoma. (Abstract 3010)
Geoffrey Thomas Gibney
Board 3
•
Combinatorial TGF-ß signaling blockade and anti-CTLA-4 antibody immunotherapy in a
murine BRAFV600E-PTEN-/- transgenic model of melanoma. (Abstract 3011)
Brent Allen Hanks
Board 4
•
A phase 1 study of MEDI3617, a selective angiopoietin-2 inhibitor, alone and in combination
with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid
tumors. (Abstract 3012)
David Michael Hyman
Board 5
•
Magnitude and quality of tumor-infiltrating T-cell response upon poxvirus-based active
immunotherapy alone and in combination with CTLA-4 immune checkpoint inhibition.
(Abstract 3013)
Susan P Foy
Board 6
•
Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in
combination with ipilimumab in patients with pretreated advanced melanoma. (Abstract
3014)
Bart Neyns
Board 7
•
Baseline tumor size as an independent prognostic factor for overall survival in patients with
metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. (Abstract
3015)
Richard Wayne Joseph
Board 8
•
Association of maintenance of pre-existing memory T-cell responses following anti-CTLA-4
antibody treatment with improved overall survival. (Abstract 3016)
Lawrence Fong
Board 9
•
Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin
lymphoma. (Abstract 3017)
Cariad Chester
Board 10
•
Association of epithelial-mesenchymal transition status with PD1/PDL1 expression and a
distinct immunophenotype in non-small cell lung cancer: Implications for immunotherapy
biomarkers. (Abstract 3018)
Yanyan Lou
Board 11
•
Clinical outcome and CD4+ differentiation in anti-CTLA-4/radiation and anti-CTLA-4/steroid
therapy. (Abstract 3019)
Anuj Bapodra
Board 12
•
Effects of ipilimumab on expanded tumor-infiltrating lymphocytes in patients with stage IV
malignant melanoma. (Abstract 3020)
Jon Bjoern
Board 13
•
T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating
lymphocytes (TILs) in early-stage breast cancer patients (pts) receiving preoperative
cryoablation (cryo) and/or ipilimumab (ipi). (Abstract 3021)
David B. Page
Board 14
•
Graded potency of chimeric antigen receptor (CAR)-engineered T cells for cancer
immunotherapy. (Abstract 3022)
Michel Sadelain
Board 15
•
A phase I, first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a
receptor involved in immune escape and tumor growth in patients with solid and hematologic
malignancies. (Abstract 3023)
Ahmad Awada
Board 16
•
Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with
advanced hematologic malignancies. (Abstract 3024)
Stephen Maxted Ansell
Board 17
•
Updated phase I data of AFM13: A bispecific tandem antibody (TandAb) in
relapsed/refractory (R/R) Hodgkin lymphoma (HL). (Abstract 3025^)
Achim Rothe
Board 18
•
Correlation of immune response with clinical outcomes in melanoma patients receiving
adjuvant therapy of pegylated interferon alpha-2b combined with gp100 peptide vaccine.
(Abstract 3026)
Luis M Vence
Board 19
•
Immunologic activity of an activating anti-CD27 antibody (CDX-1127) in patients (pts) with
solid tumors. (Abstract 3027)
Jeffrey R. Infante
Board 20
•
Phase 2 open-label study of MEDI-551 and bendamustine versus rituximab and
bendamustine in adults with relapsed or refractory CLL. (Abstract 3028)
Douglas Edward Gladstone
Board 21
•
Correlation of anti-calreticulin antibody titers with improved overall survival in a phase 2
clinical trial of algenpantucel-L immunotherapy for patients with resected pancreatic cancer.
(Abstract 3029)
Gabriela R. Rossi
Board 22
•
Matrix metalloproteinase-23 as a new immunotherapeutic checkpoint target in melanoma.
(Abstract 3030)
Duane Moogk
Board 23
•
CALM study: A phase II study of an intratumorally delivered oncolytic immunotherapeutic
agent, coxsackievirus A21, in patients with stage IIIc and stage IV malignant melanoma.
(Abstract 3031)
Robert Hans Ingemar Andtbacka
Board 24
•
IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting ?rop-2, as a novel platform
for the therapy of diverse metastatic solid cancers: Clinical results. (Abstract 3032)
Alexander Starodub
Board 25
•
ELYPSE-7: A randomized, placebo-controlled, phase 2a study evaluating the impact of IL-7
on CD4 count, hematological toxicity, and tumor progressionin metastatic breast cancer
(MBC) patients (pts). (Abstract 3033)
Jean-Yves Blay
•
Check Point Blockade: Can We Make It Better?
Charlotte Eielson Ariyan, MD, PhD
•
Immunologic Correlates of Response
Jennifer Ann Wargo, MD
•
Modulating the Antitumor Immune Response
Cassian Yee, MD
•
New Targets and New Agents
Charles G. Drake, MD, PhD
•
Panel Question and Answer
Session Title: Head and Neck Cancer
Session Type: Poster Highlights Session
Track: Head and Neck Cancer
Time: 1:15 PM - 6:00 PM
Display and Networking Time: 1:15 PM - 4:15 PM
Display and Networking Location: E354b
Discussion Time: 4:45 PM - 6:00 PM
Discussion Location: E450
•
Chair
Anthony Cmelak, MD
Board 27
•
Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy as
treatment of unresected locally advanced head and neck cancer squamous cell cancer
(HNSCC): A meta-analysis of randomized trials. (Abstract 6012)
Wilfried Budach
Board 28
•
Comparison of clinical primary tumor site (PTS) response to induction chemotherapy (IC)
with APF (nab-paclitaxel, cisplatin, and 5-FU) or APF plus cetuximab (APF+Cetux) in patients
with locally advanced squamous cell carcinoma of the head and neck (SCCHN). (Abstract
6013)
Jessica C. Ley
Board 29
•
Cisplatin versus cetuximab plus concomitant radiotherapy in locally advanced head and neck
cancer: A meta-analysis of published trials. (Abstract 6014)
Sandro Barni
Board 30
•
Induction chemotherapy (IC) followed by radiochemotherapy (RCT) versus
radiochemotherapy alone as treatment in advanced laryngeal (LC)/hypopharyngeal cancer
(HC): Phase IIb. (Abstract 6015)
Rainald Knecht
Board 31
•
Induction chemotherapy (IC) docetaxel (T), cisplatin (P), 5-fluorouracil (F) (TPF), or TP
followed by concomitant boost radiotherapy (R) with or without cetuximab (E) for functional
organ preservation (FOP) of resectable laryngeal and hypopharyngeal cancer (LHSCC): First
results of the phase II randomized DeLOS-II study. (Abstract 6016^)
Andreas Dietz
Board 32
•
A phase II study comparing metronomic chemotherapy with chemotherapy (single-agent
cisplatin), in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of
head and neck. (Abstract 6017)
Vijay Maruti Patil
Board 33
•
Cetuximab (C), fluorouracil (F), and cisplatin (P) alone or with docetaxel (D) for
recurrent/metastatic (RM) head and neck cancer (HNSCC): First analysis of AIO trial # 1108.
(Abstract 6018)
Ulrich Keilholz
Board 34
•
A phase II trial of temsirolimus plus low-dose weekly carboplatin and paclitaxel for
recurrent/metastatic HNSCC. (Abstract 6019^)
Matthew G. Fury
Board 36
•
Platinum-based chemotherapy (CT) plus cetuximab in recurrent or metastatic squamous cell
carcinoma of the head and neck cancer (R/M-SCCHN): 5-year follow-up data for the extreme
trial. (Abstract 6021^)
Jan Baptist Vermorken
Board 37
•
Meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on
4,798 patients. (Abstract 6022)
Pierre Blanchard
Board 39
•
Comparison of concurrent chemoradiation therapy with 3-weekly versus weekly cisplatin in
patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II
noninferiority trial (KCSG-HN10-02). (Abstract 6023)
Ji Yun Lee
Board 40
•
Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A
Bayesian network meta-analysis. (Abstract 6024)
Marie Yan
Board 41
•
The correlation between the severity of cetuximab-induced rash and clinical outcome for
patients with head and neck carcinoma treated with chemoradiotherapy (CRT) plus
cetuximab: The RTOG experience. (Abstract 6025)
Voichita Bar-Ad
Board 42
•
A multicenter international phase 2 trial of pazopanib in metastatic and progressive
medullary thyroid carcinoma: MC057H. (Abstract 6026)
Keith Christopher Bible
Board 43
•
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and
refractory medullary thyroid cancer (MTC). (Abstract 6027)
Jaume Capdevila
Board 44
•
Interest of pretreatment quantification of anti-cetuximab IgE to prevent severe
hypersensitivity reaction to cetuximab. (Abstract 6028)
Benoit Dupont
Board 45
•
Single-nucleotide polymorphism (SNP) of excision repair cross complementation group 1
(ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC
Study Group 0502 trial. (Abstract 6029)
Edwin Pun Hui
Board 46
•
Proteomic profiling of HPV-positive head and neck cancer to identify new candidates for
targeted therapy. (Abstract 6030)
Lauren Averett Byers
Board 47
•
Validation of two biologically distinct HPV-associated head and neck cancer subtypes and
correlation with E5 expression. (Abstract 6031)
Zhixiang Zuo
Board 48
•
Review of pathologic diagnosis in head and neck cancer patients: Why do it? (Abstract 6032)
Gefei Alex Zhu
Board 49
•
Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: A randomized, double-blind window
study in operable head and neck squamous cell carcinoma (HNSCC). (Abstract 6033)
Julie E. Bauman
Board 50
•
Harvey ras (HRAS) mutations in head and neck cancer (HNC) and dependence on PI3K
signaling and resistance to EGFR inhibition. (Abstract 6034)
Katharina Endhardt
Board 51
•
Evaluation of computational tools to determine prognostic significance of TP53 mutation in
head and neck squamous cell carcinoma (HNSCC). (Abstract 6035)
David Masica
Board 52
•
Prevalence and outcome of mutations (mut) in the Fanconi anemia (FA) DNA repair pathway
among head and neck cancer (H&N Ca) patients (pts). (Abstract 6036)
Nooshin Hashemi Sadraei
•
Where Does Chemotherapy Fit with Radiation Therapy?
Jean-Pascal H. Machiels, MD, PhD
•
Developments in Recurrent/Metastatic Disease
Ranee Mehra, MD
•
Nasopharyngeal Carcinoma
Danny Rischin, MD, MBBS
•
Interesting Biomarkers with Clinical Importance
Amanda Psyrri, MD
•
Panel Question and Answer
Session Title: Genitourinary (Nonprostate) Cancer
Session Type: General Poster Session
Track: Genitourinary Cancer
Time: 1:15 PM - 5:00 PM
Location: S Hall A2
Board 102
•
Feasibility and activity of two vinflunine (VFL)-based combinations as first-line chemotherapy
(CT) in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL-gemcitabine
(GEM) or VFL-CBDCA in a randomized international phase II trial (JASINT). (Abstract 4534)
Maria De Santis
Board 103
•
Stathmin-1 as a potential therapeutic target in urinary bladder cancer. (Abstract 4535)
Ulrika Segersten
Board 104
•
A patient-derived xenograft (PDX) platform to optimize omics-driven precision medicine in
bladder cancer. (Abstract 4536)
Chong-xian Pan
Board 105
•
Delivery of peri-operative chemotherapy for muscle-invasive bladder cancer (MIBC) in
routine clinical practice: Does regimen and timing matter? (Abstract 4537)
Christopher M. Booth
Board 106
•
Next-generation sequencing to identify molecular alterations in DNA repair and chromatin
maintenance genes associated with pathologic complete response (pT0) to neoadjuvant
accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) in muscle-invasive
bladder cancer (MIBC). (Abstract 4538)
Elizabeth R. Plimack
Board 107
•
Assessing tumor response using CT density-volume trajectory in metastatic bladder cancer.
(Abstract 4539)
Les Folio
Board 108
•
High neutrophil to lymphocyte ratio persistent during first-line chemotherapy to predict
clinical outcome in patients with advanced urothelial cancer. (Abstract 4540)
Ugo De Giorgi
Board 109
•
Preliminary product parameter and safety results from NeuACT, a phase 2 randomized,
open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at
high risk for recurrence. (Abstract 4541^)
Dean F. Bajorin
Board 110
•
External validation of nomogram to predict progression-free survival at 6 months (PFS6) in
patients receiving salvage therapy for advanced urothelial carcinoma (UC). (Abstract 4542)
Guru Sonpavde
Board 111
•
Trans Tasman Radiation Oncology Group (TROG) 02.03 phase III trial: Concurrent weekly
cisplatin and radiation therapy in localized muscle-invasive bladder cancer—Compliance,
toxicity, QOL, and overall results. (Abstract 4543)
Nirdosh Kumar Gogna
Board 112
•
Updated analysis of circulating tumor cells (CTCs) in patients with urothelial cancer (UC)
undergoing systemic treatment: Implications across the clinical stages. (Abstract 4544)
Andrea Necchi
Board 113
•
Engrailed-2 (EN2) protein expression and prognosis in bladder cancer following radical
cystectomy (RC). (Abstract 4545)
Simon J. Crabb
Board 114
•
Bladder cancer risk: Use of PLCO and NLST to identify a suitable screening cohort. (Abstract
4546)
Laura-Maria Krabbe
Board 115
•
Immunohistochemistry (IHC) to enhance the prognostic allocation of locally advanced and
metastatic urothelial cancer (UC) undergoing first-line chemotherapy (CT). (Abstract 4547)
Patrizia Giannatempo
Board 116
•
Changes in conditional survival (CS) in de novo metastatic urothelial carcinoma (mUC): A
Surveillance, Epidemiology, and End Results (SEER) database analysis. (Abstract 4548)
Kara DeWalt
Board 117
•
Long-term results and prognostic factors for survival following adjuvant chemotherapy (AC)
for muscle-invasive urothelial bladder cancer (UC): A French retrospective multicenter
cohort. (Abstract 4549)
Damien Pouessel
Board 118
•
Pathologic down-staging following standard (SD) MVAC (methotrexate-vinblastinedoxorubicine-cisplatin) or dose-dense MVAC (DD) neoadjuvant chemotherapy (NC) for
muscle-invasive urothelial bladder cancer (UC): A retrospective multicenter cohort of the
French Genitourinary Tumor Group (GETUG/AFU). (Abstract 4550)
Damien Pouessel
Board 119
•
Met signaling in urothelial carcinoma of the bladder. (Abstract 4551)
Donald P Bottaro
Board 120
•
PD-L1 expression in mononuclear cells and not in tumor cells, correlated with prognosis in
metastatic urothelial carcinoma. (Abstract 4552)
Stephanie A. Mullane
Board 121
•
Identification of potentially targetable kinases by concurrent high-throughput functional
kinomics and RNA-sequencing (seq) of muscle-invasive bladder cancer (MIBC). (Abstract
4553)
Christopher Douglas Willey
Board 122
•
Screening for carcinoma in situ (CIS) testis and occurrence of metachronous germ cell
cancer (mGCC). (Abstract 4554)
Maria Gry Gundgaard
Board 123
•
Renal impairment and late toxicity in germ-cell cancer (GCC) survivors. (Abstract 4555)
Jakob Lauritsen
Board 124
•
A contemporary population-based study of testicular sex cord stromal tumors: Presentation,
treatment patterns, and predictors of outcome. (Abstract 4556)
Lindsay M Yuh
Board 125
•
A retrospective analysis of patients with poor-risk germ cell tumor (PRGCT) treated at
Indiana University from 1990 to 2011. (Abstract 4557)
Nabil Adra
Board 126
•
Evolving patterns of care in the management of stage I non-seminomatous germ cell
tumors: Data from the California Cancer Registry. (Abstract 4558)
Stanley A Yap
Board 127
•
Bone metastases in germ cell tumors: Results from an international data base. (Abstract
4559)
Christoph Oing
Board 128
•
Salvage chemotherapy for relapsed germ cell tumors: A phase II trial of gemcitabine,
paclitaxel, ifosfamide, and cisplatin (Gem-TIP). (Abstract 4560)
Matthew James Wheater
Board 129
•
Etoposide, methotrexate, and dactinomycin alternating with cyclophosphamide and
vincristine (EMA/CO) for males with HCG-expressing, chemorefractory germ cell tumors
(GCT): Long-term efficacy and safety outcomes. (Abstract 4561)
Daniele Raggi
Board 130
•
Validation of a prognostic classification system for mediastinal nonseminomatous germ-cell
tumors (MGCT). (Abstract 4562)
Lance C. Pagliaro
Board 131
•
Chemotherapy compared to surgery: Quality-of-life analysis of the German prospective
multicenter trial in clinical stage I NSGCT (AUO AH 01/94). (Abstract 4563)
Peter Albers
Board 132
•
Fatigue in relation to treatment and gonadal function in a population-based sample of 796
testicular cancer survivors 12 and 19 years after treatment. (Abstract 4564)
Mette Sprauten
Board 133
•
Survival of good-risk germ cell tumor patients following post-chemotherapy retroperitoneal
lymph node dissection: The effect of bleomycin during induction chemotherapy. (Abstract
4565)
K. Clint Cary
Board 134
•
A two-part phase 2 randomized study of dalantercept and axitinib versus placebo plus
axitinib in advanced renal cell carcinoma: Results from the part 1 dose escalation cohorts.
(Abstract 4566)
Michael B. Atkins
Board 135
•
Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate
efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of
metastatic renal cell cancer (mRCC). (Abstract 4567)
Peter J. Goebell
Board 136
•
Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus
and the HDAC inhibitor vorinostat. (Abstract 4568)
Matthew R. Zibelman
Board 137
•
Dovitinib in first-line metastatic renal cell carcinoma and correlation of efficacy with tumor
gene status: A phase II clinical trial. (Abstract 4569)
Reuben James Broom
Board 138
•
A phase II study of bevacizumab (Bev) and temsirolimus (Tem) in VEGF-refractory
metastatic renal cell carcinoma (mRCC). (Abstract 4570)
Kathleen Margaret Mahoney
Board 139
•
Characterization of the mTOR autophosphorylation site, S2481, as a novel biomarker in renal
cell carcinoma (RCC). (Abstract 4571)
Lauren Christine Harshman
Board 140
•
Comprehensive functional kinase profiling to classify clear cell (cc)-renal cell carcinoma
(RCC). (Abstract 4572)
Amitkumar N. Mehta
Board 141
•
Pre-existing hypertension is an independent prognostic factor in metastatic renal cell
carcinoma (mRCC) patients treated with sunitinib (SU). (Abstract 4573)
Lisa Derosa
Board 142
•
Association of CpG island methylator phenotype with clear-cell renal cell carcinoma
aggressiveness. (Abstract 4574)
Gabriel Malouf
Board 143
•
105 cases of renal tumors in patients age 15 to 35: A specific entity? Experience of the
Gustave Roussy Institute. (Abstract 4575)
Charles Dariane
Board 144
•
The impact of body mass index (BMI) on treatment outcome of targeted therapy in
metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell
Cancer Database Consortium. (Abstract 4576)
Laurence Albiges
Board 145
•
Correlation of stable disease (SD) as best response with survival outcomes in patients (pts)
with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose
interleukin-2 (HD IL-2). (Abstract 4577)
Joseph Merriman
Board 146
•
Comparison of stem cell signaling pathways in long-term responders (LR) versus primary
refractory (PR) patients with metastatic clear-cell renal cell carcinoma (ccRCC) under
sunitinib (SU) treatment (SULONG study). (Abstract 4578)
Javier Puente
Board 147
•
Molecular subtypes of clear cell renal cell carcinoma: Impact of diabetes mellitus, metformin,
and immunotherapy on patient outcomes. (Abstract 4579)
Scott Mattox Haake
Board 148
•
Association of hand-foot syndrome (HFS), treatment dose reductions (TDRs), and outcomes
in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with vascular
endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). (Abstract 4580)
Erin B. Bailey
Board 149
•
Q-TWiST analysis of patients with metastatic renal cell carcinoma (mRCC) randomized to
pazopanib (PAZ) or sunitinib (SUN). (Abstract 4581)
Jennifer L Beaumont
Board 150
•
Osteopontin (OPN), TIMP-1, and interleukin (IL)-6 as prognostic (prog) for overall survival
(OS) and independent from clinical criteria in patients (pts) with metastatic renal cell
carcinoma (mRCC). (Abstract 4582)
Amado J. Zurita
Board 151
•
The effect of SETD2 mutation (mts) on histone 3 lysine 36 tri-methylation (H3K36me3) and
correlation with clinical outcome in patients (pts) with metastatic clear cell renal cell
carcinoma (ccRCC) enrolled in COMPARZ. (Abstract 4583)
Thai Huu Ho
Board 152
•
Impact of angiotensin system inhibitors (ASI) on outcome in sunitinib (SU)-treated patients
for metastatic renal cell carcinoma (mRCC): Gustave Roussy experience. (Abstract 4584)
Lisa Derosa
Board 153
•
PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases.
(Abstract 4585)
Marcella Callea
Board 154
•
Molecular characterization of renal medullary carcinoma (RMC). (Abstract 4586)
Jianjun Gao
Board 155
•
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral
cancer: Results of the international collaboration on primary urethral carcinoma. (Abstract
4587)
Georgios Gakis
Board 156
•
Phase II study of dovitinib in first line metastatic or (non resectable primary) adrenocortical
carcinoma (ACC): SOGUG study 2011-03. (Abstract 4588)
Jesús García-Donas
Board 157A
•
Pazopanib versus paclitaxel in relapsed urothelial tumors: A randomized phase II study
investigating pazopanib versus weekly paclitaxel in relapsed or progressive transitional cell
carcinoma of the urothelium (PLUTO). (Abstract TPS4589)
Robert J. Jones
Board 157B
•
A randomized, prospective, phase II study to determine the efficacy of BCG given in
combination with panvac versus BCG alone in adults with high grade non-muscle invasive
bladder cancer who failed at least one induction course of BCG. (Abstract TPS4590)
Sam Joseph Brancato
Board 158A
•
A randomized trial comparing two different retention periods of intravesical pirarubicin
instillation for intermediate risk non-muscule-invasive bladder cancer after transurethral
resection. (Abstract TPS4591)
Yoshiaki Kawano
Board 158B
•
Development of a phase 2 study of the aurora kinase-A inhibitor alisertib (MLN8237) in
pretreated patients (pts) with urothelial cancer (UC). (Abstract TPS4592)
Andrea Necchi
Board 159A
•
The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (apatorsen) plus
docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer.
(Abstract TPS4593^)
Toni K. Choueiri
Board 159B
•
Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in
patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier
Oncology Group QL12-153. (Abstract TPS4594)
Costantine Albany
Board 160A
•
ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in
subjects at high risk of recurrent renal cell carcinoma (RCC). (Abstract TPS4595^)
Tae Gyun Kwon
Board 160B
•
Phase Ib study of axitinib in combination with crizotinib in patients with advanced solid
tumors. (Abstract TPS4596)
Dale Randall Shepard
Board 161A
•
A-PREDICT: A phase II study of axitinib in patients with metastatic renal cell cancer
unsuitable for nephrectomy (CRUKE/11/061). (Abstract TPS4597)
Rosalie A. Fisher
Board 161B
•
Dose adjustment of axitinib based on AUC monitoring in sunitinib-refractory advanced renal
cell carcinoma. (Abstract TPS4598)
Yuji Miura
Board 162A
•
Enrollment insights in the synchronous mRCC population: An update from the ongoing
ADAPT* phase 3 study experience. (Abstract TPS4599^)
Robert A. Figlin
Board 162B
•
Principal: A prospective observational study of real-world treatment patterns and treatment
outcomes in patients with advanced or metastatic renal cell carcinoma (mRCC) receiving
pazopanib. (Abstract TPS4600^)
Aristotelis Bamias
Board 163A
•
Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with clear
cell renal cell carcinoma (METEOR). (Abstract TPS4601)
Toni K. Choueiri
Board 163B
•
Qualitative study of social and working life aspects of patients with metastatic renal cell
carcinoma (mRCC) on palliative therapy. (Abstract TPS4602)
Sandra Meyer-Moock
Board 164B
•
A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects
with advanced renal cell carcinoma. (Abstract TPS4604^)
David F. McDermott
Board 165A
•
A multicenter, open-label, single-arm, phase 2 study of the S1P inhibitor sonepcizumab
(LT1009) in patients with previously treated metastatic renal cell carcinoma (mRCC).
(Abstract TPS4605)
Rupal Satish Bhatt
Board 165B
•
Phase II efficacy trial of pazopanib in non-clear cell metastatic renal cell carcinoma (PINCR
trial). (Abstract TPS4606)
Brian Addis Costello
Board 166A
•
Phase 1 study of ATR-101 in adrenocortical carcinoma (ACC): ATR-101-001. (Abstract
TPS4607)
Aung Naing
Session Title: Genitourinary (Prostate) Cancer
Session Type: General Poster Session
Track: Genitourinary Cancer
Time: 1:15 PM - 5:00 PM
Location: S Hall A2
Board 167
•
Long-term versus short-term androgen deprivation combined with high-dose radiotherapy for
intermediate and high-risk prostate cancer: A randomized controlled trial (DART01/05).
(Abstract 5038)
Almudena Zapatero
Board 168
•
Activity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer
(mCRPC) patients (pts) previously treated with ketoconazole (keto): A prospective phase II
study from the Prostate Cancer Clinical Trials Consortium. (Abstract 5039)
Won Kim
Board 169
•
Time to chemotherapy following treatment with sipuleucel-T: Data from PROCEED. (Abstract
5040)
Christopher Michael Pieczonka
Board 170
•
A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and
androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC):
Preliminary clinical data. (Abstract 5041)
Emmanuel S. Antonarakis
Board 171
•
Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus
prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has
progressed during or following docetaxel. (Abstract 5042)
Karim Fizazi
Board 172
•
The impact of baseline serum testosterone and duration of first-line androgen deprivation
therapy on the efficacy of docetaxel in patients with metastatic castration-resistant prostate
cancer (mCRPC). (Abstract 5043)
Robert J. van Soest
Board 173
•
Changes in androgen deprivation therapy overuse: Reimbursement response and
characteristics of persistent overusers. (Abstract 5044)
Shellie D. Ellis
Board 174
•
Obesity and the odds of weight gain following androgen deprivation therapy for prostate
cancer: Toward a risk adapted approach for ADT use. (Abstract 5045)
Lior Zvi Braunstein
Board 175
•
The in vivo efficacy of docetaxel and cabazitaxel in a cell-line based xenograft of castrationresistant prostate cancer (CRPC) previously treated with enzalutamide. (Abstract 5046)
Robert J. van Soest
Board 176
•
Prognostic role of derived neutrophil to lymphocyte ratio (dNLR) in men with metastatic
castration resistant prostate cancer (mCRPC) treated in a phase 3 trial (VENICE). (Abstract
5047)
Arnoud J. Templeton
Board 178
•
The potential of peripheral blood HERV-K expression as a biomarker for diagnosis with
prostate cancer in older men. (Abstract 5049)
Sharon A. Glynn
Board 179
•
The effect of change in PSA velocity on overall survival (OS) in men with biochemically
recurrent prostate cancer (BRPC) treated with nonhormonal agents: Combined analysis of
four phase 2 trials. (Abstract 5050)
Daniel L. Suzman
Board 180
•
Safety results of the enzalutamide expanded access program in the United States and
Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously
treated with docetaxel. (Abstract 5051)
Anthony M. Joshua
Board 181
•
A pilot study of supraphysiologic testosterone (T) and oral etoposide (E) in men with
castrate-resistant prostate cancer (CRPC). (Abstract 5052)
Michael Thomas Schweizer
Board 182
•
15-year outcomes following conservative management among patients with screen-detected
localized prostate cancer. (Abstract 5053)
Grace L. Lu-Yao
Board 183
•
Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase
3 PREVAIL trial comparing enzalutamide to placebo. (Abstract 5054)
Michael J. Morris
Board 184
•
Comparison of prostate health index and PCA3 values in patients with clinical or biologic
suspicion of prostate cancer. (Abstract 5055)
Pierre-Jean Lamy
Board 185
•
Development and validation of a prognostic index for fracture risk in older men undergoing
prostate cancer treatment. (Abstract 5056)
Tisheeka Graham-Steed
Board 186
•
Longitudinal assessment of general health-related QOL in patients undergoing active
surveillance (AS) for low-risk prostate cancer: Interim results of the PRIAS-JAPAN cohorts.
(Abstract 5057)
Mikio Sugimoto
Board 187
•
Predicting response to abiraterone acetate (AA): mRNA biomarker analysis of study COU-AA302. (Abstract 5058)
Deborah Sokol Ricci
Board 188
•
Validation of an RNA cell cycle progression (CCP) score for predicting prostate cancer death
in a conservatively managed needle biopsy cohort. (Abstract 5059)
Jack M. Cuzick
Board 189
•
Phase I trial of docetaxel (D), prednisone, and pasireotide (P) (SOM230) in metastatic
castrate-resistant prostate cancer (mCRPC). (Abstract 5060)
Hema M. Vankayala
Board 190
•
Final analysis of a large, open-label global early access protocol (EAP) with abiraterone
acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
progressing after chemotherapy. (Abstract 5061)
Cora N. Sternberg
Board 191
•
Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic
castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone
acetate (Abi). (Abstract 5062^)
Fred Saad
Board 192
•
A study of ERG, PTEN, and ki-67 in a phase III trial assessing docetaxel and estramustine in
high-risk localized prostate cancer (GETUG 12). (Abstract 5063)
Shanna Rajpar
Board 193
•
Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostatespecific membrane antigen (PSMA) monoclonal antibody 177lu-J591 in patients with
metastatic, castration-resistant prostate cancer (mCRPC). (Abstract 5064)
Scott T. Tagawa
Board 194
•
Management trends in the United States for low-, intermediate-, and high-risk prostate
cancer. (Abstract 5065)
Kamran A. Ahmed
Board 196
•
Bone density in men receiving androgen deprivation therapy for prostate cancer: A
randomized comparison between transdermal estrogen and luteinising hormone-releasing
hormone agonists. (Abstract 5067)
Ruth E Langley
Board 197
•
Enzalutamide monotherapy: One-year extended follow-up of a phase 2 study in hormonenaive prostate cancer patients. (Abstract 5068)
Bertrand F. Tombal
Board 198
•
Patient-reported quality of life (QOL) analysis of radium-223 dichloride (Ra-223) evaluating
pain relief from the phase 3 ALSYMPCA study. (Abstract 5069)
Sten Nilsson
Board 199
•
1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) safety in patients with
castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the
phase 3 ALSYMPCA study. (Abstract 5070)
Chris Parker
Board 200
•
Evaluation of the prostate health index (PHI) as a novel biomarker in active surveillance of
prostate cancer. (Abstract 5071)
Andrew Eichholz
Board 201
•
A safety study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic
castrate-resistant prostate cancer (mCRPC). (Abstract 5072)
Fatima Karzai
Board 202
•
An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant,
castration-resistant metastatic prostate cancer (CRPC). (Abstract 5073)
Fairooz F. Kabbinavar
Board 203
•
A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant
prostate cancer (mCRPC). (Abstract 5074)
Michelle A. Ojemuyiwa
Board 204
•
Symptomatic skeletal events (SSE) in patients with advanced prostate cancer: Results from a
phase III trial of denosumab for the prevention of skeletal-related events. (Abstract 5075)
Laurence Klotz
Board 205
•
Genetic variant in fragile histidine triad gene (FHIT) and mortality in prostate and breast
cancers: Results from the Prostate, Lung, Colon, Ovarian Cancer Screening Trial (PLCO) and
Women’s Health Initiative (WHI). (Abstract 5076)
Yan Ding
Board 206
•
Low-dose abiraterone (abi) with food in men with metastatic castration-resistant prostate
cancer (mCRPC): The Princess Margaret Cancer Centre experience. (Abstract 5077)
Raya Leibowitz-Amit
Board 207
•
Population-based analysis of a novel prognostic model for metastatic castration-resistant
prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA). (Abstract
5078)
Arun Azad
Board 208
•
Long-term efficacy and safety of androgen receptor inhibitor ODM-201 in ARADES phase I/II
trial. (Abstract 5079^)
Christophe Massard
Board 209
•
Role of serum lipids and glucose as biomarkers of prostate cancer severity. (Abstract 5080)
Alejo Rodriguez-Vida
Board 210
•
Improving the specificity of prostate cancer screening for early detection of lethal disease.
(Abstract 5081)
Hans Lilja
Board 211
•
A biopsy-based molecular diagnostic test for prediction of aggressive prostate cancer despite
variability in pathology assessment. (Abstract 5082)
Jeffry P. Simko
Board 212
•
Active surveillance in phenotypically heterogeneous early-stage prostate cancer. (Abstract
5083)
John W. Davis
Board 213
•
Prognostic value of free testosterone (FT) levels during salvage chemotherapy with
carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate
cancer (mDRPC). (Abstract 5084)
Christoph W. Reuter
Board 214
•
Neuroendocrine differentiation patterns in metastases from advanced prostate cancer.
(Abstract 5085)
Rafael E. Jimenez
Board 215
•
Effect of abiraterone acetate and low-dose prednisone on PSA in patients with nonmetastatic
castration-resistant prostate cancer: The results from IMAAGEN core study. (Abstract 5086)
Charles J. Ryan
Board 216
•
Dose escalation with high-dose-3D-conformal (HD-3D-CRT) or low-dose 3D-conformal
radiotherapy PLUS HDR brachytherapy (LD-3D-CRT+HDR-B) for intermediate- or high-risk
prostate cancer: Higher disease control and survival with lower toxicity. (Abstract 5087)
Benjamin Guix
Board 217
•
Molecular profiling of metastatic castration-resistant prostate cancer (mCRPC): Preliminary
results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).
(Abstract 5088)
George Thomas
Board 218
•
Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic
castration-resistant prostate cancer (mCRPC) patients (pts): A multicenter Italian experience.
(Abstract 5089)
Orazio Caffo
Board 219
•
Distinguishing aggressive versus nonaggressive prostate cancer using a novel prognostic
proteomics biopsy test, ProMark. (Abstract 5090)
Fred Saad
Board 220
•
The influence of insurance status on racial disparities in the treatment of African American
men with high-risk prostate cancer. (Abstract 5091)
Brandon A. Mahal
Board 221
•
Identifying biomarkers specific to bone metastases in castrate-resistant prostate cancer.
(Abstract 5092)
Maahum Ali Haider
Board 222
•
Incidence of second primary malignancies in veterans after prostate cancer diagnosis.
(Abstract 5093)
Narjust Perez-Florez
Board 223A
•
PROSPER: A phase 3 study of enzalutamide in nonmetastatic (M0) castration-resistant
prostate cancer (CRPC) patients. (Abstract TPS5094)
Maha Hussain
Board 223B
•
Prevention of symptomatic skeletal events with denosumab administered every 4 weeks
versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE). (Abstract
TPS5095)
Arnoud J. Templeton
Board 224A
•
Randomized phase II study of abiraterone acetate maintenance in combination with
docetaxel after disease progression to abiraterone acetate in metastatic castration-resistant
prostate cancer (mCRPC): ABIDO SOGUG trial. (Abstract TPS5096)
Miguel Angel Climent
Board 224B
•
A phase 1-2 study of the type I progesterone receptor (PR) antagonist onapristone (ONA) in
patients (pts) with advanced castration-resistant prostate cancer (CRPC). (Abstract TPS5097)
Joaquin Mateo
Board 225A
•
A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients
with localized prostate cancer and high-risk features of relapse. (Abstract TPS5098)
Karim Fizazi
Board 225B
•
Prostate Adenocarcinoma: TransCutaneous Hormones, PR09 (PATCH): A randomized
controlled trial of transdermal estrogen patches versus luteinising hormone releasing
hormone agonists in locally advanced and metastatic prostate cancer. (Abstract TPS5099)
Ruth E Langley
Board 226A
•
A randomized double-blind, comparative study of ARN-509 plus androgen deprivation
therapy (ADT) versus ADT alone in nonmetastatic castration-resistant prostate cancer (M0CRPC): The SPARTAN trial. (Abstract TPS5100)
Matthew Raymond Smith
Board 226B
•
Carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following
chemotherapy and androgen pathway inhibitors. (Abstract TPS5101)
Guru Sonpavde
Board 227A
•
SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT)
plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed metastatic
hormone-sensitive prostate cancer (HSPC) (NCT01809691). (Abstract TPS5102)
Neeraj Agarwal
Board 227B
•
A randomized open-label phase 2a study evaluating the efficacy and safety of radium-223
dichloride (Ra-223) in combination with abiraterone acetate or enzalutamide in patients with
castration-resistant prostate cancer (CRPC) and bone metastases. (Abstract TPS5103)
Daniel Peter Petrylak
Board 228A
•
Identifying enzalutamide resistance mechanisms in men with castration-resistant prostate
cancer. (Abstract TPS5104)
Joshi J. Alumkal
Board 228B
•
Establishing a neoadjuvant platform for developing targeted agents: Degarelix prior to
prostatectomy for patients with intermediate- and high-risk prostate cancer. (Abstract
TPS5105)
Karim A. Touijer
Board 229A
•
Targeting reciprocal feedback inhibition in the clinic: ARN509 and PI3K pathway inhibition in
patients with metastatic castration-resistant prostate cancer (mCRPC). (Abstract TPS5106)
Dana E. Rathkopf
Board 229B
•
A phase I/II study of the investigational drug alisertib in combination with abiraterone and
prednisone (AP) for patients with metastatic castration-resistant prostate cancer (mCRPC)
progressing on abiraterone. (Abstract TPS5107)
Jianqing Lin
Board 230A
•
Abiraterone plus prednisone alone or with dasatinib in chemotherapy-naive metastatic
castrate-resistant prostate cancer (mCRPC). (Abstract TPS5108)
Tanya B. Dorff
Board 230B
•
Presurgical axitinib and androgen deprivation therapy (ADT) in prostate cancer (PCa)
patients (pts) presenting with lymph node (LN) metastasis. (Abstract TPS5109)
Amado J. Zurita
Board 231A
•
A phase II randomized, open label study of sipuleucel-T versus sipuleucel-T and tasquinimod
in patients with metastatic castrate-resistant prostate cancer (CRPC). (Abstract TPS5110)
Roberto Pili
Board 231B
•
A randomized, double-blind phase 2 study of sipuleucel-T followed by indoximod or placebo
in the treatment of patients with asymptomatic or minimally symptomatic metastatic
castration-resistant prostate cancer. (Abstract TPS5111)
Gautam Gopalji Jha
Session Title: Health Services Research
Session Type: General Poster Session
Track: Health Services Research
Time: 1:15 PM - 5:00 PM
Location: S Hall A2
Board 1
•
Media reporting of practice-changing clinical trials in oncology: A North American
perspective. (Abstract 6538)
Peter Andrew
Board 2
•
A prospective comparison of times to presentation and treatment of rural and urban head
and neck cancer patients in Queensland, Australia. (Abstract 6539)
Zulfiquer Ali Otty
Board 3
•
Relationships among financial distress, emotional symptoms, and overall distress in insured
cancer patients. (Abstract 6540)
Yu-Ning Wong
Board 4
•
Impact of care at NCI comprehensive cancer centers (NCICCC) on cancer outcome: Results
from a population-based study. (Abstract 6541)
Julie Anna Wolfson
Board 5
•
Effect of pre-existing mental health comorbidities (MHC) on stage and timeliness of care of
solid tumors in Veterans Affairs Connecticut Healthcare System (VACHS). (Abstract 6542)
Roxanne Jimmy Wadia
Board 6
•
Accrual of adolescents and young adults with cancer to eligible clinical trials: A report from
the NCIC Clinical Trials Group (NCIC-CTG). (Abstract 6543)
Lesleigh S. Abbott
Board 7
•
Exclusion of patients with prior cancers from clinical trials: Is this justified? (Abstract 6544)
Noelia Tarazona
Board 8
•
Barriers to insurance coverage of next-generation tumor sequencing by U.S. payers.
(Abstract 6545)
Julia Rachel Trosman
Board 9
•
A national survey of breast cancer screening in rural America. (Abstract 6546)
Jeffrey M. Peppercorn
Board 10
•
A targeted intervention to improve awareness to molecular testing in NSCLC. (Abstract 6547)
Alona Zer
Board 11
•
BRCA1/BRCA2 (BRCA) testing in young women with breast cancer: Patterns, motivations,
and implications for treatment decisions. (Abstract 6548)
Shoshana M. Rosenberg
Board 12
•
Burnout among Canadian oncologists and oncology residents. (Abstract 6549)
Thao Phuong Nguyen
Board 13
•
Do special access programs facilitate off-label prescribing? The experience of enzalutamide
in prostate cancer. (Abstract 6550)
Nimira S. Alimohamed
Board 14
•
Choosing a cancer surgeon: Analyzing factors in patient decision making using a best-worst
scaling methodology. (Abstract 6551)
Aslam Ejaz
Board 15
•
Why is it so difficult to enroll patients in clinical trials? (Abstract 6552)
Norma Kanarek
Board 16
•
The cost of thromboembolic events in French hospitalized patients with breast or prostate
cancer. (Abstract 6553)
Isabelle Borget
Board 17
•
Physician communication on cost of cancer care under the Affordable Care Act. (Abstract
6554)
Laura LaNiel Tenner
Board 19
•
A cost-effectiveness analysis evaluating allogeneic hematopoietic cell transplantation (AHCT)
versus consolidation chemotherapy for the treatment of acute myeloid leukemia (AML) in
first complete remission. (Abstract 6556)
Abby Statler
Board 20
•
Developing a predictive model for cancer clinical trial accrual. (Abstract 6557)
Wendy R. Tate
Board 21
•
How much is the pharmaceutical industry's cost of capital for clinical research of novel
drugs? (Abstract 6558)
Henry Jacob Conter
Board 22
•
Does cancer treatment-related financial distress worsen over time? (Abstract 6559)
Lena Van Nimwegen
Board 23
•
Estimation of drug cost avoidance (DCA) and pathology cost avoidance (PCA) through
participation in NCIC clinical trials group (NCIC-CTG) phase III clinical trials in Canada.
(Abstract 6560)
Patricia A. Tang
Board 24
•
Physician experience and attitudes toward addressing the cost of cancer care. (Abstract
6561)
Ivy Altomare
Board 25
•
Cancer cost evaluation in chemotherapy (chemo)-naive patients (pts) treated under a payersponsored pathway program. (Abstract 6562)
Bruce A. Feinberg
Board 26
•
Patients and physicians can discuss the actual costs of cancer treatment with high interest
and little conflict. (Abstract 6563)
Ronan Joseph Kelly
Board 27
•
Staging in early breast cancer: Help or hindrance? (Abstract 6564)
Naera Waters
Board 28
•
Cost-effectiveness of alternative adjuvant bisphosphonate regimens in postmenopausal
women with early breast cancer. (Abstract 6565)
Katherine Elizabeth Reeder-Hayes
Board 29
•
Impact of prior cancer on eligibility for lung cancer clinical trials. (Abstract 6566)
David E. Gerber
Board 30
•
Asian and non-Asian disparities in outcomes of head and neck cancer (HNC). (Abstract 6567)
Jason D. Kim
Board 31
•
Socioeconomic status and lifestyle behaviors in cancer survivors. (Abstract 6568)
Hiten Naik
Board 32
•
Impact of patient navigation on women with cervical abnormalities. (Abstract 6569)
Electra D. Paskett
Board 33
•
Urban and rural differences in outcomes of head and neck cancer (HNC). (Abstract 6570)
Tian Yang Darren Liu
Board 34
•
Bridges to care: Results from a novel cancer outreach initiative. (Abstract 6571)
Christopher S. Lathan
Board 35
•
Patterns of hospice use for metastatic cancer in the American Indian/Alaska Native and nonHispanic white populations. (Abstract 6572)
Stacey Shiovitz
Board 36
•
The association between American Indian/Alaska Native race and time to treatment initiation
for nonmetastatic breast, colorectal, and lung cancer patients in Medicare. (Abstract 6573)
Scott V. Adams
Board 37
•
Impact of race on outcome of stage II colon cancer subjects not receiving adjuvant therapy.
(Abstract 6574)
Amy L. Cleveland
Board 38
•
Low area-level socioeconomic status and breast cancer biologic features in a diverse
population-based sample. (Abstract 6575)
Jennifer J. Griggs
Board 39
•
Disparities in breast cancer surgery: The lingering effect of race. (Abstract 6576)
Vanessa Sheppard
Board 40
•
Impact of location to repeat mobile mammography utilization trends: 10-year analysis of a
comprehensive urban cancer center. (Abstract 6577)
Elizabeth Carloss Riley
Board 41
•
Misconceptions in colorectal cancer among a community-based population and CRC
screening adherence. (Abstract 6578)
Thomas Guerrero
Board 42
•
Disparities in age-related incidence of colon and rectal cancer in the United States, 19752010. (Abstract 6579)
Christina Edwards Bailey
Board 43
•
Use of the 21-gene recurrence score assay (RS) and chemotherapy (CT) across health care
(HC) systems. (Abstract 6580)
Anosheh Afghahi
Board 44
•
Current quality gaps in rectal cancer pathology reports. (Abstract 6581)
Zaid M. Abdelsattar
Board 45
•
Survival of U.S. Medicare patients with advanced non-small cell lung cancer by line of
therapy. (Abstract 6582)
John R. Penrod
Board 46
•
Influence of age on incident diabetes (DM) and cardiovascular disease (CVD) among prostate
cancer survivors receiving androgen deprivation therapy (ADT). (Abstract 6583)
Alicia Katherine Morgans
Board 47
•
Reporting quality of abstracts in cancer clinical trials. (Abstract 6584)
Shanthi Sivendran
Board 48
•
Factors associated with loss of employment among metastatic patients. (Abstract 6585)
Amye Tevaarwerk
Board 49
•
Impact of National Cancer Institute (NCI)-mandated scientific review on protocol
development and content. (Abstract 6586)
Ning Ning
Board 50
•
Looking beyond the first cycle in phase I cancer clinical trials. (Abstract 6587)
Shing Mirn Lee
Board 51
•
The risks of debilitating falls (DFs) in patients (pts) with cancer: The Manitoba experience.
(Abstract 6588)
Joel Roger Gingerich
Board 52
•
Medical oncology patient readmissions: Are they preventable? (Abstract 6589)
Andrew S. Epstein
Board 53
•
Evaluating the utility of baseline cardiac function assessment in early-stage breast cancer
treatment. (Abstract 6590)
Sandy Rose Truong
Board 54
•
What is the extent of the AYA gap for young adults with cancer? (Abstract 6591)
Julie Anna Wolfson
Board 55
•
Utilizing nomogram-predicted outcomes as the control group in randomized clinical trials.
(Abstract 6592)
Arielle C. Lutterman
Board 56
•
Experimental fertility preservation (FP) interventions in prepubertal (PP) boys with cancer: A
report on preferences of teenage cancer survivors, parents, and providers. (Abstract 6593)
Abha A. Gupta
Board 57
•
Comparison of RCC surveillance guidelines: Competing tradeoffs. (Abstract 6594)
Tracey Lynn Krupski
Board 58
•
Biomarker testing and time-to-treatment decision in patients with advanced non-small cell
lung cancer. (Abstract 6595)
Charles Henry Lim
Board 59
•
Staging imaging for metastatic disease in patients with early stage breast cancer: What do
physicians think of the ASCO top-5 recommendation? (Abstract 6596)
Demetrios Simos
Board 60
•
A rank-based randomized phase II design when the phase III design is based on overall
survival (OS). (Abstract 6597)
William Leonard Mietlowski
Board 61
•
Impact of weekend admission on hospital length of stay and organ failure in pediatric
leukemia patients at free-standing U.S. children’s hospitals. (Abstract 6598)
Elizabeth Kimbell Goodman
Board 62
•
Conditional survival in melanoma and thyroid cancer patients. (Abstract 6599)
Megan Rist Haymart
Board 63
•
Clinical utility of tumor measurement (TM)-based metrics in phase II (P2) to predict phase
III (P3) overall survival (OS) outcomes using the RECIST 1.1 database. (Abstract 6600)
Sumithra J. Mandrekar
Board 64
•
A virtual consult service to optimize clinical trial participation in patients with metastatic
breast cancer. (Abstract 6601)
Karen Anne Cadoo
Board 65
•
Improving cancer clinical trial accrual in Ontario, Canada: The clinical trials infrastructure
fund (CTIF) experience. (Abstract 6602)
Lesleigh S. Abbott
Board 66
•
The clinical oncology treatment plan and summary implementation guide: An interoperable
HL7 document standard to improve the quality of cancer care. (Abstract 6603)
Jeremy Warner
Board 67
•
Febrile neutropenia and mortality in patients with breast cancer, lung cancer, and nonHodgkin lymphoma. (Abstract 6604)
Aniket A Kawatkar
Board 68
•
Trends in the quality of preventive care before and after prostate cancer diagnosis. (Abstract
6605)
Lauren P. Wallner
Board 69
•
Treatment decision making in advanced cancer: Communication about patient values and
preferences. (Abstract 6606)
Hanneke W.M. Van Laarhoven
Board 71
•
Trends and safety of image-guided percutaneous pleural biopsies in cancer patients.
(Abstract 6608)
Melissa Kate Accordino
Board 72
•
The association of treatment breaks with survival in metastatic cancer. (Abstract 6609)
Kuan Rui (Sean) Tan
Board 73
•
Influence of extent of lymphadenectomy on survival for localized non-small cell lung cancer.
(Abstract 6610)
Daniel Jacob Becker
Board 74
•
The impact of PET-CT on staging, management, and prognostication of small-cell lung
cancer. (Abstract 6611)
Alona Zer
Board 75
•
Measurement of urinary incontinence after prostate surgery from data-mining electronic
health records (EHR). (Abstract 6612)
Tina Hernandez-Boussard
Board 76
•
Improved access to tobacco cessation services for cancer patients using a statewide
collaborative approach. (Abstract 6613)
Jane Alcyne Severson
Board 77
•
Prevalence of prescribing errors resulting in administration of incorrect dosages of
antineoplastic treatment. (Abstract 6614)
Thea Otto Mattsson
Board 78
•
Can we identify patients at risk for discordance in preferred and actual role in cancer
treatment decision making? (Abstract 6615)
Leah L. Zullig
Board 79
•
Which formats for communicating patient-reported outcomes (PROs) work best? (Abstract
6616)
Michael Donald Brundage
Board 80
•
NCI pilot intervention program to assist accrual for challenging late-phase clinical trials.
(Abstract 6617)
Andrea Denicoff
Board 81
•
Next steps for IBM Watson Oncology: Scalability to additional malignancies. (Abstract 6618)
Andrew S. Epstein
Board 82
•
Impact of recent clinical trials on the use of chemotherapy for resectable non-small cell lung
cancer in the United States. (Abstract 6619)
Ravi Rajaram
Board 83
•
HIV and predictors of advanced cancer at presentation: Uganda. (Abstract 6620)
Manoj Menon
Board 84
•
Relationship between type of therapeutic intervention and funding source in randomized
clinical trials (RCTs) in oncology. (Abstract 6621)
Fernando Costa Santini
Board 85
•
Permanent stoma use in rectal cancer surgery in Canada: A population-based analysis.
(Abstract 6622)
Geoffrey A. Porter
Board 86
•
Standardized criteria for required palliative care consultation on the solid tumor oncology
service. (Abstract 6623)
Kerin B. Adelson
Board 87
•
Development of a new oncology quality metric: The rate of evidence-based adherence.
(Abstract 6624)
Kerin B. Adelson
Board 88
•
Associations among socioeconomic status (SES), patterns of care and outcomes in breast
cancer (BC) patients (pts) in a universal health care system: Ontario’s experience. (Abstract
6625)
Alexander Kumachev
Board 89
•
Practice of venous thromboembolism (VTE) prophylaxis in hospitalized cancer patients at a
comprehensive cancer center. (Abstract 6626)
Maria Alma Rodriguez
Board 90
•
An electronic prompt prior to myelosuppressive therapy to improve hepatitis B virus
screening. (Abstract 6627)
Jordan J. Feld
Board 91
•
Coordinating cancer care: What organizations do to deliver high-quality breast cancer care.
(Abstract 6628)
Nina A. Bickell
Board 92
•
An international survey of health care providers involved in the management of cancer
patients exposed to cardiotoxic therapies. (Abstract 6629)
Susan Faye Dent
Board 93
•
Combining survival and toxicity effect sizes from clinical trials into an interpretable, qualityadjusted survival effect size estimate of treatment efficacy. (Abstract 6630)
Jeff A. Sloan
Board 94
•
Abnormal screening mammogram follow-up: Improving time and timeliness benchmarks.
(Abstract 6631)
Seyed S. Pairawan
Board 95
•
Defining quality and value in a prospective study of an emergency department (ED) febrile
neutropenia pathway (FNP). (Abstract 6632)
Michael Kenneth Keng
Board 96
•
Risk of hematologic malignancies following radiation treatment for well-differentiated thyroid
cancer in the United States over 37 years. (Abstract 6633)
Surbhi Sidana
Board 97
•
Implementation of a written chemotherapy consent form with explicit goals of treatment in a
university center. (Abstract 6634)
Brendan F. Curley
Board 98
•
Impact of pretreatment variables on overall survival of patients with stage IV NSCLC: An
analysis of the Veterans Affairs Central Cancer Registry. (Abstract 6635)
Danielle Marie File
Board 99
•
Outcomes of in-hospital cardiopulmonary resuscitation in patients with metastatic cancer.
(Abstract 6636)
Touqir Zahra
Board 100
•
Enhancing pathway adherence in a quality initiative for breast cancer. (Abstract 6637)
Johnathan M. Lancaster
Board 101A
•
Simone-simulation in medical oncology education: Part I—Pilot feasibility study. (Abstract
TPS6638)
Shelly Sud
Board 101B
•
Prospective survey on patient satisfaction and quality-of-life impact concerning the
administration of fentanyl pectin nasal spray for breakthrough pain in cancer: Qualipec
study. (Abstract TPS6639)
Ignacio Delgado
Session Title: Leukemia, Myelodysplasia, and Transplantation
Session Type: General Poster Session
Track: Leukemia, Myelodysplasia, and Transplantation
Time: 1:15 PM - 5:00 PM
Location: S Hall A2
Board 319
•
The effect of anti-thymocyte globulin on outcomes of reduced intensity conditioning for acute
myelogenous leukemia. (Abstract 7034)
Patrick Alan Hagen
Board 320
•
Allogeneic stem cell transplantation (SCT) using a CAT-bu conditioning regimen in patients
with advanced myelodysplastic/myeloproliferative disorders (MDS-MPDs). (Abstract 7035)
Julie Cote
Board 321
•
Reduced-intensity cord blood transplantation following a regimen using fludarabine and
busulfan in adult patients with advanced hematologic malignancies. (Abstract 7036)
Naoko Takei
Board 322
•
Inflammation and depression in allogeneic stem cell transplant recipients. (Abstract 7037)
Alexandra A. Erdmann
Board 323
•
Effects of acute graft-versus-host-disease on physical and psychological functioning following
hematopoietic stem cell transplantation. (Abstract 7038)
Mackenzie L Erdmann
Board 324
•
Haploidentical stem cell transplantation (Haplo-HSCT) with nonmyeloablative conditioning
regimen (NMAC) and postinfusion cyclophosphamide in advanced non-Hodgkin lymphoma
(NHL) patients. (Abstract 7039)
Sylvain Garciaz
Board 325
•
Optimizing donor selection for public cord blood banking in Korea. (Abstract 7040)
Jung Lim Lee
Board 326
•
Myeloablative busulfan with cyclophosphamide (BuCy) versus busulfan with fludarabine
(BuFlu) in myeloid neoplasms. (Abstract 7041)
Renju V. Raj
Board 327
•
Cyclophosphamide/fludarabine-based nonmyeloablative matched related/unrelated
allotransplant for myelodysplasia. (Abstract 7042)
Muhammad Rizwan-ul-Haq Khawaja
Board 328
•
Next-generation sequencing to identify mutations that may predict outcome after allogeneic
stem cell transplantation for AML. (Abstract 7043)
Marlise Rachael Luskin
Board 329
•
Trends in hospitalization outcomes of elderly patients undergoing allogeneic stem cell
transplantation for acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). (Abstract
7044)
Guru Subramanian Guru Murthy
Board 330
•
LINAC-based intensity modulated total marrow irradiation (TMI) in addition to myeloablative
fludarabine/IV busulfan conditioning prior to allogeneic stem cell transplant for high-risk
hematologic malignancies: A phase I study. (Abstract 7045)
Pritesh Rajni Patel
Board 331
•
The impact of CD34+ cell dose and comorbidities on engraftment following autologous
hematopoietic stem cell transplantation (ASCT). (Abstract 7046)
Mark A Fiala
Board 332
•
Impact of body mass index (BMI) on plerixafor efficacy during hematopoietic progenitor cell
(HPC) mobilization. (Abstract 7047)
Rebecca M. Gonzalez
Board 333
•
Early rituximab failure (ERF) in relapsed diffuse large b-cell lymphoma (DLBCL) and
prediction of futility of autologous hematopoietic cell transplantation (AHCT). (Abstract 7048)
Mehdi Hamadani
Board 334
•
Social connectivity and outcomes for adolescents and young adults (AYAs) with acute
lymphoblastic leukemia (ALL). (Abstract 7049)
Andrew Fintel
Board 335
•
Cytogenetic and molecular testing in patients with chronic myeloid leukemia (CML) in a
prospective observational study (SIMPLICITY). (Abstract 7050)
Stuart L. Goldberg
Board 336
•
Chronic myelomonocytic leukemia: Next-generation sequencing in 30 treatment-naive cases.
(Abstract 7051)
Priyanka Priyanka
Board 337
•
Is obinutuzumab cost-effective in the first-line treatment of CLL? (Abstract 7052)
David Leroy Veenstra
Board 338
•
Feasibility of BIBF1120 (nintedanib) combined with low-dose cytarabine in elderly patients
with AML ineligible for intensive treatment. (Abstract 7053)
Utz Krug
Board 339
•
Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic
myeloid leukemia in chronic phase: A mixed-treatment comparison. (Abstract 7054)
Belal Firwana
Board 340
•
Association of obesity with cytogenetic risk in adult acute myeloid leukemia (AML). (Abstract
7055)
Laura Elizabeth Finn
Board 341
•
Prospective assessment of chemotherapy-induced peripheral neuropathy (CIPN) in children
with standard-risk acute lymphoblastic leukemia (SR ALL): Results of Children’s Oncology
Group (COG) AALL0932. (Abstract 7056)
Nina S. Kadan-Lottick
Board 342
•
Covariation of psychological and inflammatory variables in patients with chronic lymphocytic
leukemia receiving ibrutinib. (Abstract 7057)
Neha Niranjan Godiwala
Board 343
•
Effect of syk inhibition by TAK659 on proliferative, survival, and migratory signals from the
microenvironment in chronic lymphocytic leukemia. (Abstract 7058)
Noelia Purroy
Board 344
•
Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic
leukemia (CLL) and non-Hodgkin lymphoma (NHL). (Abstract 7059)
Paul M. Barr
Board 345
•
Long-term evaluation of vascular toxicity in patients with Ph+ leukemias treated with
bosutinib. (Abstract 7060)
Jorge E. Cortes
Board 347
•
Lipid cell membrane composition: A novel therapeutic target in cancer. (Abstract 7062)
Ravi Kiran Bobba
Board 348
•
Preliminary safety and efficacy of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (IBR)
in patients (pts) with hairy cell leukemia (HCL). (Abstract 7063)
Jeffrey Alan Jones
Board 349
•
Phase II study of combination of hyperCVAD with ponatinib in front-line therapy of patients
(pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL).
(Abstract 7064)
Susan Mary O'Brien
Board 350
•
Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline
therapy for adults with CD-20 positive ALL. (Abstract 7065)
Elias Jabbour
Board 351
•
Landmark analysis of overall survival (OS) in patients with chronic (CP) or accelerated (AP)
phase chronic myeloid leukemia (CML) treated with omacetaxine mepesuccinate. (Abstract
7066)
Meir Wetzler
Board 352
•
Correlation of KIT expression with higher FLT3 mutations and impact on clinical outcome in
patients newly diagnosed with acute myeloid leukemia (AML). (Abstract 7067)
Hassan Alkhateeb
Board 353
•
Predicting prognosis in patients with acute myeloid leukemia: The role of next-generation
sequencing and mutational profiling. (Abstract 7068)
Caroline E Sloan
Board 354
•
Impact of circulating members of the insulin-like growth factor receptor (IGF-1R) axis on
outcomes in acute myeloid leukemia. (Abstract 7069)
Reem Karmali
Board 355
•
ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML).
(Abstract 7070)
Masamichi Mori
Board 356
•
ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in combination with cytarabine
and anthracycline in acute myeloid leukemia (AML). (Abstract 7071)
Yoko Ueno
Board 357
•
One-year and longer-term molecular responses to nilotinib and dasatinib for newly diagnosed
chronic myeloid leukemia: A matching-adjusted indirect comparison. (Abstract 7072)
James E. Signorovitch
Board 358
•
ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid
leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib
(IM). (Abstract 7073)
Richard A. Larson
Board 359
•
ASCO 2014: High prevalence of FLT-3 ITD mutations in patients (pts) with AML who present
with CNS relapse. (Abstract 7074)
Simon Abi Aad
Board 360
•
Outcomes among patients with isolated myeloid sarcoma: A SEER database analysis.
(Abstract 7075)
Maryam Movassaghian
Board 361
•
Role of wnt/ß-catenin pathway in myeloid neoplasms with 5q deletion: A new therapeutic
target. (Abstract 7076)
Nupur Mittal
Board 362
•
Correlation between peripheral blood and bone marrow regarding FLT3 ITD and NPM1
mutational status in patients with AML. (Abstract 7077)
Weigang Tong
Board 363
•
Longer-term follow up of a phase 1 study of ponatinib in patients (pts) with Philadelphia
chromosome-positive (Ph+) leukemias. (Abstract 7078)
Moshe Talpaz
Board 364
•
Comparison of angiopoietin-1 and -2 and VEGF expression in bone marrow and peripheral
blood leukemic cells of patients with acute promyelocytic leukemia. (Abstract 7079)
Mariana Scaranti
Board 365
•
Central nervous system relapse in adults with acute lymphoblastic leukemia. (Abstract 7080)
Muhamed Baljevic
Board 366
•
Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias
resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term
follow up of the PACE trial. (Abstract 7081)
Hagop M. Kantarjian
Board 367
•
Phase 1 study of the angiopoietin 1/2 neutralizing peptibody, trebananib, in acute myeloid
leukemia. (Abstract 7082)
Eunice S. Wang
Board 368
•
Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic
leukemia (CLL): Results of the phase II GAGE (GAO4768g) trial. (Abstract 7083)
Joseph M. Flynn
Board 369
•
Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in
patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias. (Abstract 7084)
Andreas Hochhaus
Board 370
•
Trends in first-line TKI prescribing preferences (PPrefs) among U.S.-based hematologyoncology physicians (HOPs) for patients with chronic phase chronic myelogenous leukemia
(CP-CML). (Abstract 7085)
Neil P. Shah
Board 371
•
Standardized costs and outcome in children treated with gemtuzumab on the AAML0531
trial: A report from the Children’s Oncology Group. (Abstract 7086)
Richard Aplenc
Board 372
•
Distinct biomarkers as prognostic in chronic lymphocytic leukemia patients treated with
alvocidib and lenalidomide as single agents or combination regimens thereof. (Abstract
7087)
William E. Pierceall
Board 373
•
Hyperdiploidy in AML: Outcomes of acute myelogenous leukemia (AML) patients (pts) with a
hyperdiploid karyotype. (Abstract 7088)
Aditya Shetty
Board 374
•
European leukemia net (ELN) 2013 response categories: Impact on clinical outcomes across
four frontline tyrosine kinase inhibitor (TKI) modalities in chronic phase CML. (Abstract 7089)
Preetesh Jain
Board 375
•
CD96 antibody TH-111 for detection of AML leukemic stem cells, and purging of autografts
for stem cell transplantation. (Abstract 7090)
Matthias Staudinger
Board 376
•
Economic burden of tyrosine kinase inhibitor (TKI) treatment failure in patients with chronic
myeloid leukemia (CML). (Abstract 7091)
Yaozhu J Chen
Board 377
•
Association of epidemiologic exposures with complete remission after therapy in acute
myeloid leukemia (AML). (Abstract 7092)
Laura Elizabeth Finn
Board 378
•
The benefit of treatment with quizartinib and subsequent bridging to HSCT for FLT3-ITD(+)
patients with AML. (Abstract 7093^)
Mark J. Levis
Board 379
•
Clinical significance of MYC expression in acute myeloid leukemia. (Abstract 7094)
Maro Ohanian
Board 380
•
Expression and function of TIM-3, a potential therapeutic target in acute myeloid leukemia.
(Abstract 7095)
Catherine Joy Lee
Board 381
•
A next-generation sequencing approach to capturing CEBPA: A hematologic malignancy
sequencing panel capturing clinically useful targets. (Abstract 7096)
Jennifer J. Morrissette
Board 382
•
Propensity score matched comparison of intermediate-intensity chemotherapy induction
versus intensive chemotherapy induction in elderly patients (age = 60) with acute myeloid
leukemia (AML). (Abstract 7097)
Koichi Takahashi
Board 383
•
Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid
leukemia (AML) and high-risk myelodysplastic syndrome (MDS). (Abstract 7098)
Naval Guastad Daver
Board 384
•
Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with
relapsed chronic lymphocytic leukemia (CLL): Phase 3 results. (Abstract 7099)
Paolo Ghia
Board 385
•
Final results of a randomized phase 2 study showing the clinical benefit of quizartinib
(AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia.
(Abstract 7100)
Gary J. Schiller
Board 386
•
A decision-analytic model of idelalisib and rituximab combination therapy versus rituximab
monotherapy in relapsed, unfit chronic lymphocytic leukemia. (Abstract 7101)
Alexander Xenakis
Board 387
•
Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML)
receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance).
(Abstract 7102)
Heidi D. Klepin
Board 388
•
Comprehensive genetic characterization of 12 AML cell lines using a novel AML targeted
sequencing strategy. (Abstract 7103)
Andrew R. Carson
Board 389
•
A DNA methylation signature for stemness in acute myeloid leukemia. (Abstract 7104)
Timothy J. Triche
Board 390
•
Treatment patterns, mortality, and costs of care in unfit patients (pts) with relapsed chronic
lymphocytic leukemia (CLL). (Abstract 7105)
Helen Varker
Board 391
•
Activity of the Wee1 inhibitor MK1775 plus cytarabine in AML through interference with DNA
repair capacity at the DNA level. (Abstract 7106)
Raoul Tibes
Board 392
•
Cellular level of Abelson interactor-1 as a marker predicting chemoresistance. (Abstract
7107)
Anna Chorzalska
Board 393
•
The clinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid
leukemia: A retrospective multicenter study. (Abstract 7108)
Serdal Korkmaz
Board 394
•
GATA1 in patients with essential thrombocythemia and anagrelide treatment. (Abstract
7109)
Ciro Roberto Rinaldi
Board 395
•
Predictive analysis of microenvironment impact on clinical outcomes to drug agents using
simulation of myeloproliferative neoplasms. (Abstract 7110)
Peter P. Sayeski
Board 396
•
A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis.
(Abstract 7111)
Koji Sasaki
Board 397
•
Survival outcomes of primary myelodysplastic syndrome in United States. (Abstract 7112)
Guru Subramanian Guru Murthy
Board 398
•
PKC412 (midostaurin) is safe and highly effective in systemic mastocytosis: Follow up of a
single-center Italian compassionate use. (Abstract 7113)
Cristina Papayannidis
Board 399
•
Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1
results. (Abstract 7114)
Srdan Verstovsek
Board 400
•
Clinical relevance of genetic mutations on treatment response to the demethylating agents in
myelodysplastic syndromes. (Abstract 7115)
Hyun Ae Jung
Board 401
•
Impact of high-dose radiation exposure on myelodysplastic syndrome patients treated with
azacitidine in Nagasaki atomic bomb survivors. (Abstract 7116)
Tatsuro Jo
Board 402
•
Impact of palifermin use on pediatric patient (PedPts) hematopoietic cell transplant (HCT)
outcomes. (Abstract 7117)
Wael Saber
Board 403
•
Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Male
predominance, propensity for extramedullary involvement, and poor outcomes. (Abstract
7118)
Naveen Pemmaraju
Board 404A
•
An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an
investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with
previously treated chronic myeloid leukemia (CML). (Abstract TPS7119)
Kimmo Porkka
Board 404B
•
Multicenter, phase III, open-label, randomized study in relapsed/refractory CLL to evaluate
the benefit of GDC-0199 (ABT-199) plus rituximab compared with bendamustine plus
rituximab. (Abstract TPS7120^)
Mehrdad Mobasher
Board 405A
•
A phase 2 open-label study of the efficacy of ABT-199 (GDC-0199) in patients with relapsed
or refractory (R/R) chronic lymphocytic leukemia (CLL) harboring 17p deletion. (Abstract
TPS7121)
William G. Wierda
Board 405B
•
DUO: A phase 3 trial of the PI3K-d,? inhibitor IPI-145 versus ofatumumab in patients with
relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
(Abstract TPS7122)
Ian Flinn
Board 406A
•
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and
safety of idelalisib in combination with bendamustine and rituximab for previously untreated
chronic lymphocytic leukemia. (Abstract TPS7123)
Gilles A. Salles
Board 406B
•
Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic
myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and
ENESTpath. (Abstract TPS7124)
Francois-Xaxier Mahon
Board 407A
•
Phase 3 study of oral lenalidomide as maintenance therapy for patients with B-cell chronic
lymphocytic leukemia (CLL). (Abstract TPS7125)
Asher Alban Akmal Chanan-Khan
Board 407B
•
Connect MDS and AML: The myelodysplastic syndromes (MDS) and acute myeloid leukemia
(AML) disease registry. (Abstract TPS7126)
David P. Steensma
Board 408A
•
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and
safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously
treated chronic lymphocytic leukemia (CLL). (Abstract TPS7127)
Herbert Aaron Eradat
Board 408B
•
RESPONSE 2: A phase 3b study evaluating the efficacy and safety of ruxolitinib in patients
with hydroxyurea (HU)-resistant/intolerant polycythemia vera (PV) versus best available
therapy (BAT). (Abstract TPS7128^)
Francesco Passamonti
Session Title: Lymphoma and Plasma Cell Disorders
Session Type: General Poster Session
Track: Lymphoma and Plasma Cell Disorders
Time: 1:15 PM - 5:00 PM
Location: S Hall A2
Board 233
•
Chemotherapy or combined modality therapy for early-stage Hodgkin lymphoma: A
comparative, population-based study. (Abstract 8546)
Rajesh Shrestha
Board 234
•
Pharmacokinetics and tolerability of doxorubicin in newly diagnosed lymphoma patients with
hepatic impairment. (Abstract 8547)
Catherine Lai
Board 235
•
Survival of patients with different AIDS-related lymphoma subtypes. (Abstract 8548)
Marcus Hentrich
Board 236
•
Utility assessment of interim FDG-PET/CT in frontline therapy of patients with diffuse large Bcell lymphoma (DLBCL). (Abstract 8549)
Scott F. Huntington
Board 237
•
Differences in disease characteristics, treatment patterns, and outcomes between men (M)
and women (W) with follicular lymphoma (FL): Prospective evaluation of 2,650 U.S. patients
(pts). (Abstract 8550)
Chadi Nabhan
Board 238
•
A phase 1 multicenter clinical trial of alemtuzumab and CHOP chemotherapy for peripheral Tcell lymphomas. (Abstract 8551)
Rena Buckstein
Board 239
•
Extranodal natural killer T-cell lymphoma, nasal-type: A new staging system from CSWOG—A
multicenter study. (Abstract 8552)
Tongyu Lin
Board 240
•
The Bruton’s tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with
relapsed and refractory non-GCB-DLBCL. (Abstract 8553)
Martin Dyer
Board 241
•
Retrospective analysis of treatment patterns and outcomes with subcutaneous (SQ)
bortezomib (BTZ) in patients (pts) with relapsed mantle cell lymphoma (MCL). (Abstract
8554)
Vijayveer Bonthapally
Board 242
•
The outcome of patients with "nodal" peripheral T-cell lymphomas in a complete response
following standard chemotherapy. (Abstract 8555)
Jean-Michel Lavoie
Board 243
•
Results of a phase I study of bendamustine in combination with ofatumumab, carboplatin,
and etoposide (BOCE) for refractory or relapsed aggressive B-cell non-Hodgkin lymphomas
(NHL). (Abstract 8556)
Sameh Gaballa
Board 244
•
Post-treatment PET scan is highly predictive of outcome (PFS and OS) in MCL pts treated
with R-Hyper-CVAD in the frontline setting regardless of MIPI score. (Abstract 8557)
Anthony R. Mato
Board 245
•
Utility of surveillance imaging in patients with non-Hodgkin lymphoma. (Abstract 8558)
Rangaswamy Chintapatla
Board 246
•
First-in-human study of 4SC-202, a novel oral HDAC inhibitor in advanced hematologic
malignancies (TOPAS study). (Abstract 8559)
Bastian von Tresckow
Board 247
•
A multicenter study of 66 patients with spinal cord compression at diagnosis of B-cell nonHodgkin lymphoma. (Abstract 8560)
Isabelle Fleury
Board 248
•
Stage migration and survival in DLBCL patients before and after the approval of positron
emission tomography (PET) scan: Population-based analysis using the U.S. National Cancer
Data Base (NCDB). (Abstract 8561)
Anusha Reddy Madadi
Board 249
•
Early negative circulating EBV DNA as prediction of survival in extranodal NK/T-cell
lymphoma, nasal type (ENKL). (Abstract 8562)
Chaoyong Liang
Board 250
•
Responses to romidepsin by line of therapy in patients with relapsed/refractory (R/R)
peripheral T-cell lymphoma (PTCL). (Abstract 8563)
Francine M. Foss
Board 251
•
Treatment outcomes and prognostic factors for primary mediastinal B-cell lymphoma: The
MD Anderson experience. (Abstract 8564)
Mohamed Amin Ahmed
Board 252
•
The utility of HTS TCR analyses in the management of patients with T-cell malignancies.
(Abstract 8565)
Ilan Lanny Kirsch
Board 253
•
A phase 1/2 study of lenalidomide and bendamustine (LEBEN) in chemorefractory Hodgkin
lymphoma. (Abstract 8566)
Gaetano Corazzelli
Board 254
•
Temsirolimus (TEM) and lenalidomide (LEN) in relapsed/refractory Hodgkin lymphoma
including in patients with prior exposure to brentuximab vedotin (BV). (Abstract 8567)
Jagoda Jasielec
Board 255
•
Allogeneic hematopoietic stem cell transplantation in a cohort of 314 advanced lymphoma
patients. (Abstract 8568)
Sylvain Garciaz
Board 256
•
PET/CT in lymphoma surveillance: A large single-center experience. (Abstract 8569)
Lourdes M. Mendez
Board 257
•
CNS involvement in patients with AIDS-related lymphomas. (Abstract 8570)
Jitesh Joshi
Board 258
•
Association of helicobacter pylori CagA translocation with the expression of CagA-signaling
transduction molecules in gastric mucosa-associated lymphoid tissue lymphoma. (Abstract
8571)
Sung Hsin Kuo
Board 259
•
Hodgkin lymphoma-like post-transplant lymphoproliferative disorder (HL-PTLD):
Characteristics, survival, and prognostication in a large U.S. cohort. (Abstract 8572)
Aaron Seth Rosenberg
Board 260
•
Polymorphism BCL2 c(-717)a and prognosis in diffuse large B-cell lymphoma patients.
(Abstract 8573)
Angelo Borsarelli Carvalho Brito
Board 261
•
Reverse phase protein microarray for identification of IL6 receptor ligation-induced insulin
receptor, PI3K/AKT, and JAK/STAT signaling pathways in the CARD11 mutated lymphoma
cell line OCI-Ly3. (Abstract 8574)
Greg Coffey
Board 262
•
Responses to romidepsin in patients with cutaneous T-cell lymphoma (CTCL) with tumors
and/or folliculotropic involvement. (Abstract 8575)
Francine M. Foss
Board 263
•
Effect of siltuximab on lean body mass (LBM) in multicentric Castleman’s disease (MCD)
patients (pts). (Abstract 8576)
Michael B. Sawyer
Board 264
•
Feasibility and efficacy of high doses of antimetabolites followed by high-dose sequential
chemoimmunotherapy (R-HDS) and autologous stem cell transplant (ASCT) in patients (pts)
with systemic B-cell lymphoma (BCL) and central nervous system (CNS) involvement: A
multicenter phase II trial. (Abstract 8577)
Andres J.M. Ferreri
Board 265
•
Hepatitis C co-infection in HIV-positive patients treated for lymphoma. (Abstract 8578)
Ashwin Sridharan
Board 266
•
Longitudinal diffusion MRI in PCNSL treated with methotrexate, rituximab, and temozolomide
(MRT). (Abstract 8579)
Vyshak Chandra
Board 267
•
Antitumor activity of inhibiting SYK kinase with TAK-659, an investigational agent, in DLBCL
models. (Abstract 8580)
Jessica Huck
Board 268
•
Efficacy, safety, and cost efficiency of rituximab, gemcitabine, dexamethasone, and
oxaliplatin (RGDOx) in B-cell NHL: Report of the prospective multicentric trial NCT01019863.
(Abstract 8581)
Marco Lefebvre
Board 269
•
A phase I/II trial of the combination of romidepsin and lenalidomide in patients with
relapsed/refractory lymphoma and myeloma: Phase I results. (Abstract 8582)
Matthew Alexander Lunning
Board 270
•
Treatment of HIV-associated plasmablastic lymphoma: A single-center experience with 25
patients. (Abstract 8583)
Ibrahim Fuad Ibrahim
Board 271
•
Older patients and risk of developing and dying from bleomycin-induced lung toxicity.
(Abstract 8584)
Preethi Reddy Marri
Board 272
•
Mantle cell lymphoma: Toll-like receptors (TLRs) and B-cell receptor (BCR) gene expression
analysis for identification of a distinct BCR-activated subset, with germinal center signature
and indolent biology. (Abstract 8585)
Ariz Akhter
Board 273
•
Cyclophosphamide, bortezomib, and dexamethasone (CYBORD) treatment for
relapsed/refractory multiple myeloma. (Abstract 8586)
Jorge Monge
Board 274
•
Focal bone marrow processes and early bone lesions in patients with multiple myeloma (MM)
precursor diseases??: A prospective study using molecular imaging. (Abstract 8587)
Manisha Bhutani
Board 275
•
Effect of combination of proteasome inhibitor marizomib and immunomodulatory agent
pomalidomide on synergistic cytotoxicity in multiple myeloma. (Abstract 8588)
Dharminder Chauhan
Board 276
•
MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose
dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor
(PI)-exposed myeloma. (Abstract 8589)
Paul G. Richardson
Board 278
•
A randomized phase 3 trial of thalidomide and prednisone (TP) as maintenance therapy
following autologous stem cell transplantation (ASCT) in patients with multiple myeloma
(MM): An updated analysis of the NCIC Clinical Trials Group MY10 trial. (Abstract 8591)
Annette E. Hay
Board 279
•
Age-related trends in utilization and outcome of autologous haematopoietic cell
transplantation for multiple myeloma. (Abstract 8592)
Holger W Auner
Board 280
•
Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose
dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall
survival (OS) results of MM-003 after adjustment for crossover. (Abstract 8593)
Gareth J Morgan
Board 281
•
Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating
weekly carfilzomib in combination with dexamethasone for patients with relapsed or
refractory multiple myeloma. (Abstract 8594^)
James R. Berenson
Board 282
•
Free light chain assay and cytogenetic abnormalities for identification of high-risk smoldering
myeloma. (Abstract 8595)
Jeremy Todd Larsen
Board 283
•
Treatment of dendritic cell sarcoma: 18-year experience at the MD Anderson Cancer Center.
(Abstract 8596)
Preetesh Jain
Board 284
•
Large granular lymphocyte (LGL) subsets in smoldering multiple myeloma (SMM):
Immunophenotypic profiles that predict progression to multiple myeloma (MM). (Abstract
8597)
Talib Dosani
Board 285
•
Outcomes after relapse from first autologous stem cell transplantation in multiple myeloma.
(Abstract 8598)
Wilson I. Gonsalves
Board 286
•
Effect of a novel agent, SL-401, targeting interleukin-3 receptor (IL-3R) on plasmacytoid
dendritic cell (pDC)-induced myeloma cell growth and osteolytic bone disease. (Abstract
8599)
Dharminder Chauhan
Board 287
•
ECOG multiple myeloma (MM) clinical trial (CT) accrual performance evaluation utilizing the
NCI–Trial Complexity and Elements Scoring (NCI-TCES) and the NCI Myeloma Steering
Committee Accrual Working Group (NCI MYSC AWG) scoring models. (Abstract 8600)
Matthias Weiss
Board 288
•
Autologous stem cell transplantation in dialysis-dependent myeloma patients. (Abstract
8601)
Riad Omar El Fakih
Board 290
•
Further exploring the mutational landscape of multiple myeloma via a targeted gene panel
assay. (Abstract 8603)
Donald Joseph Johann
Board 291
•
Differentiating asymptomatic monoclonal gammopathy (AMG including MGUS and AMM)
from clinical multiple myeloma (CMM) by gene expression profiling of purified plasma cells
(PC-GEP). (Abstract 8604)
Rashid Khan
Board 292
•
Clarifying immunoglobulin gene usage in immunoglobulin light chain amyloidosis by mass
spectrometry of amyloid in clinical tissue specimens. (Abstract 8605)
Taxiarchis Kourelis
Board 293
•
Plerixafor plus G-CSF (P+G) compared with G-CSF alone (G) for hematopoietic progenitor
cell (HPC) mobilization in AL amyloidosis (AL). (Abstract 8606)
Binod Dhakal
Board 294
•
Modeling the risk of progression in smoldering multiple myeloma. (Abstract 8607)
Adam J Waxman
Board 295
•
Trends in survival of patients with primary plasma cell leukemia: A population-based
analysis from 1973 to 2010. (Abstract 8608)
Wilson I. Gonsalves
Board 296
•
Outcomes of young patients with Waldenstrom macroglobulinemia (WM). (Abstract 8609)
Nishanth Vallumsetla
Board 297
•
Clinical and cost benefit of aprepitant in patients receiving high-dose chemotherapy prior to
autologous peripheral blood stem cell transplantation. (Abstract 8610)
Ayumi Nakamura
Board 298A
•
A phase 3 study of ibrutinib in combination with either bendamustine and rituximab (BR) or
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients
with previously treated follicular lymphoma or marginal zone lymphoma. (Abstract
TPS8611^)
Nathan Hale Fowler
Board 298B
•
Phase 3 trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of
patients (pts) with CD30+ mature T-cell lymphomas (MTCL). (Abstract TPS8612)
Owen A. O'Connor
Board 299A
•
Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A
+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line
treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study. (Abstract
TPS8613)
Stephen Maxted Ansell
Board 299B
•
AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus
rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent nonHodgkin lymphoma (NHL). (Abstract TPS8614)
John Leonard
Board 300A
•
A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination
with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in
subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell
lymphoma (DLBCL). (Abstract TPS8615^)
Anas Younes
Board 300B
•
Phase 1-2 open-label, multiple-dose, dose-escalation study to evaluate the safety and
tolerability of intravenous infusion of SNS01-T, a first-in-class modulator of eukaryotic
translation initiation factor 5A (eIF5A) in patients (pts) with relapsed or refractory B-cell
malignancies. (Abstract TPS8616)
Michael Craig
Board 301A
•
MAGNIFY: A phase 3B, randomized trial of lenalidomide plus rituximab induction and
maintenance therapy followed by lenalidomide single-agent versus rituximab maintenance in
patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL). (Abstract TPS8617)
David J Andorsky
Board 301B
•
LEGEND: A randomised phase II study comparing lenalidomide plus rituximab, gemcitabine,
and methylprednisolone (R-GEM-L) to rituximab, gemcitabine, methylprednisolone, and
cisplatin (R-GEM-P) in second-line treatment of diffuse large B-cell lymphoma (DLBCL).
(Abstract TPS8618)
Mary Gleeson
Board 302A
•
DYNAMO: A phase 2 trial of the PI3K-d,? inhibitor IPI-145 in patients with refractory indolent
non-Hodgkin lymphoma. (Abstract TPS8619)
Nina Wagner-Johnston
Board 302B
•
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and
safety of idelalisib in combination with rituximab for previously treated indolent non-Hodgkin
lymphomas (iNHL). (Abstract TPS8620)
Gilles A. Salles
Board 303A
•
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and
safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously
treated indolent non-Hodgkin lymphomas (iNHL). (Abstract TPS8621)
Myron Stefan Czuczman
Board 303B
•
Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator’s choice of
chemotherapy in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL).
(Abstract TPS8622)
Adrienne Alise Phillips
Board 304A
•
Phase 3 study of anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in
relapsed or refractory cutaneous T-cell lymphoma (CTCL). (Abstract TPS8623)
Youn H. Kim
Board 304B
•
SWOG 1211: A randomized phase I/II study of optimal induction therapy for newly
diagnosed high-risk multiple myeloma (HRMM). (Abstract TPS8624)
Saad Zafar Usmani
Board 305A
•
The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose
dexamethasone (POM + LoDEX) in refractory or relapsed and refractory multiple myeloma.
(Abstract TPS8625)
Meletios A. Dimopoulos
Board 305B
•
MM-013: An ongoing phase 2 trial of pomalidomide and low-dose dexamethasone (POM +
LoDEX) in relapsed/refractory multiple myeloma (RRMM) with moderate or severe renal
impairment (RI) including patients (pts) undergoing hemodialysis. (Abstract TPS8626)
Pieter Sonneveld
Board 306A
•
MM-014: A phase 2 trial evaluating efficacy, safety, and biomarkers of pomalidomide plus
low-dose dexamethasone (POM + LoDEX) in relapsed/refractory multiple myeloma (RRMM)
following second-line lenalidomide plus dexamethasone (LEN + DEX). (Abstract TPS8627)
David Samuel DiCapua Siegel
Board 306B
•
A randomized, double-blind, multinational trial comparing denosumab with zoledronic acid
for treatment of bone disease in adults with newly diagnosed multiple myeloma. (Abstract
TPS8628)
Noopur S. Raje
Board 307A
•
Efficacy of lenalidomide maintenance (LEN) therapy versus placebo, after melphalan,
prednisone, bortezomib (MPV) induction therapy in patients (pts) with newly diagnosed
multiple myeloma (NDMM): The ARUMM (MM-026) trial. (Abstract TPS8629)
Cyrille Hulin
Board 307B
•
Continuous lenalidomide (LEN) therapy versus observation following nonimmunomodulatory
compound-based induction therapy in newly diagnosed multiple myeloma (NDMM): MM-027
trial. (Abstract TPS8630)
Saad Zafar Usmani
Session Title: A Brave New World: Contemporary Management of HER2-Positive Breast Cancer
Session Type: Education Session
Track: Breast Cancer
Time: 3:00 PM - 4:15 PM
Location: N Hall B1
•
An Embarrassment of Riches: Optimal Selection and Sequencing of New Therapies for HERPositive Metastatic Breast Cancer
Shanu Modi, MD
•
More for Less? Evolving Adjuvant Management of Small HER2-Positive Tumors
Eric P. Winer, MD - Chair
•
First Things First: New Choices and Paradigms in Preoperative Therapy for HER2-Positive
Breast Cancer
Lisa A. Carey, MD
•
Panel Question and Answer
Session Title: Beyond Stage and Anaplasia: New Approaches to Risk Stratification for Wilms
Tumor
Session Type: Education Session
Track: Pediatric Oncology
Time: 3:00 PM - 4:15 PM
Location: S504
•
Risk Stratification and Therapy of Wilms Tumor: The Children's Oncology Group Approach
Jeffrey Dome, MD - Chair
•
Risk Stratification and Therapy of Wilms Tumor: The International Society of Paediatric
Oncology Approach
Norbert Graf, MD, PhD
•
Novel Biomarkers for Wilms Tumor
Elizabeth Perlman, MD
•
Panel Question and Answer
Session Title: Lymphoma and Myeloma: Where We Were, Where We Are, Where We Are Going
Session Type: Education Session
Track: Lymphoma and Plasma Cell Disorders
Time: 3:00 PM - 4:15 PM
Location: S100a
•
Where We Were, Where We Are, Where We Are Going: Mantle Cell Lymphoma As a
Paradigm for Progress in Lymphoma
Martin H. Dreyling, MD - Chair
•
Where We Were, Where We Are, Where We Are Going: Progress in Multiple Myeloma
P. Leif Bergsagel, MD
•
Panel Question and Answer
Session Title: Migration from Carcinogen to Virus: 50 Years of Evolution in Epidemiology and
Treatment of Head and Neck Cancer
Session Type: Education Session
Track: Head and Neck Cancer
Time: 3:00 PM - 4:15 PM
Location: E450
•
Epstein-Barr Virus As a Paradigm in Head and Neck Cancer: From Lab to Clinic
Anthony T. C. Chan, MD, FRCP - Chair
•
Etiology and Clinical Implications Involving HPV Infection in Head and Neck Cancer
Stephen Schwartz, PhD
•
Surgery in the HPV Era: The Role of Robotics and Microsurgical Techniques
John A. Ridge, MD, PhD
•
Panel Question and Answer
Session Title: Rare Gynecologic Tumors: New Targets, New Therapies
Session Type: Education Session
Track: Gynecologic Cancer
Time: 3:00 PM - 4:15 PM
Location: E354a
Location: E354a
•
Novel Approaches to Improve the Treatment of Rare Gynecologic Cancers: Research
Opportunities and Challenges
Jonathan A. Ledermann, MD, FRCP - Chair
•
Management of Vulval and Vaginal Melanomas: Current and Future Strategies
Mario M. Leitao, MD
•
Molecular Profiling of Rare Uterine Tumors: A Potential Guide to Treatment?
Michael J. Birrer, MD, PhD
•
Panel Question and Answer
Session Title: Breast Density: Clinical Impact and Emerging Legal Issues - Ticketed Session
Session Type: Clinical Problems in Oncology Session
Track: Cancer Prevention/Epidemiology
Time: 3:00 PM - 4:15 PM
Location: E451b
•
Why Breast Density Matters: Biology and Risk Factors
Norman Boyd, MBBS, DSc
•
Evidence-Based Imaging Standards
Maxine S. Jochelson, MD
•
Mandated Density Reporting: Effect on Practice
Debra M. Ikeda, MD - Chair
Session Title: Lung Cancer - Non-small Cell Metastatic
Session Type: Oral Abstract Session
Track: Lung Cancer
Time: 3:00 PM - 6:00 PM
Location: E Hall D2
•
Chair
Grace K. Dy, MD
•
Chair
Egbert F. Smit, MD, PhD
•
Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC:
Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung
(OAM4971g) global trial. (Abstract 8000)
David R. Spigel
•
Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell
lung cancer (NSCLC). (Abstract 8001)
D. Ross Camidge
•
Two Faces of MET
Federico Cappuzzo, MD
•
Panel Question and Answer
•
Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell
lung cancer (NSCLC): Results of the ASCEND-1 trial. (Abstract 8003^)
Dong-Wan Kim
•
Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut):
Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6
[LL6]) comparing afatinib with chemotherapy (CT). (Abstract 8004^)
James Chih-Hsin Yang
•
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced
EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label
randomized trial. (Abstract 8005)
Terufumi Kato
•
Right Patient, Right Drug, Right Time
Howard Jack West, MD
•
Randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients
with asymptomatic cerebral oligo-metastases in non-small cell lung cancer (NSCLC).
(Abstract 8037)
Sung Hee Lim
•
Discussion
Kathryn Beal, MD
•
Panel Question and Answer
Panel Discussion
•
REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab
(RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV
non-small cell lung cancer (NSCLC) following disease progression after one prior platinumbased therapy (Abstract LBA8006^)
Maurice Perol
•
Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small
cell lung cancer (NSCLC). (Abstract 8007)
Naiyer A. Rizvi
•
A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC)
chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line
treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).
(Abstract 8008^)
Nick Thatcher
•
When Antibodies Attack
Julie R. Brahmer, MD
•
Panel Question and Answer
Panel Discussion
Session Title: Melanoma/Skin Cancers
Session Type: Oral Abstract Session
Track: Melanoma/Skin Cancers
Time: 3:00 PM - 6:00 PM
Location: E Arie Crown Theater
•
Co-Chair
Jason John Luke, MD
•
Co-Chair
Georgina V. Long, MD, PhD
•
Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with
melanoma (MEL). (Abstract LBA9000^)
Antoni Ribas
•
Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic
melanoma. (Abstract 9001)
Michael B. Atkins
•
Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL)
treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. (Abstract
9002)
F. Stephen Hodi
•
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO,
anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced
melanoma (MEL). (Abstract LBA9003^)
Mario Sznol
•
Anti-PD1 Antibody Therapy for Melanoma
Jeffrey S. Weber, MD, PhD
•
Panel Question and Answer
•
Correlation between pre-existing MEK1P124 mutations and clinical and in vitro response to
BRAF inhibitors in metastatic melanoma. (Abstract 9004)
Matteo S. Carlino
•
BRAFV600 mutation levels and response to vemurafenib in metastatic melanoma. (Abstract
9005)
Celeste Lebbe
•
Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK
inhibition in patients with advanced BRAF mutant melanoma. (Abstract 9006^)
Grant A. McArthur
•
Correlates with Response to RAF Inhibition
Keith Flaherty, MD
•
Panel Question and Answer
Panel Discussion
•
Comparative health care (HC) costs in patients (pts) with metastatic melanoma (mM).
(Abstract 9007)
Chun-Lan Chang
•
Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy
and safety results from the EORTC 18071 phase III trial. (Abstract LBA9008)
Alexander M. Eggermont
•
Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene
laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colonystimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV
melanoma. (Abstract 9008a)
Howard Kaufman
•
Balancing the Costs and Benefits of New Melanoma Therapies
Jeffrey E. Gershenwald, MD
Session Title: Patient and Survivor Care
Session Type: Oral Abstract Session
Track: Patient and Survivor Care
Time: 3:00 PM - 6:00 PM
Location: E253
•
Chair
Tessa Cigler, MD, MPH
•
Chair
Shari Beth Goldfarb, MD
•
Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in
women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial. (Abstract
LBA9500^)
Gabriel N. Hortobagyi
•
Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal-related events (SREs)
in patients with metastatic bone disease: Subgroup analyses by baseline characteristics.
(Abstract 9501)
Allan Lipton
•
Phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron, for
prevention of chemotherapy-induced nausea and vomiting during repeated moderately
emetogenic chemotherapy (MEC) cycles. (Abstract 9502)
Matti S. Aapro
•
Aprepitant versus metoclopramide, both combined with dexamethasone, for preventing
cisplatin-induced delayed emesis: A randomized, double-blind study. (Abstract 9503)
Fausto Roila
•
Less Is More and Old versus New: The Art of Symptom Management
Thomas J. Smith, MD, FACP, FASCO, FAAHPM
•
Panel Question and Answer
•
Long-term risk of heart failure associated with adjuvant trastuzumab in breast cancer
patients. (Abstract 9504)
Hart Adam Goldhar
•
Cardiovascular diseases after Hodgkin lymphoma treatment: 35-year disease risk and
sequence of events. (Abstract 9505)
Frederika A. van Nimwegen
•
Increasing cardiovascular screening in at-risk adult survivors of pediatric malignancies: A
randomized controlled trial. (Abstract 9506)
Melissa M. Hudson
•
Cardiovascular Complications in Cancer Survivors
Kevin C. Oeffinger, MD
•
Panel Question and Answer
Panel Discussion
•
Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer
survivors: Trial N10C1 (Alliance). (Abstract 9507)
Debra L. Barton
•
NCCTG N10C2 (Alliance): A double-blind, placebo-controlled study of magnesium
supplements to reduce menopausal hot flashes. (Abstract 9508)
Haeseong Park
•
Management of Menopausal Symptoms in Breast Cancer Patients: What Really Works?
Patricia A. Ganz, MD
•
Panel Question and Answer
Panel Discussion
Session Title: Tumor Biology
Session Type: Oral Abstract Session
Track: Tumor Biology
Time: 3:00 PM - 6:00 PM
Location: S100bc
•
Chair
James M. Ford, MD
•
Chair
David Potter, MD, PhD
•
A novel “diapeutic” molecular imaging agent for combined oncologic diagnosis and therapy in
a broad spectrum of human cancers: Preliminary clinical experience with CLR1404. (Abstract
11000)
Perry J. Pickhardt
•
PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab
emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC). (Abstract 11001)
Geraldine Gebhart
•
Detection of metastases in breast cancer: Is whole body PET/MR better than PET/CT?
(Abstract 11002)
Komal L. Jhaveri
•
The Cutting Edge in PET Imaging
David A. Mankoff, MD, PhD
•
Panel Question and Answer
•
A pilot laboratory study comparing the 21-gene assay and PAM50-ROR. (Abstract 11003)
Che Prasad
•
Genomic heterogeneity in primary breast cancer: Clinical implications. (Abstract 11004)
Lucy Rebecca Connolly
•
Met heterogeneity evaluation by immunohistochemistry (IHC) and fluorescence in situ
hybridization (FISH) in nonsquamous non-small cell lung cancer (nsNSCLC). (Abstract 11005)
Edurne Arriola
•
Challenges in Assessing Tumor Heterogeneity
Lajos Pusztai, MD, PhD
•
Panel Question and Answer
Panel Discussion
•
Emergence of new ALK mutations at relapse of neuroblastoma. (Abstract 11006)
Gudrun Schleiermacher
•
A new nationwide genomic screening system in Japan for the development of targeted
therapies against advanced non-small lung cancers with rare driver mutations. (Abstract
11007)
Shingo Matsumoto
•
Comprehensive genomic profiling of solid tumors from 677 adolescents and young adults for
revealing a distinct spectrum of targetable genomic alterations. (Abstract 11008)
Deborah Morosini
•
Next-Generation Sequencing: Impact and Applications
Elaine Mardis, PhD
•
Panel Question and Answer
Panel Discussion
Session Title: 50 Years of Pediatric Oncology: From Chemotherapy to Genomics to Targeted
Therapy
Session Title: 50 Years of Pediatric Oncology: From Chemotherapy to Genomics to Targeted
Therapy
Session Type: Education Session
Track: Pediatric Oncology
Time: 4:45 PM - 6:00 PM
Location: S504
•
Pediatric Oncology: Progress over the Past 50 Years and a Glance at the Future
Audrey E. Evans, MD
•
Pediatric Cancer: From Cytogenetics to Deep Sequencing and Beyond
Scott Armstrong, MD, PhD
•
Targeted Therapy in Pediatric Cancer: Where Are We Now and Where Do We Go from Here?
Jeffrey Toretsky, MD - Chair
•
Panel Question and Answer
Session Title: MOC 101: Orientation to MOC Requirements
Session Type: Education Session
Track: Professional Development
Time: 4:45 PM - 6:00 PM
Location: E354a
•
Chair
Richard M. Stone, MD - Chair
Session Title: Second Cancers: Genomics and Detection
Session Type: Education Session
Track: Cancer Genetics
Time: 4:45 PM - 6:00 PM
Location: S404
•
The Rising Tide of Second Cancers: 16% and Climbing
Lindsay M. Morton, PhD - Chair
•
Clinical Patterns of Second Cancers in Long-term Cancer Survivors
Gregory T. Armstrong, MD, MSCE
•
Genomic Approaches to the Etiology of Second Cancers
Kenan Onel, MD, PhD
•
Panel Question and Answer
Session Title: The Past, Present, and Future of Noncolorectal Gastrointestinal Cancers: Have We
Moved the Bar?
Session Type: Education Session
Track: Gastrointestinal (Noncolorectal) Cancer
Time: 4:45 PM - 6:00 PM
Location: N Hall B1
•
5FU to FOLFIRINOX: Pitfalls, Progress, and Promise
Robert J. Mayer, MD - Chair
•
Biology and Biomarkers
Andrew M. Lowy, MD
•
Emerging Therapeutics
Pamela L. Kunz, MD
•
Panel Question and Answer
Session Title: Management of Hepatocellular Cancer: Right Patient, Right Treatment, Right Time Ticketed Session
Session Type: Meet the Professor Session
Track: Gastrointestinal (Noncolorectal) Cancer
Time: 4:45 PM - 6:00 PM
Location: E451a
•
The Right Treatment at the Right Time: Applying the Evidence to Your Patient
Andrew X. Zhu, MD, PhD
•
The Right Patient: Geographic Differences in Hepatocellular Carcinoma Care
SuPin Choo, MD
Session Title: Successes in Gastrointestinal Stromal Tumors: Long-term Considerations and
Survivorship - Ticketed Session
Session Type: Clinical Problems in Oncology Session
Track: Sarcoma
Time: 4:45 PM - 6:00 PM
Location: E451b
•
Gastrointestinal Stromal Tumor: Long-term Survival and Survivorship
George D. Demetri, MD - Chair
•
Surgical Considerations for the Long-term Survivor with Metastatic Disease
Alessandro Gronchi, MD
•
Living with Gastrointestinal Stromal Tumor: A Patient's Perspective
Marina Symcox, PhD

Clinical Trials – February 2011

2014-10-15 AKB Zinsprognose Internet - Aargauische Kantonalbank

1 | Citeline © 2014 All rights reserved.

日本胃癌学会全国胃癌登録解析結果 ―2001 年症例―

HER 2 Positive Breast Cancer